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ABSTRACT 
 Prostate cancer (PrCA) screening aimed at detecting aggressive disease represents 
a significant public health issue. Development of biomarkers to predict PrCA that is 
likely to kill if left untreated is a major challenge. This dissertation focused on analyzing 
existing repeated measures of prostatic specific antigen (PSA) to develop and validate a 
tool to improve both sensitivity and specificity of the PSA-based screening test to detect 
high-risk PrCA. We used the Prostate Lung Colorectal and Ovarian trial data (PLCO) for 
PSA growth model building. Using 6 years of annual PSA measurements we established 
the PSA growth curves for four groups of men; those who developed high-risk PrCA, 
those who developed low-risk PrCA, those who developed benign prostatic hyperplasia 
(BPH) and those who were not diagnosed with either PrCA or BPH. We used these 
curves to estimate PSA annual rate of change at defined time points; one and two years 
before diagnosis for each individual in the cohort. We then examined the area under the 
curve (AUC) to estimate the specificity and the sensitivity of PSA annual rate thresholds.  
We validated our work by replicating the PSA growth models in a cohort of screened 
men in The Department of Veterans Affairs. Our results show that PSA annual change 
rates varied significantly by cancer status in both cohorts. The difference between the 
means of PSA rate values across the four groups of men was high and robust. Annual 
individual PSA rates showed substantial variability; however, a distinct range and 
significantly higher values were observed among men who developed high-risk PrCA. 
This resulted in high AUC (0.97) in the logistic regression model. A threshold of 
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0.37ng/ml/year had the best combination of sensitivity and specificity; i.e., of 97.2%, and 
97.3% respectively.  In the VA validation cohort, the same pattern was observed. 
However, men in the low-risk PrCA group had higher annual PSA rates as compared to 
the same group in the PLCO cohort. This resulted in a lower AUC of 93.3 (92.86-93.71) 
and the threshold of 0.37ng/ml/year predicted high-risk PrCA with a sensitivity and 
specificity of 95.5% and 86.2 % retrospectively. 
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CHAPTER 1: INTRODUCTION 
 
Prostate cancer (PrCA) is a major source of morbidity in the US population [1]. After 
skin cancer (basal cell and squamous cell) and in situ cancers, it is the most common 
cancer, accounting for 27% of all cancers in men [1]. PrCA has a relatively high 
incidence that is coupled with racial disparities [2, 3] making it a public health challenge. 
About 1 in 7 American men are diagnosed with PrCA during their lifetime[1]. However, 
PrCA is considered relatively indolent, as 83% of those clinically diagnosed are reported 
to die from something else [6] – in fact, during autopsy many men are found to have 
incidental PrCA that had never become clinically evident[4].  
There is now consensus that most men, if they lived long enough, will develop 
histological PrCA[5]. Still, most of these men will die due to reasons unrelated to PrCA. 
Once PrCA is clinically detected the survival is strongly related to its aggressiveness at 
the time of detection. Men with localized PrCA have a 5-year relative survival rate of 
100%,  while those with distant metastases have less than one third the relative survival 
rate (31.9%) [6]. Early detection of men with virulent tumors might reduce PrCA 
mortality and morbidity, while early detection of men with indolent low-risk PrCA that is 
less aggressive, may increase iatrogenic morbidity without impacting mortality.  
Prostate specific antigen (PSA) was initially identified as a marker for the 
management of PrCA, and over the past 20 years it had become a routine, inexpensive 
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PrCA screening tool [7]. Aggressive use of this tool is thought to have led to an 
increase in the identification of indolent low-risk PrCA as most of the newly diagnosed 
PrCAs were found to have low prognostic risk (i.e., Prognostic group I, IIA) – a concept 
called ‘PrCA stage migration’ [8-10]. In 2011, The American College of Preventive 
Medicine (ACPM) [11], American Urological Association (AUA) [12], American Cancer 
Society and the U.S. Preventive Services Task Force (USPSTF) [13]  recommended 
against the use of PSA for routine population-based PrCA screening. The over detection 
of indolent PrCA coupled with over-treatment and iatrogenic harm became the basis for 
the recent controversies on PSA-based screening recommendations [14].  
PSA-based screening is not thought to be able to differentiate between aggressive 
PrCA and indolent PrCA. Much of the work to improve PSA-based screening, including 
PSA kinetics, complexed PSA, PSA density, free PSA, aimed to increase the screening 
sensitivity and specificity of PrCA [15]. Up until now, there has been no conclusive 
evidence to suggest that PSA-based screening is able to distinguish aggressive PrCA 
from other prostate pathologies such as indolent PrCA, benign prostatic hypertrophy 
(BPH) or even normal prostate.  
In 1993 Carter et.al. first proposed a concept of using serial PSA tests over a long-
time as a PrCA screening tool [16]. The use of serial PSA measures has been variously 
described as PSA kinetics, PSA velocity and/or PSA rate. Although PSA velocity was not 
commonly used during PrCA screening, it was widely used in the management of 
prostate cancer (i.e., among men who had undergone prostatectomy) [17]. The main idea 
is that the continuum of PSA values reflects tumor activity and provides additional value 
over one single PSA value. Until today there is no clinical trial that has examined the 
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effectiveness of PSA kinetics in predicting PrCA and findings from observational studies 
have not been conclusive in resolving this issue. Another problem is the lack in 
methodological homogeny in the PSA kinetics literature.  
When taken together, current literature suggests the following three key messages 
related to PSA kinetics: first, when measured rigorously the rate of PSA change is 
quantitatively and qualitatively different by prostate pathology such that it may be 
possible to distinguish aggressive PrCA, non-aggressive PrCA, benign prostatic 
hyperplasia (BPH) and normal prostate [12, 17-19]. Second, there is no single threshold 
for a linear PSA rate/PSAV that has been found to significantly enhance the prediction of 
(any) PrCA over a single recent PSA value [10]. Finally, there is an opportunity to use 
PSA kinetics in predicting aggressive PrCA [18, 19].  
In the absence of a reliable method for PrCA screening, the burden of the disease 
is expected to grow. The main concern must be aggressive PrCA, a virulent disease 
associated with high clinical risks that requires medical treatment and is expected to 
impact the morbidity and mortality of the affected individual. The challenge is to improve 
screening specificity for clinically high-risk, aggressive disease and to avoid over 
detection and treatment of insignificant, indolent low-risk PrCA [20].  
We conducted this dissertation with the aim of using repeated measures of PSA in 
order to develop, refine and validate a tool that will improve both sensitivity and 
specificity of the current PSA-based screening test for high-risk aggressive PrCA – the 
hypothesis was that the use of multiple repeated PSA tests over time will be able to 
distinguish virulent, high-risk PrCA from other underlying prostate pathology including 
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low-risk PrCA, BPH and normal prostate. If results obtained from the study are 
consistent with our hypothesis, then a significant portion of the unnecessary prostate 
biopsies and PrCA treatment, for men with low-risk PrCA, may be avoided. This will 
reduce unwanted expenses while improving quality of life and cost-effectiveness. 
In this dissertation, we modeled PSA change to develop PSA growth 
graphs/curves based on statistical models of repeated PSA measurements from men with 
high-risk aggressive PrCA, low-risk indolent PrCA, BPH and normal prostate. The data 
was then used to test our hypothesis that these curves are significantly different, with 
differences described quantitatively. Through these graphs, estimates of PSA change over 
time may be derived at an individual level at any time before diagnosis – giving an 
estimate of an individual patient’s probability that their prostate biopsy would identify 
high-risk PrCA vs. any of the other conditions.  
We used an innovative and robust approach to achieve our aims while considering 
accumulated evidence. We used two independent large population-based data sources: 
the Prostate Lung Colorectal and Ovarian (PLCO) clinical trial data [21] and the national 
clinical data from the routine care of patients of The Department of Veterans Affairs 
(VA). The PLCO clinical trial data was used for model building while the VA data was 
used for model validation. Our statistical modeling approach allows for broad 
generalizability by avoiding unrealistic assumptions and restrictions -the goal is to ensure 
that the tool may be used for individual level decision making at the bed-side. We used 
nonlinear mixed models [22] that explicitly account for between and within individual 
variability, while also estimating the overall mean PSA growth trajectory across the two 
data sets without imposing unrealistic statistical assumptions. This is a ‘change-point 
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model’ that assumes that PSA level changes in a time-dependent manner, starting in a 
linear form and then changing to a non-linear form – called ‘change point’ – during the 
natural history of the disease.  
We believe that this dissertation work has important clinical implications for early 
detection and prevention of high-risk PrCA, especially for population subgroups that are 
at higher-than-average risk of virulent PrCA such as African Americans and young men.  
1. A. Objectives  
The overall goal of this research work was to identify and refine a means for 
differentiating “significant” prostate cancer (i.e., virulent/aggressive disease with high 
potential for causing harm) from any other condition that could be related to an increase 
in PSA level at any particular point in time. To achieve this, the specific aims of our work 
are: 
1. To describe and establish separate graphical reference growth curves for 
different patterns of PSA change over time according to disease presence and virulence 
using longitudinal repeated measures of PSA from patients confirmed to: a) have no 
clinically detected PrCA, b) have low-risk PrCA, c) have high-risk PrCA. The curves 
were adjusted for age, race, initial PSA and BMI. The model was built using data from 
the PLCO Cancer Screening trial [21]. (See chapter 4)  
2. To compare the curves from patients with high-risk (clinically significant) 
PrCA to those without and estimate test characteristics, especially specificity and 
sensitivity, based on the resulting curves. (See chapter 5) 
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3. To validate the resulting curves in a different population in which individuals 
have multiple PSA measures, but measured opportunistically as opposed to on a regular, 
fixed schedule. To achieve this aim we will apply the same analysis techniques as 
developed in PLCO using enterprise-wide national electronic health record data from the 
Veterans Department of Veterans Affairs (VA). (See chapter 6)  
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CHAPTER 2: BACKGROUND 
 
2. A. Prostate cancer  
Globally, Prostate cancer (PrCA) is the 2nd most common cancer and the 6th 
leading cause of cancer related deaths among men [23]. With the aging world population, 
global burden of PrCA is on the rise. The number of new cases is expected to increase to 
about 1.7 million in 2030. Significant variation persists internationally [23]. While it is 
hard to compare incidence rate across the world, due to differences in screening patterns 
and cancer registration procedures, PrCA appears to be more common in Western 
populations such as Europe and the USA. However, in these countries the rates appear to 
have started to decline.  
In the USA , 233,000  new cases and  29,480 deaths are estimated to occur in 
2014 [1]. Combined with Lung cancer, PrCA account for about 50% of all cancers among 
American men [1]. The lifetime probability of being diagnosed with PrCA cancer is 
15.3% (1 in 7) and the median age at diagnosis is 66 years old [1]. Trends have been 
changing since 1992.  
Figure 2.1 and .2.2 represent long-term trends in cancer incidence and death rates 
for PrCA. The graphs show a general decreasing trend of PrCA incidence rates since
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 2000. However, year to year fluctuation is evident. This fluctuation is due to the 
variation in the use of prostate specific antigen (PSA) screening across the years. The 
estimated annual decline between 2006 and 2010 for PrCA incidence rate is about 
2%/year, and the decline in mortality rate for the same period is about 3%/year [1]. In the 
US, the peak of PrCA mortality was around 1992-1993; since then and until 2010, death 
rates have declined by 45% as a result of enhancement in screening and treatment. There 
is considerable geographical variation in PrCA occurrence, which might be confounded 
by racial distribution and some differences in PSA test utilization (figure 2.3); for 
example, the age -adjusted incidence rate is the highest in the District of Columbia (194.4 
per 100,000 men) and the lowest in Arizona (112.7 per 100,000). Also, District of 
Columbia has the highest age- adjusted death rate of 38.8 per 100,000, while Hawaii has 
the lowest death rate of only 15.7 per 100,00.  
 
 
Figure 2.1 Historical mortality trends of Prostate Cancer in the United States 
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Figure 2.2 Historical Incidence trends of Prostate Cancer in the United States 
 
 
 
Figure 2.3 Incidence rate of Prostate Cancer (2007-2011) by state 
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Prostate cancer is a heterogeneous disease with multiple genetic and 
environmental factors involved in its etiology. However, the main known risk factors are 
age, race and genetic/family history [24]. The risk of prostate cancer increases with age; 
it is an extremely rare disease among those under 40 years old (1 in 10,000) and 
relatively common among those above 60 years of age (1 in every 15) [25]. However, 
those at younger age are more likely to present with highly aggressive disease [26]. 
African Americans continue to have some of the highest incidence and mortality rates in 
the world [25]. They are 1.6 times more likely to be diagnosed with prostate cancer and 
2.4 times more likely to die of the disease when compared to European Americans [25]. 
African Americans tend to present with more aggressive characteristics of PrCA upon 
detection when compared to others [3]. Disparities also persist in screening, treatment 
regimens, disease quality of life and survivals [5]. Evidence suggests that the disease has 
different etiology among African Americans as compared to other races[5]. The 
determinants of this observed racial disparity across the continuum of PrCA occurrence 
and management seem to be complex; including genetic/biological, environmental 
(socio-economic and socio-cultural) and health services factors. Men with immediate 
relatives who have or had PrCA are twice as likely to have PrCA when compared to those 
who don’t. Five  to ten percent of PrCA cases are believed to be mainly caused by high-
risk inherited genetic factors or prostate cancer susceptibility genes [27]. There is some 
evidence that accumulation of genetic risks is also associated with an aggressive PrCA 
but the findings are not conclusive. Some dietary exposures may also increase the risk of 
PrCA, these include; fat and/or meat consumption, lycopene, and dairy 
products/calcium/vitamin D. The evidence regarding these factors is yet not conclusive 
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[24]. Similarly, there is some evidence that BMI /obesity and endogenous hormones 
(androgens and estrogens) alter the risk of PrCA.  
PrCA screening has been the central focus for cancer research over the past 
couple of decades. The discovery of PSA is a significant milestone in the history of PrCA 
prevention and early detection. However, there are other biomarkers, imaging and clinic- 
based screening methods that have been proposed and studied. In this section we will 
provide summary information on some of these non-PSA-based screening tools. In the 
next section, we will provide a more detailed description of the evidence behind PSA-
based-diagnostics.  
One of the oldest and common methods for PrCA detection is digital rectal 
examination (DRE). This clinical exam detects abnormalities such as asymmetry, 
induration or nodules in the posterior and lateral aspects of the prostate gland. Most cases 
detected via DRE are likely to be very advanced, as lower staged PrCA such as T1 (TNM 
stage) cancers are by definition non-tangible. The estimated sensitivity, specificity and 
positive predictive value of DRE to predict PrCA is 59% , 94 % and 28% respectively 
[28] . Most of PrCA cases detected by DRE are clinically advanced, making the value of 
the test (stand alone) questionable [29]. Clinical control trials have not shown 
improvement in PrCA outcome when detected by DRE [29]. The evidence is stronger for 
benefit when DRE is used in combination with a PSA screening test [30]. Observational 
studies have shown that PSA test and DRE complement each other’s and thus combining 
the two can improve PrCA screening [7, 31-33]. However, the PLCO clinical trial did not 
demonstrate significant survival benefits for men who underwent combined PSA and 
DRE screening [34, 35].  
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Prostate cancer antigen 3 (PCA3) is a main emerging biomarker for PrCA. It is a 
noncoding RNA that has been shown to be overexpressed (>90%) in PrCA tissue [36]. 
This biomarker is both sensitive and specific to PrCA and unlike PSA it is not sensitive to 
non-cancerous factors like BPH or prostate volume or prostatic infection[36]. Urine 
samples, that contain cells shed from prostate during urination, can be used as non-
invasive tool to determine a PCA3 score. The main limitation though is the sensitivity of 
urine PCA3 test ranged from 47-69% across different studies. Currently the use of PCA3 
is in combination with PSA[36]. The FDA approved the use of PCA3 for PrCA detection 
for men with persistent high PSA levels and a previous negative biopsy. The studies that 
investigated PCA3 are insufficient, but there is promising indication that this biomarker 
may have future role in PrCA screening. In general advances in genetic mapping have 
shifted biomarkers research to the potential of the “-omics” diagnostics. Other promising 
biomarkers are; TMPRSS-ERG gene fusions, he enzyme alpha-methylacyl-CoA 
racemase (AMACR), Germline prostate cancer risk loci etc. Also, some imaging-based 
technologies such as transrectal ultrasound, computed tomography , magnetic resonance 
imaging and positron emission tomography have been shown to improve PrCA screening.  
2. B. Prostate specific antigen (PSA)  
PSA discovery has revolutionized PrCA occurrence and treatment. The steep 
decline of PrCA mortality in the population after the widespread use of PSA based 
screening can’t be a coincidence but does not indicate causality [6, 37]. The other 
hallmarks of PSA testing are the dramatic increase of PrCA incidence and the migration 
to a lower stage disease[37]. The approval for adapting PSA based screening at 
population wide level was made in absence of any evidence from controlled trials, 
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making it a controversial topic[38]. Today and after the completion of two population 
based randomized clinical trials, the controversy is still persistent. 
2. B.1. What is Prostate specific antigen (PSA)  
PSA is a normal, abundant prostate-secreted serine proteinase with a half-life of 
2.2 days [39]. It is encoded by the KLK3 gene and is secreted by prostate gland 
epithelial, normal prostatic acini and abnormal neoplastic prostatic cells. PSA is a major 
protein in the semen, its main function is to cleave and liquefy semen allowing sperms to 
swim freely [39]. It also dissolves cervical mucosa to allow the entry of sperm into the 
uterus [39]. During the secretory process a small fraction (active and inactive form) leaks 
into the bloodstream through the normal gaps found in the loose prostate basement 
membrane barrier [40]. Thus it can be measured in the blood and may serve as a marker 
for prostate activity.  
Neoplastic prostatic cells are generally less mature compared to normal secretory 
cells, and their absolute per-cell PSA secretion is lower compared to normal cells. 
However, the circulating levels of leaked serum PSA is much higher in PrCA compared 
to when there is no PrCA. This is because cancer cells disrupt the basement membrane 
leading to increased leakage of PSA into circulation[41]. This disturbance of the 
basement membrane is pathognomonic of cancer and its growth. Thus, among patients 
with confirmed PrCA , the use of PSA has been established to reliably and non-
invasively predict the extent of PrCA and estimate the response of PrCA to therapy[41].  
PSA test was discovered in 1970’s and was originally approved by the  Food and 
Drug Administration (FDA) in 1986 to monitor the progression of prostate cancer in men 
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already diagnosed with the disease [42]. It was also used to detect recurrence of the tumor 
after therapeutic intervention of prostate cancer. Later on, some large scale observational 
studies showed that PSA can also be used for PrCA detection [43]. Eventually the FDA 
approved its use for early diagnosis of prostate cancer in 1994  [42].Throughout the last 
15 years it has been routinely used as an inexpensive screening tool for PrCA.  
2. B.2. PSA test performance for detecting PrCA  
Recent research studies such as the Prostate Cancer Prevention Trial have been 
unable to identify a definitive PSA cut off point that has the most optimal sensitivity and 
specificity for PrCA [44]. It is now universally accepted that there is a continuum of risk 
for PrCA at all levels of PSA, with higher levels being associated with the highest risk 
PSA. The cutoff point of 4ng/ml leads to a sensitivity of (70-90%) for prostate cancer, 
and since PSA is also produced by non-malignant cells the 4ng/ml threshold has a 
specificity of only 20-40% a positive predictive value (PPP) of about 30%. Further, PSA 
is not specific to high-risk prostate cancer; about 75% of cases with PSA level of (4-10 
ng/ml) are diagnosed with locally confined disease that is considered of low-clinical risk 
– indolent PrCA. Most patients with such low-risk PrCA are more likely to die from other 
causes before PrCA becomes clinically advanced enough to cause morbidity and 
mortality. 
Over the years of the “PSA era” a new stage of low-grade, low-stage, low-risk 
(indolent) prostate cancer widely emerged among the screened populations. The 
introduction of PSA testing as a population based screening of “normal-risk” 
asymptomatic men led to the detection of many such new cases. From 1985 to 1995 the 
trends of prostate cancer completely shifted, ‘stage migration’, the incidence  doubled but 
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only 1 of 5 detected cases was likely to be virulent[45, 46]. It is argued that diagnosing 
and treating such low-risk PrCAs is more likely to cause harm to a patient’s health than 
benefit.  
Some common benign conditions can also elevate PSA level resulting in many 
false positive and some false negative results are: 
 Age: There is a slight natural increase of PSA with age. It is estimated that PSA 
increase by 0.2ng/ml/year. This increase in value is attributed to the growth of the 
prostate with time/aging [47]. 
 Race/ethnicity: There is some evidence that African American men tend to have 
naturally higher PSA at a given age while Asian tends to have lower PSA when 
compared to Caucasians. Some of these differences can be explained by the 
differences in the prostate gland size or prostate gland volume - others are 
attributable to genetic factors [47].  
 Medications: Finasteride (5 alpha-reductase inhibitor) blocks the conversion of 
testosterone to dihydrotestosterone which leads to decreases in prostate volume 
and lower serum PSA. In one study, it was estimated that men who took 
finasteride had a 50% decrease in serum PSA level after 1 year of treatment [48] 
  Prostate gland inflammation/infections: PSA level increase and fluctuate with 
prostatitis. Changes vary depending on the category of the inflammatory process. 
Also, PSA seem to increase in men with signs and symptoms of urinary tract 
infection (UTI) with positive bacterial culture. Among these men PSA level may 
increase reaching levels of 14.1 ng/mL during the acute phase of an infection 
[49].  
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 Benign prostate hyperplasia (BPH): This is the main factor of high PSA levels in 
non-cancer cases. The increased amount of benign prostatic tissue, increases 
serum PSA significantly. This is a very common condition among men and the 
risk increases with age. Men with BPH can have PSA levels as high as 15 ng/ml.  
 BMI:  There is an inverse relationship between BMI and PSA levels. It is 
estimated that there is 5% to 21% decrease in PSA value in men with BMI > 30 
compared to men with normal BMI. This effect is primarily thought to be due to 
hemodilution [50].  
 Other factors include trauma and lab variability, DRE examination and 
ejaculation.  
 
2. B.3 The effectiveness of PSA based screening (findings of randomized control 
trials): 
In 2011, The U.S. Preventive Services Task Force (USPSTF) and other medical 
agencies recommended against the use of PSA for routine population-based PrCA 
screening[51]. This recommendation was heavily based on the findings of two 
randomized control trials that investigated the effectiveness of PSA based screening in 
improving PrCA outcomes[52]. We will discuss below seven relevant randomized 
clinical trials; the Quebec[53-55], the two  Sweden studies - the Norrkoping [56, 57] and 
Kjellman et [58]; European randomized study of screening for prostate cancer (ERSPC) 
[59-61] , French ERSPC[62], Gothenburg[63], and the Prostate, Lung , Colorectal and 
Ovarian (PLCO) cancer screening trial [64-66]. Two of these still ongoing (ERSPC and 
PLCO) at the time of this review.  
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The 1988 Quebec prospective randomized controlled trial by Labrie et al. [53-55], 
was one of the earliest clinical trials. Through 15 years, 31,133 men identified from 
Quebec City were randomly assigned to PSA and digital rectal examination (DRE) 
screening with 15,353 men as their controls. Only 24% (7,348 men) of the intervention 
arm complied (76%) didn’t. In the control arm, 7% (1,122 men) performed screening at 
one point of the follow up. Given this significant contamination, the authors didn’t 
perform an intention to screen analysis. Instead the analysis was done based on whether 
man actually underwent screening or not. The relative risk for PrCA death among the 
screened group when compared to the non-screened group was 0.39 (95% CI, 0.21-0.71). 
There were 11 PrCA deaths among screened group and 217 deaths among the 
unscreened. The core limitation here is the breaking of the randomization, especially that 
the authors didn’t adjustment for potential confounding. Such analysis essentially 
represents an observational study. However, in one of their subsequent publications the 
authors provided data on intention to screen analysis. Using this approach, there was no 
significant difference in PrCA mortality between the intervention and the control groups 
(RR= 1.09; 95% CI 0.82- 1.43). 
In 2004, Sandblom et al. [56, 57] published their work of 15 years follow-up of a 
quasi-randomized pilot study. Starting 1987, the investigators used the national 
population register to randomly assigned 1,494 men into PSA and DRE screening - every 
three years. 7,532 men served as the control group. Forty three cases (3%) of PrCA were 
detected in the intervention group compared to 292 (4%) in the control group. There was 
no difference in PrCA or overall mortality between the two groups. The study was not 
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powered to detect statistical difference in PrCA mortality, as the detected cases are not 
big enough to detect significance different between the 2 groups.  
Kjellman et.al [58] published another Sweden trial that started in 1988 and 
compared one-time PrCA screening using a combination of PSA, DRE and transrectal 
ultrasonography with a control group of no screening. The study included 1,796 men who 
agreed to participate as an intervention group (out of 2400 men who were between 55 to 
70 year of age and living within a defined geographical area in Stockholm - randomly 
selected by investigators). 24,804 men from the remaining source population served as 
the control group for the trial. After 15 years of follow-up there was no significance 
difference in PrCA deaths between the intervention group and control group. There were 
53 PrCA deaths in the intervention group (26% of diagnosed) and 506 deaths in the 
control group (28% of diagnosed) leading to an incidence rate ratio of 1.10; 95% CI, 
0.83-1.46. Limitations of this study include; use of high PSA cut off point for biopsy 
(≥10ng/ml), the screening group simultaneously underwent a combination of screening 
methods making it hard to isolate the effect of PSA and making the application side 
challenging and it was not clear whether the committee who assigned the cause of death 
were blinded to the screening allocation, a potential deferential misclassification bias. 
The three aforementioned trials provided an early useful context for PrCA 
screening using PSA. However, each of them had some critical methodological 
limitations, especially when it comes to allocation concealment, description of loss of 
follow up and blinding of assignment to assessors. The recent USPSTF review on the 
topic considered those three trials as “poor-quality trials” and used their evidence with 
lower weights towards the overall recommendation[51].  
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The ERSPC [59-61] is an ongoing cross-national trial that has included eight 
European countries; France, Sweden, Netherlands, Finland, Belgium, Spain, Italy and 
Switzerland. The trial was launched in 1990’s with 182,160 men between 50 and 74 years 
who were randomly assigned to screening arm with PSA testing or a control arm without 
(72,890 screening arm vs. 89,353 as control). The protocol and the implementation varied 
slightly by country; randomization took place prior to consent in three countries and post 
consent in five, France joined later in 2001 and thus its data was not included in the first 
(ERSPC) 2009 publication, instead the French data was published separately. While most 
countries included PSA measures in the intervention arm, the cut off point for biopsy 
varied; 3 ng/ml was commonly considered as positive results. The most important source 
of variation was differences in screening frequency: six countries tested every 4 years, 
Sweden screened every 2 years and Belgium had one screening every 7-years. Overall, 
82.2% of men in the screening group actually underwent screening at least one test with 
some variation among the 8 countries. The authors reported that the study was designed 
to have sufficient power to account for a 20% contamination rate; however they did not 
provide enough information about actual rates of screening in the control arm. The study 
included age range of 50-74 but the investigators predefines a “core” group of 162,387 
men with a narrower age group of 55-69. Men were followed up for an average of 8.8 
years (median of 9 years). In the main and overall study population analysis there was 
some reduction in PrCA mortality in the intervention arm when compared to the control 
arm but this was not statically significant (rate ratio 0.85; CI 95% 0.73-1.00). However, 
in the predefined “core” group there was a statistically significant reduction (20%) in 
PrCA mortality among the intervention arm when compared to the control arm. There 
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were 214 PrCA deaths in the screened group vs. 326 deaths in the control group: RR of 
0.80; 95% CI 0.65-0.98). This reduction started to emerge after about 8 years of the 
follow up and is translated into an absolute reduction of 0.71 PrCA deaths per 1,000 men. 
In addition, the investigators performed exploratory analysis on different age groups and 
reported interesting findings; there was a significant PrCA death reduction among men 
aged 65 to 69 years (RR of 0.74; 95%CI 0.56-0.99), in contrary there was statistically 
non-significant trend toward increased risk of PrCA death among younger men (50 to 54 
years old) with a RR of 1.47; 95%CI 0.41-5.19. Similar trend was observed among the 
oldest age group (70 to 74 years old) with a RR of 1.26; 95%CI 0.80-1.99. The overall 
findings can be interpreted as 1,410 men aged between 55 and 69 years needing to be 
screened and 48 additional prostate cancers needed to be treated (NNT) to prevent or 
delay one PrCA death. This is considered a high relatively NNT number, making PSA – 
if considered useful not efficient. Recently published, is the third and the most updated 
results for the study [67], these included an extended follow up of 13 years. The rate ratio 
of prostate cancer mortality was 0.79 (95%CI 0.69-0.91) at 13 years, the non-
participation adjusted RR was 0.73 (95% CI 0.61-0.88). The absolute risk reduction of 
death from prostate cancer at was 0.11 per 1000 person-years which translates into one 
prostate cancer death averted for every 27 (17-66) additional PrCA detected [67]. These 
latest findings provide strongest evidence supporting the PSA screening. However, as the 
authors point out, this trial didn’t consider the harm of over detection and over treatment 
associated with screening, and they concluded that more evidence is still needed.  
 The French ERSPC [62] is originally part of the ERSPC study, but as mentioned 
above, was reported separately. The whole study included 84,781 men aged 55 to 69 
 21 
years; 42 590 men were included in the screened group and 42,191 in the control group. 
Men in the screening group were repeatedly invited by mail to be screened while nothing 
was done for the control group. The protocol included randomization before information 
and consent. Knowledge of any pre-existing PSA test was obtained through the health 
insurance database. Cumulated incidence of PrCA with a four years follow-up was 2.48% 
(n=1,053) in screening and 1.99% (n=840) in control group, with a relative risk (RR) of 
1.242. Mortality measures were not yet reported due to short period of follow up. The 
published accessible work does not provide enough information to make conclusion on 
the effectiveness of PSA screening to reduce mortality. Another published work was 
released but with limited access [62]. 
The Gothenburg trial [63] is also related to the ERSPC study as it included men 
previously reported in the ERSPC study. In the Gothenburg trial 19,904 participants were 
enrolled in three birth cohorts (1930-1934, 1935-1939, and 1940-1944). The first two, 
(1930-1934, 1935-1939) are basically the Swedish cohort (n=1,185) of the ERSPC study. 
For these, the Gothenburg trial provided longer follow up than the ERSPC. Men in the 
screening group (9,925) were invited for PSA screening and only men with raised PSA 
concentrations were offered additional tests such as digital rectal examination and 
prostate biopsies. Men in the control group (9,952) were offered nothing. The absolute 
cumulative risk reduction of death from PrCA at 14 years was 0.40% (95% CI 0.17-0.64), 
from 0.90% in the control group to 0.50% in the screening group. The rate ratio for death 
from PrCA was 0.56 (95% CI 0.39-0.82; p=0.002) in the screening compared with the 
control group. The rate ratio of death from PrCA for attendees compared with the control 
group was 0.44 (95% CI 0.28-0.68; p=0.0002). Overall, 293 (95% CI 177-799) men 
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needed to be invited for screening and 12 needed to be diagnosed to prevent one PrCA 
death. What is interesting is that the authors of this study were the only ones to conclude 
that the benefit of PrCA screening compares favorably to other cancer screening 
programs, namely breast and colorectal cancer despite the high risk of over treatment and 
over diagnoses. This study reported the highest effect of PSA screening to reduce overall 
PrCA mortality and had the longest time of follow up. Concerns of the results are related 
to unclear information from loss of blindness and the contamination of randomization.  
The (PLCO) trial [64-66] assigned randomly 76,685 men aged 55 to 74 years at 
10 US study centers to annual PrCA screening (38,340 men) or usual-care opportunistic 
screening (38,345men). The screening included annual PSA measurements for 6 years 
along with DRE for 4 years. Men with more than one PSA screening in the three years 
prior to randomization were excluded. A PSA threshold of > 4ng/ml was considered a 
positive screen and an indication for further diagnostic procedure by subjects private 
health care providers. Compliance among the control group was an issue; 40%-60% in 
the control group underwent PSA testing on the 1st and the 6th year respectively. 85% of 
the screening group complied with PSA testing. All incident PrCA and deaths from PrCA 
through 13 years of follow-up or through December 31, 2009, were ascertained. 
Approximately 92% of the study participants were followed for 10 years and 57% for 13 
years. There was no statistically significant difference in PrCA mortality. The cumulative 
mortality rates from PrCA in the screened and control groups were 3.7 and 3.4 deaths per 
10,000 person-years, respectively, resulting in a non-statistically significant difference 
between the two arms (RR = 1.09, 95% CI = 0.87 to 1.36). These results indicate that 
after 13 years of follow-up, there was no evidence of a mortality benefit for organized 
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annual screening in the PLCO trial compared with opportunistic screening. The main 
limitation was that many men in the opportunistic screening arm did indeed screen for 
PrCA using at least one PSA test.  
The PLCO and the ERSPC are considered the best current evidence to the issue of 
PSA screening and its efficiency to decrease cancer mortality - however with limitations. 
While they were both considered of “fair” quality in the 2011 USPSTF review,  it is 
important to note here that the up to date findings of the two studies are divergent. The 
ERSPC considered PSA testing life-saving but with high related costs, the PLCO didn’t 
find any statistically significant mortality gains but with higher mortality trend among the 
screened group. The discrepancy is what some scientist referred to as “the controversy 
that refuses to die”[68]. The length of follow up is important to consider here. The lead 
time for PSA screening and PrCA mortality is estimated around 15 years. Very recently 
the ERSPC has reached this point of follow up and the updated results indicate stronger 
and moderate benefits for the PSA screened group. The PLCO study has not yet 
completed this duration and additional benefits may emerge later. The contamination 
among the control group is another important consideration; in the PLCO study (44%-
50%) of the control group underwent PSA testing. Additionally, more than 40% of the 
enrolled men have had up to 2 PSA testing before the enrolment, leaving the possibility 
of detecting a cancer lower than expected in both groups. In the ERSPC the 
contamination rates are not clearly described for most sites, 20% contamination rate 
among the control group was reported from Rotterdam site and was extrapolated for the 
whole study. Another two important methodological differences between the 2 trials are 
the interval of screening and the engagement of the control group in the trial; in the 
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PLCO study, men followed an annual PSA testing protocol for 6 years , in the ERSPC 
trial men were screened either every 2 or 4 years. The PLCO trial reported high rates of 
over diagnoses of indolent cancer among the screened group and high number of invasive 
treatment such as prostatectomy among the treated group when compared to the control 
group - when compared to the ERSPC trial screened group. The more frequent PSA 
testing may have resulted in relative increase in the number of indolent PrCA diagnosis 
along with the invasive treatments (which have high mortality rate) might explain the net 
harm (higher mortality) among the screened group in the PLCO study. Finally, in the 
ERSPC trial men in the control group were not aware that they are participating in the 
trial, those who were tested and diagnosed among them received treatment in their own 
regular place. Those who were diagnosed in the screened group were followed at specific 
care centers and might have received different level of treatment and medical 
care/expertise. In the PLCO trial both groups were treated the same and were referred to 
their own health care providers.  
The totality of the evidence described in all the trials above, indicate that PSA 
based screening for PrCA is associated with over diagnoses, over treatment and high 
costs; with a possible slight to moderate gain in mortality. It is critical to note here, that 
none of these studies considered race as a potential effect modifier. That is, we do have 
enough evidence that PrCA is more invasive among African American, especially those 
who are also younger age [69]. The majority of participants in these trials were 
Caucasians; consequently the findings might not be generalizable to African Americas in 
whom there is a different natural history of PrCA [25].  
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2. C. Prostate specific antigen kinetics  
PSA kinetic can be mathematically defined and referred to by multiple ways; PSA 
velocity (PSAV) is the change in PSA (ng/ml) per the change in time that is also referred 
to as PSA rate. If the change in time is fixed on one unit of change (say one year), then it 
is the annual PSA rate. The change can also be represented as a percentage that would be; 
PSA annual percentage change (APC). PSA doubling time (PSADT) is the time it takes 
for one PSA test result to double. The continuum of change across long period of time is 
referred to as PSA growth curves (longitudinal change over time with a certain trend). 
Similar to PSA single test, PSA kinetics was initially introduced to monitor PrCA 
progression after diagnosis. Until today, PSA kinetics were widely used in the 
management of prostate cancer [70]. 
2. C.1. The use of PSA kinetics in screening for Prostate cancer (evidence from 
observational studies)  
Carter et al. [16, 71] were the 1st to propose the concept of PSA change and its 
potential implication in PrCA early detection. In an earlier work, Carter et al. described 
the long term change of PSA across a group of men who developed PrCA using data 
from up to 14 years prior to the clinical detection of the disease. They compared the 
pattern and the magnitude of the change (in what they called PSA growth curves) with a 
control group of healthy men and others with BPH. They were able to show that there is a 
transition time at which PSA starts to accelerate among individuals who developed PrCA, 
while both control groups showed monotonic nonaccelerating patter. They reported that 
the transition/acceleration take place years prior to the clinical diagnosis. They also 
showed higher and earlier PSA progression (transition) among those who were diagnosed 
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with metastatic disease as compared to local disease. This pattern was later confirmed by 
others [72] [73]. The inflection point represents a clinical change from the slow gradual 
expansion of prostatic epithelial volume due to normal prostate age-related growth to a 
rapid increase of peripheral PSA due to rupture in the prostate basement from significant 
tumor growth[72]. Despite the evidence provided by these early reports, the value PSA 
kinetics to improve PrCA screening has not been confirmed. This is because data from 
control trials is lacking and evidence from subsequent observational studies varied. We 
will discuss below several observational studies that investigated the value of PSA 
kinetics in PrCA screening 
Carter et.al[74] defined three groups of men from subjects in the Baltimore 
Longitudinal Study of Aging (BLSA) [75] which is an ongoing long-term prospective 
aging study of the National Institute of Aging. Participants are of community-dwelling 
volunteers with the continued recruitment. More than 1,400 men and women are study 
volunteers. They range in age from their 20s to their 90s. Participants in this study return 
every 2 years for a series of tests and donate blood for current and future studies. 
Previous analysis of the sub-population of men [75] revealed the age-specific incidence 
of prostate disease to be similar to that in the general white male population. Carter et.al 
estimated PSA growth curves from serial PSA measurements using frozen sera from 
three groups of men: (a) 16 men with no prostatic disease by urological history and 
examination; (b) 20 men with a histological diagnosis of benign prostatic hyperplasia 
(BPH) who had undergone simple prostatectomy; and (c) 18 men with a histological 
diagnosis of PrCA. The median number of repeated PSA measurements over an 8 to 26 
year period prior to histological diagnosis or exclusion of prostate disease was 8 and 11 
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for non-cancer and cancer subjects, respectively. Predicted rates of change in PSA were 
linear and curvilinear for control and BPH subjects, respectively. Subjects with cancer 
demonstrated both a linear and an exponential phase of PSA velocity. Based on time to 
double PSA, Carter et.al showed that the rate of PSA increase was higher among PrCA 
patients compared to BPH patients or those with normal prostate. They proposed a PSA 
velocity (PSAV) threshold of 0.75ng/ml/year to differentiate PrCA and BPH in men with 
elevated PSA. [76] Thus they concluded that it would be expected that “serum PSA 
would change faster with time in men with PrCA than in men without prostate cancer” 
and that estimates of prostatic growth rate from changes in PSA may be useful clinically 
in management of men with prostate disease. Following Carter et.al, in 1994 Pearson et 
al [72, 77] conducted similar analysis using updated data on the same cohort. They 
concluded that the most significant factor affecting change of serum PSA levels with age 
is the development of prostate disease and that the “rate of change in PSA levels may be a 
sensitive and specific early clinical marker for the development of prostate cancer”. 
Using the same source of data, Morrell et al., [78] tried a different statistical approach 
(non-linear mixed models) to estimate the growth curves of PSA with time among men 
with and without cancer (all before cancer diagnoses) and found that local/regional and 
advanced/metastatic cancers had similar rates of PSA progression that is significantly 
different from PSA change in healthy mean, but advanced/metastatic cancers are 
diagnosed later. [78] . Loeb et al. [79] reported similar results on additional data from the 
BLSA study. They reported that having a PSAV over the threshold of 0.4 ng/ml/y 
increased the risk of life threatening PrCA by 13.6% while a PSA threshold of 3ng/ml for 
PSA incensed the risk by only 3%. Again using the BLSA data, Fang et al. [80] estimated 
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the sensitivity and specificity of PSAV among 89 men with serial PSA of 2-4 ng/ml for at 
least 28 month. The sensitivity and specificity of a threshold of 0.1ng/ml/year was 81% 
and 50%, respectively. The cumulative probability of PrCA during the next 10 years was 
only 2.9% when PSAV was less than 0.1ng/ml/year and 35.2% when PSAV was more 
than 0.1ng/ml/year.  
Vickeres et. al. [81] used data from 5519 participants in the PCPT trial who 
underwent biopsy to build a multivariable model predicting PrCA. They compared the 
area under the curve (AUC) of two models, with and without PSA velocity (used at the 
threshold of 0.35, 0.5. 0.75). Both models included age, PSA, digital rectal examination, 
family history and previous biopsy. They also evaluated the number of biopsies avoided 
and the additional cases detected by using PSA velocity in men with low PSA and 
negative DRE. They reported a trivial increase in AUC (from 0.702 to 0.709 ) when PSA 
was included in the model. Surprisingly, the gains were even smaller for high-grade 
cancer. Also, using the PSAV thresholds in men with low PSA and negative DRE results 
led to a large number of additional biopsies. Their PSA thresholds had a better 
combination of specificity and sensitivity when compared to comparable PSAV 
thresholds. Ulmert et al.[82] assessed the additive the value of adding PSAV into a model 
using PSA to predict PrCA. The analysis was done using the Malmo preventive study 
where participants were 5,722 Swedish men (44-50 years) who underwent 2 PSA 
screening test, 6 years apart. There measurements were taken 10 to 15 years prior to 
PrCA diagnosis. The authors reported that PSAV was highly and independently 
associated with PrCA but didn’t improve the predictive value of PSA.   
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Finally, two recently published studies concluded that PSA change over time does 
in deed improve prostate cancer detection. Wallner et al. [18] evaluated whether the rate 
of change in serum PSA levels (represented by annual percent change) accurately detects 
prostate cancer in a managed population of 219,388 men passively followed from 1998 to 
2008. Their results indicated that longitudinal measures of PSA improved the accuracy of 
aggressive prostate cancer detection when compared to single measurements of PSA. 
Orsted et al.[19] investigate the same question among 7,455 men in the Copenhagen city 
heart study. They also concluded that adding long-term PSAV to baseline PSA values 
improves classification of PrCA risk and morality. The results of these two recent studies 
provide insight into the potential use of PSA annual rate as a predictive marker for 
aggressive prostate cancer.  
Due to main methodological differences, it is hard to compare the results of all 
these observational studies. In a recent systematic review, Loughlin [83] defined several 
problems in the PSA kinetics literature. He emphasizes on the methodological 
heterogeneity. Further, he showed that many studies on this topic do not conform to the 
original definition of PSA Velocity. In their systematic review, Vickers et al. [84] 
concluded that; studies that investigated PSA kinetics either found single PSA to be a 
better predictor than PSA kinetics, or found  trivial differences in favor of PSA kinetics, 
or had serious methodological shortcomings.  
In conclusion, the accumulating evidence indicates that; when measured 
rigorously the rate of PSA change is quantitatively and qualitatively different among men 
who developed life-threatening PrCA. These differences may be detected 5-10 years prior 
to the clinical detection of the disease [12, 17-19]. PSAV as commonly measured in 
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many studies may be highly correlated with PSA and thus may not improve PSA 
predictive value. However, some recent publications have shed the light on a significant 
potential value of PSA kinetics in particularly predicting high-risk prostate cancer. More 
studies with robust methodologies are required to further accumulate evidence on the 
value of PSA kinetics in improving PrCA screening. 
 31 
CHAPTER 3: METHODS 
 
For this dissertation we aim to identify and refine a means for differentiating high-risk 
prostate cancer (PrCA) from any other condition that could be related to an increased prostate 
specific antigen (PSA) measure at any particular point in time. In this chapter we will describe 
the overarching theme behind the methods of this research. Specific descriptions of 
methods used in each of the three separate objectives will be provided in individual 
chapters that are designed to be stand-alone manuscripts. 
3. A. Overall Epidemiological Design: 
We followed a nested case-control study design. The cases were always patients 
with confirmed diagnoses of high-risk PrCA. Two different control groups were 
identified; patients without any prostatic disease and patients with low-risk PrCA. Using 
a classic retrospective approach, we “followed” all patient’s repeated PSA measures over 
time and describe the trajectories at which those measures changed with time. We used 
repeated measures statistical methods to obtain a description of the mean and individual 
PrCA growth in the cases and the controls over the study time.  
3. B. data sources 
The data for this study was obtained from two different data sources; the Prostate, Lung, 
Colorectal, and Ovarian (PLCO) Cancer Screening trial [21], and the Veterans affair 
administration (VA) data
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1. The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening trial: 
The PLCO trial [21] is a large population-based randomized trial designed and sponsored 
by the National Cancer Institute (NCI). The overall objective was to determine the effects 
of screening on cancer-related mortality in men and women aged 55 to 74 participating in 
10 screening centers around the country. The 10 screening centers were: the University of 
Colorado, Georgetown University, Pacific Health Research Institute (Honolulu), Henry 
Ford Health System, and University of Minnesota, Washington University in St Louis, 
University of Pittsburgh, University of Utah, Marshfield Clinic Research Foundation, and 
University of Alabama at Birmingham. The enrolment took place between 1993 and 2001 
and screening component of the trial was completed in 2006. Participants are being 
followed for outcome assessment through 2015. Figure 3.1 illustrates the schematic view 
of the trial design. Approximately 155,000 participants were enrolled and individually to 
the control arm or intervention arm equally. Participants in the intervention arm received 
screening exams for prostate, lung, colorectal and ovarian cancers while those at the 
control arm received usual medical care. At the time of this analysis the median follow-
up time was 12.4 years 
 
 
Figure 3.1 schematic of the PLCO trial design 
Legend: Source (http://prevention.cancer.gov/plco/background) 
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For this dissertation, we used data from men who were randomized to the prostate 
cancer intervention arm and thus received PSA and digital examination screening. For 
this dissertation we obtained access and used the following items from the wide set of 
data provided by the PLCO study: 
a. The baseline questionnaire which includes demographic, life-style and 
medical history data for all participants enrolled in the trial at the time of 
enrolment.  
b. Screening data: This includes serial PSA measurements for about 38,000 
males who were randomized to the prostate cancer intervention arm. Each 
participant was expected to comply with 6 six annual blood draws. Each draw 
was sent to a central lab to assess the level of PSA. In addition to PSA tests 
results, digital rectal examination results were also obtained. Overall, data on 
about 177,000 PSA exams and 128,000 DREs were obtained. PSA results are 
contained in the data in both numeric and qualitative result (i.e., negative, 
positive, inadequate), where levels above 4.0 ng/ml are considered positive. 
c. Diagnostic procedure: Data were collected and obtained on procedures that 
were part of a diagnostic work-up for prostate cancer and for staging 
procedures following a diagnosis. Two different types of events triggered the 
collection of diagnostic procedure information; a positive screening PSA 
(above 4.0mg/ml) exams or abnormal suspicious DRE or when a participant 
was diagnosed with prostate cancer within the trial period.  
d. Cancer diagnoses: Complete data on PrCA diagnosis were obtained. The 
PLCO trial confirmed diagnoses of PrCA through medical record abstraction 
 34 
(MRA) of men suspected/reported by the trial to have prostate cancer. Clinical 
stage was almost always available (98% of prostate cancers). Pathologic stage 
was only available for men who had a prostatectomy (37% of prostate 
cancers). Gleason scores were collected from both biopsies (98%) and 
prostatectomies (37%) and assessed at pathology labs local to the screening 
center. Information on Gleason score was captured on a 2 to 10 scale.  
2. The Department of Veterans Affairs (VA) data: 
We have obtained access to national VA electronics health record (EHR) Corporate Data 
Warehouse (CDW) data extracts. This included nationwide demographic, administrative 
claims, vital signs, mortality, laboratory results, pharmacy dispensation and oncology 
record via the Veterans Affairs Informatics and Computing Infrastructure (VINCI) 
platform. All these data sources are linkable using a common individual patient-level 
identifier; i.e., scrambled SSN. The utility, accuracy, validity, and access methodology of 
the available data is transparently maintained by the VA has been previously described 
[85-88]. The components of each of the VA data source are listed below:  
a) VA medical SAS datasets: contains International Statistical Classification of 
Diseases and Related Health Problems-9 (ICD9), Current Procedural 
Terminology (CPT), cost, demographic, socioeconomic, health care utilization 
information 
b) VA Decision support system datasets: contains laboratory, pharmacy, cost, 
demographic, socioeconomic, health care utilization information 
c) VA vital status file: Contains demographic and mortality information 
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d) VA Corporate data warehouse: Provides vital measures such as height, weight, 
waist circumference, blood pressure, pharmacy and related information. It also 
includes raw data extract from oncology files; which includes field on Gleason 
score and TNM stage.  
3. C. Cohort definition: 
PLCO trial participants are uncompensated volunteers recruited from the general 
population in the geographic area of each of the screening centers [21]. A potential 
participant was considered eligible for the PLCO trial if he did not meet any of the 
following exclusion criteria: 
 Less than 50 or greater than or greater than or equal to 75 years of age at the 
time of randomization. 
 Individuals undergoing treatment for cancer at the time of randomization 
(excluding basal-cell and squamous-cell skin cancer). 
 Individuals with known prior cancer of the colon, rectum, lung, prostate.  
 Individuals with previous surgical removal of the entire colon, one lung, or the 
entire prostate. 
 Individuals who were participating in another cancer screening or cancer 
primary prevention trial. 
 Males who had taken Proscar/Propecia/finasteride in the 6 months prior to 
randomization. 
 Males who had more than one PSA blood test in the three years prior to 
randomization. 
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 Individuals who had a colonoscopy, sigmoidoscopy, or barium enema in the 
three years prior to randomization. 
 Individuals who were unwilling or unable to sign the informed consent form. 
We applied further eligibility specific criteria based on the specific aims of this 
dissertation. Please see chapter 4 and 5 for details on the PLCO cohort selection and 
characteristic for aims one and 2.  
The VA is one of United States largest integrated health care system consisting of 
150 medical centers, nearly 1,400 community-based outpatient clinics, community living 
centers, Vet Centers and Domiciliaries [89]. These facilities serve more than 8.3 million 
Veterans each year [89]. To approximate the VA cohort to the PLCO clinical trial cohort 
- we identified male veterans between 50 and 75 years of age who had their first VA 
based PSA test in the calendar years of 2002 and 2011, and did not have any prostate 
cancer diagnosis, BPH diagnosis or prostate procedures such as biopsy, prostatectomy 
(partial or complete) or other prostate surgeries, orchiectomy or dispensation of 5-alfa 
reductase inhibitors, any cancer. Chapter 6 describes the details of the VA cohort 
characteristics.  
3. D. Data definition and measurements: 
Exposure/biomarker: long term PSA annual rate of change (ng/ml/year) derived 
from PSA growth curves. PSA growth curve is the longitudinal repeated measure of PSA 
over multiple years of time. The derivation of PSA annual rate depends on the equation 
that best fits the observed change of PSA over time (PSA growth curve). PSA is a 
numeric continuous variable measured in certain time intervals over multiple years prior 
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to any clinical presentation of PrCA. In the PLCO trial, PSA was measured on serum 
obtained and frozen within 2 hours of blood draw at each of the 10 screening centers. The 
samples were then shipped to the UCLA Immunogenetics Center on dry ice where the 
analysis was performed centrally. The quality control measures for the collection and 
storage of blood samples and tissue is an integral component of the trial and all described 
in details elsewhere [21]. PSA serum measurements at the VA hospitals labs are all done 
in compliance with the quality control standards of the of the Clinical Laboratory 
Improvement Amendments (CLIA). All laboratory testing is subject to onsite inspection 
and accreditation by a nationally recognized accreditation body, either College of 
American Pathologists (CAP) or Joint Commission (JC). 
Outcome: The outcome is a pathological diagnosis of PrCA. We defined the stage 
and the extent of PrCA separately for the two cohorts using the VA oncology files and 
the cancer diagnoses file in the PLCO data. Based on this information we classified the 
PrCA into clinically high-risk and low-risk PrCA. The definition of high-risk PrCA was 
based on the prognostic classification of PrCA introduced in 2010 by American Joint 
Committee on Cancer (AJCC) [90]. The committee considered a PrCA meeting any of 
the following criteria as a PrCA with high clinical risk; PSA level ≥ 20ng/ml, cancer that 
invades prostate capsule, PrCA that involves more than one lobe, or Gleason score >7. In 
the PLCO study all diagnosed cancers, deaths, and causes of death were ascertained by 
annual follow-up questionnaire and periodic linkage to the National Death Index. Follow-
up clinical stage was determined from the clinical assessment of the extent of tumor 
involvement using the TNM staging system. Tumor stage was categorized according to 
the fifth edition of the American Joint Committee on Cancer (AJCC) Cancer Staging 
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Manual (5). Gleason grade was determined using the biopsy Gleason score (range 2-10). 
The underlying cause of death was determined in a uniform and unbiased manner from 
the death certificate and relevant medical records, as has been described in detail 
previously [21].  
Covariates: baseline Age, race, body mass index [BMI=weight(kg)/height(m)2] 
and clinical history of benign hyperplasia (BPH)  are important variables that were 
controlled for while modeling the PSA growth curves. These baseline measurements 
were available in both data sets. In the PLCO data, these measurements were available as 
part of the baseline questionnaire. For the VA data, the VA CDW data extracts in VINCI 
had reliable measures for these variables.  
Study time period: In the VA data we obtained access to all VA data for calendar 
year 2002 to 2011. The total study period will be 10 years - details on the distribution of 
the follow up time are provided in chapter 6. For the PLCO data the PSA measurements 
started in 1993 and cancer outcome were collected up to 2009, median follow-up time 
was 12.4 years with 6 years of PSA measures completed in 2006.  
Startup date: For the VA data that will be defined as the date of 1st PSA measure. For 
the PLCO data that will be defined as the enrolment date to the study (Randomization 
date).  
Date of end of follow-up (Right censor): For individuals who developed PrCA at any 
time during the course of the follow up, the exit date was the date they were diagnosed 
with PrCA either through pathological diagnosis of PrCA or death due to PrCA or 
received treatment for PrCA (radiotherapy, chemotherapy or surgical) which ever 
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happened earlier. For those who have no evidence of PrCA diagnosis, the exit date is a 
predetermined end of follow up date; December 2009 (or up to 13 years from trial entry) 
and December 2011 for the PLCO and VA respectively.  
3. E. Statistical approach 
Baseline data was subjected to simple descriptive statistical methods [(i.e., using Proc 
Univariate, Means, and Freq in SAS® 9.4 (SAS institute N.C.)] to determine mean, 
median, standard deviation and proportions (as appropriate). For the VA data, all analysis 
was performed inside the VINCI environment which provided us with SAS/Grid cloud 
based parallel computing environment with raw data sources provided through Microsoft 
SQL Server 2014. The PLCO data was processed, cleaned and provided for the purposes 
of this research project by the NCI Cancer data access system (CDAS). All analytics 
were carried using standard statistical procedures from SAS® 9.4 (SAS institute N.C.). 
3. E.1. Repeated measure analysis (overview)   
The term repeated measures refers to data sets with multiple measurements of a 
response variable on the same experimental unit [91]. Multiple measurements of PSA 
(annually in the case of PLCO) are available for different groups of men. In this basic 
setup, there are two factors, group/(s) and time. Group is called the between-subject 
factor because levels/categories of groups can change only between subjects and; all 
measurements on the same subject will represent the same group. Time is called a 
within-subject factor because different measurements on the same subject are taken at 
different times. In repeated measures studies, where a group effect is hypothesized, main 
interests are (1) how group(s) means differ (the effect of the group), (2) how group means 
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change over time (the effect of time), and (3) how difference between group means 
change over time (slope). In other words, is there a group main effect (difference by 
group), is there a time main effect, and is there a group-by-time interaction?  
What makes repeated measure data analysis distinct is the covariance structure [92], that 
is, pattern at which the repeated measures (for the same subject) are correlated. For 
example, two measurements taken at adjacent time points are typically more highly 
correlated than two measurements taken further apart in time; and such temporal ordering 
usually violates the independence assumption. Effort will be applied at the beginning of 
the statistical analysis to assess the covariance structure of the data in order to avoid 
biases and model assumption violations.  
3. E.2. Statistical approaches to repeated measure analysis (mixed-effect models):  
There are several approaches to modeling repeated/correlated response data [92]. 
The two basic approaches are the use of 1) marginal models and 2) mixed-effect models. 
With marginal models, the emphasis is on population-average inferences (i.e., comparing 
the average change in PSA for the different groups), or the marginal expectation of the 
response ( mean PSA-measures) [93]. As in all longitudinal measure analysis, the within-
individual correlation of the response variable – PSA – is accounted for, but this is solely 
through the specification of a marginal variance-covariance structure. The regression 
parameters derived from a marginal model only describe the population mean response 
and do not describe the mean response at a single-individuals level.  
In contrast, with a mixed effect model, the regression parameters are able to 
describe an individual’s mean response; i.e., the response is subject-specific. Mixed-
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effect models are called “mixed” because they estimate both random and fixed effects. 
Fixed effects involve only factor effects that are treated as unknown constants. An effect 
is fixed if the levels in the study represent all possible levels of the factor, or at least all 
levels about which inferences are to be made. Random effects are used in the study to 
represent only a sample (usually a random sample) of a larger set of possible levels. For 
example, in a longitudinal repeated measure study, time and individuals can have a 
random effect as we have limited number of observed times for each participants. A 
factor is considered random if its levels reasonably represent a larger population with a 
probability distribution (usually normal distribution). The ability of mixed-effect models 
to consider both random and fixed effect make them appropriate for numerous 
experimental and observational data and study designs including repeated measures 
designs. Here correlation is accounted for through specification of subject-specific 
random effects and possibly on intra-subject covariance structure. Unlike marginal 
models, the fixed-effect regression parameters of mixed-effect models describe the 
average of an individual’s response and are more informative when advising individuals 
of their expected outcome. 
Additional approaches include semi parametric approaches to mixed models [94]. 
Penalized splines regressions using a Bayesian approach is one well-known application. 
These methods are similar to parametric mixed models in terms of their ability to 
estimate inferences that are more likely to be subject-specific in scope with the focus 
centering on the individual’s mean response rather than estimating marginal, or 
population inferences. However, fitting mixed models using spline regressions allow 
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higher level of flexibility in modeling complicated relationships between the response 
and covariates in various longitudinal studies. 
To effectively achieve the overall goal of this dissertation, the subject oriented 
approaches are more appropriate as we are interested in predicting individual’s outcome 
rather than only population’s means. In fact, the differences in mean PSA rate or velocity 
among men who develop PrCA as compared to those who don’t are known and well 
documented in all studies discussed in in chapter 2. What this dissertation aims to 
investigate is whether the individual PSA rate can be used to predict PrCA outcome. We 
are also interested in accounting for the random effect of the heterogeneity in PSA values 
and the rate of change in PSA within the population. Mixed-effect models (either 
parametric or semi parametric) can be used to estimate the pattern of change of PSA with 
time. Such a model also estimates the influence of individual characteristics of PSA. It 
can be assumed that each individual has his own true PSA pattern, and that these true 
patterns vary about the population average. Thus the models allow PSA patterns to differ 
according to PrCA category (group), even among men with the same characteristics. In 
addition, the model allows observed PSA for each individual to vary about his true 
values, because of measurement error and day-to-day variation. 
Mixed models include different types/categories of models determined by the 
mean structure (The relationship between PSA and time/age in our case) and the type of 
data (The distribution function). Table 3.1 below summarizes five basic types.  
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Table 3.1 Mixed effect models category 
 
Model Mean structure  Cumulative distribution 
function  
Linear mixed-effect  Linear  Normal 
Generalized Linear mixed-effect  Linear General 
Non-linear mixed-effect models Non-linear  Normal 
Generalized non-linear mixed-
effect 
Non-linear  General  
Semi parametric mixed models   Non-
parametric  
General 
  
Previous studies and our preliminary analyses indicate that PSA levels increase 
with age, but that the growth rate may not be constant (i.e., linear-monotonic) with time,  
especially in those with PrCA or BPH (or possibly other prostatic diseases) [95, 96]. 
Several previously published studies have modeled long term PSA repeated measures 
with time among individuals with PrCA; most of them indicated a non-linear change of 
PSA with time and modeled a longitudinal profile of (log-transformed) PSA with some 
sort statistical technique to overcome the non-linearity. The log-transformation was likely 
done to make the distribution less skewed and to allow for normal distribution 
assumption. Almost all the studies agreed on the following pattern of PSA over time; an 
observed linear increase of PSA when considering normal patients. However, among 
individuals with PrCA, PSA trends seemed to be linear up to a certain point (before PrCA 
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diagnoses) at which both the trend and the rate change appeared to accelerate in an 
exponential pattern. That point is what statistician refers to as the acceleration point or 
inflection point [73].  
These previous findings suggest that the use of linear mixed-effect models may 
not be appropriate for our data and not suitable to obtain reasonable statistical inferences. 
Non-linear mixed models [92] where parameters enter the model individually and 
nonlinearly can be used to correctly establish PSA growth curves. Another alternative 
and more stable approach to overcome the linearity assumption is penalized spline 
regressions and the use of Bayesian approaches to mixed models (semi-parametric 
approach) [94, 97]. The two approaches are similar in many ways and, in theory, should 
lead to the similar results, especially when employing large sample sizes.  
3. E.3. Non-linear mixed-effect model for modeling PSA growth curves  
Statistically speaking, nonlinear models are models whose parameters enter the 
model individually and nonlinearly. Traditional nonlinear models have the general form  
𝒚 = 𝒇(𝒙, 𝜷) + 𝒆 
Where: f is a nonlinear function of known constants (x) and unknown parameter (β) and 
the errors (e) are additive. In our case, we would like to fit a model that simultaneously 
accounts for the nonlinear mean structure as well as the variability between and within 
subjects while taking account for both inter-subject variability and intra-subject 
correlation and heterogeneity.  
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We will start by demonstrating the observed longitudinal profiles/trajectories of 
PSA for all participants as a function of age for each study group. The observed 
individual trajectories are helpful in determining the suitable statistical model (non-linear 
function) for the observed data. This is because the inference here focuses on features or 
mechanisms that underlie individual profiles of repeated measurements of the PSA and 
how these vary in the population. Non-linear mixed effect models are theoretical or 
empirical models for individual profiles with parameters that may be interpreted as 
representing such features or mechanisms. For example, if the observed individual curves 
display a mildly nonlinear S-shaped growth trend the logistic growth model such as 
𝑬[𝒚] = 𝜷𝟏/(𝟏 + 𝜷𝟐𝒆
𝜷𝟑𝑿)  would be interpretable and appropriate. However, such 
assumption cannot be made at this early stage. The link function could be anything that is 
a good fit for the observed curves in each study group.  
NLMIXED [92] procedure in SAS is a recent addition and is currently considered 
the 1st choice for fitting non-linear mixed-effect models. PROC NLMIXED fits non-
linear mixed-effect models by numerically maximizing an approximation to the marginal 
likelihood - that is, the likelihood integrated over the random effects. Different integral 
approximations are available [92]. The resulting marginal likelihood can be maximized 
using a variety of alternative optimization techniques. Successful convergence of the 
optimization problem results in a maximum likelihood parameters estimates along with 
their approximate standard errors based on the second derivative matrix of the likelihood 
function. PROC NLMIXED enables the use of the estimated model to construct 
predictions of unknown functions using Bayes estimates of the random effect. Also, one 
can estimate arbitrary functions of the non-random parameters, and PROC NLMIXED 
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computes their approximate standard errors using the delta method. Nonlinear mixed 
models have important applications in wide variety of fields and are effective ways to 
model correlated data with a nonlinear relationship between independent and dependent 
variables [72, 92].  
3. F. Sample size justification  
Sufficient sample size is necessary to reliably estimate growth models. However, 
in such a design determining what is sufficient might be problematic. This is because the 
power calculation  here  depends - in part - on other factors of the research design such as 
complexity of the growth model and the variance expected to be  explained by the model 
[98]. One of the main determinant  is  relation between the number of individuals and the 
number of repeated observations per individual; so that , the total number of person*time 
observations is what ultimately defines the statistical power in a given study [92]. In 
general , growth models require – on average – three repeated measures per individual, 
although this requirement can also be ambiguous [92]. For example, in an unbalanced 
data, some individuals might have just one or two observations, whereas others have 
three or more and this is usually acceptable. Since three repeated measures over-identify 
the trajectory, 3 measures are preferred for at least a sizeable portion of the cases. 
Another consideration is the estimation method; for typical maximum likelihood (ML) 
method , it is assumed that the repeated measures are continuous and normally distributed 
[92]. However, there are alternative methods for estimation which allow for measures 
that are continuous and not normally distributed.  
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In conclusion, growth models can fit and explain multiple types of data structures; 
careful selection of proper models and methods of estimation should be done based on 
the characteristics of the given data set which also allows appropriate sample size 
calculations. Growth models have successfully been fitted to samples as small as small as 
22 [98], although sample sizes approaching at least 100 are often preferred. 
Some statistical work has been done to estimate sample size requirements based 
on different data distribution and mean structures. As in Overall and Doyle (1994), 
sample size of contrast c of group population means across n time points: 
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2 = Common variance in the groups at time point  
𝜎𝑖𝑗 = co𝑚𝑚𝑜𝑛 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑡𝑤𝑜 𝑔𝑟𝑜𝑢𝑝𝑠 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑡𝑖𝑚𝑒 𝑝𝑜𝑖𝑛𝑡𝑠 𝐼 𝑎𝑛𝑑 𝑗  
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In 1999, Hederk et al. [99], extended the above formula for non-balanced data and 
created tables for sample size required in repeated measures assuming different variance -
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covariance structures and random effect. For our study, we are estimating the difference 
of PSA trajectories in two different data sets with an average of 3 time points in each 
dataset for each individual. 
Based on Hederk et al. [99] published tables for sample size calculations of 
repeated measure data and assuming the following: at least 3 time points per individual, 
Power of 0.8 for a 2-tailed 0.5 test, test of a group effect over time, attrition rate of 0.1, a 
small effect (a between group difference of 0.2 SD unit at each time point) and random 
effect structure with a random slop and random residual; for this we will need 237 
participants in each group.  
We are proposing a population-based study that will include all eligible patients 
receiving care at the VAMC (i.e., > 5 million men). Though not nearly as huge, the 
PLCO data is large data set of 36,000 men. Both data sets exceed the minimum number 
needed participants in each study group. We also had access to the technology platform 
to conduct analysis on such large sample (distributed parallel processing on a Linux 
operating system based SAS grid platform of the VA VINCI).  
 49 
CHAPTER 4 
 
Understanding long-term changes in serum Prostate-specific antigen in the 
PLCO study cohort1 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
1 Shoaibi , A., Rao, G., Cai, B., Rawl, J., Hebert, J.. Understanding long-term changes in serum Prostate-specific 
antigen in the PLCO study cohort. To be submitted to Aanals of Epidemiology. 
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Introduction:  
Prostate cancer (PrCA) is the most common visceral cancer in the United States 
and the second leading cause of cancer deaths among men [25] . In 2014, about 233,000 
new cases of PrCA were diagnosed, and 29,480 men died of the disease [1].   In May 
2012, The U.S. Preventive Services Task Force (USPSTF) released a guideline 
recommending against routine prostate specific antigen (PSA)-based screening [100].  
Currently, the American Urological Association and American College of Physicians 
recommend limited PSA-based screening only in high-risk populations.  For non-high-
risk men, they recommend individualized informed decision-making [101] .  The 
increased detection of low-risk PrCA based on PSA-based screening is the foundation of 
the controversy that led to the current recommendations against screening.  
PrCA is generally a relatively indolent disease, with the lowest mortality to 
incidence ratio compared to any other epithelial cancer [102, 103] and a lifetime risk of 
death of only 2.9% [104]. The unique combination of high incidence and low virulence 
drives the debate around the value of current screening strategies using a single elevated 
PSA level or digital rectal exam. The fact that PSA is not an exclusive marker of 
malignancy is a major shortcoming of this biomarker. While a single elevated PSA 
measurement is highly sensitive to PrCA it is of low specificity and does not distinguish 
well between indolent and aggressive PrCA or even non-malignant conditions; thus, 
burdening patients with biopsies, ineffective and sometimes hazardous treatments and, 
concomitantly, large and unjustifiable health expenditures [105] . 
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In response to the need for better screening strategies, especially among those at 
higher risk of developing aggressive disease, previous studies proposed using PSA 
change over time to improve detection of PrCA  [15, 83, 106] . The use of serial 
measurements of serum PSA levels represents an attempt to model PSA kinetics or PSA 
velocity (PSAV).  This concept has been widely used in the management of PrCA. 
Starting in the early 90’s, investigators used frozen serum samples collected prior to 
PrCA diagnosis to provide information about natural history of PSA change or 
‘growth’[16].  Since then, several researchers have modeled PSA change using different 
definitions, assumptions, and statistical computation methods on differing populations 
[83]. The results have varied with some concluding that PSAV did improve PrCA 
detection [18, 19, 76], while others refuted these suggestions [83, 106, 107]. Many have 
questioned the incremental value of the PSAV beyond that of a single PSA result, 
describing the concept of PSA dynamics as a “sticky” concept that further perpetuates the 
issue of over-detection and over-treatment of an indolent disease [83, 106, 107].    
The totality of the evidence indicates that there is major heterogeneity in 
PSAV/PSA change definitions [83]. No single threshold for PSAV has been found to 
significantly enhance the clinical value of PSAV over PSA alone [106],  but when 
measured rigorously  the rate of PSA change is quantitatively and qualitatively different 
by various groups such as aggressive PrCA patients, non-aggressive PrCA, benign 
prostatic hyperplasia (BPH) and healthy men [16, 72, 108, 109]. Finally, PSA change is 
sensitive to many biological and bio-behavioral characteristics, such as BMI, race, age, 
medications and smoking. All of these factors have the potential to influence PSA 
measures and modify its change over time.  
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Given this controversy and the potential important implications for clinical 
practice, this study aims to utilize advanced unrestrictive statistical methods to fully 
describe and quantify PSA change over time in three groups of men: men with no 
evidence of PrCA, men who have been diagnosed with low-risk  PrCA and men who 
have been diagnosed with high-risk PrCA using data from the Prostate, Lung, Colorectal 
and Ovarian Cancer Screening Trial (PLCO)  cohort [21]. We aim to quantify and 
compare PSA growth curves in years prior to the clinical diagnosis of disease or exit 
from the study while considering baseline factors such as age, race, BMI and initial PSA. 
Methods: 
We conducted a retrospective analysis using PLCO data. Cases were patients with 
confirmed diagnoses of high-risk PrCA. Two different control groups were identified: 
participants without evidence of PrCA and patients with low-risk PrCA. Using a classic 
retrospective approach, we “followed” all patients’ repeated PSA measures over time 
until they were confirmed to either have PrCA or have exited from the study. For each 
individual, we describe the trajectories of the repeated PSA measures over time.  
Setting: 
The PLCO trial [21] is a large population-based randomized trial designed to 
determine the effects of screening on cancer-related mortality and secondary endpoints in 
men and women 55 to 74 years of age participating at one of 10 screening centers in 10 
cities in the US: Birmingham, AL; Denver, CO; Detroit, MI; Honolulu, HI; Marshfield, 
WI; Minneapolis, MN; Pittsburgh, PA; Salt Lake City, UT; St Louis, MO; and 
Washington, DC. For the PrCA component of the trial, participants were enrolled 
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between November 1993 and July 2001 and were individually randomized to the control 
arm or intervention/screening arm in equal proportions.  We conducted our analysis on 
38,340 men who were randomized into the screening arm. Each man was expected to 
comply with up to 6 six annual blood draws and digital rectal examination (DRE) in the 
six years of enrollment. Blood samples were sent to a central lab to assess PSA level. 
Men were enrolled and actively screened (for six years) between 1993 and 2006, after 
which they were passively followed-up for seven additional years. Data were collected on 
cancer diagnoses and deaths from all causes that occurred through December 31, 2009 or 
up to 13 years from trial entry resulting in a median follow-up time of 12.4 years.   
Participants:  
Trial participants were volunteers recruited from the general population in the 
geographic area in the ten screening centers.  Participants were excluded if they were; " 
less than 50 or greater than or equal to 75 years of age at the time of randomization;  
undergoing treatment for cancer at the time of randomization (excluding basal-cell and 
squamous-cell skin cancer); individuals with known prior cancer of the colon, rectum, 
lung or prostate; individuals with previous surgical removal of the entire colon, one lung, 
or the entire prostate; individuals who were participating in another cancer screening or 
cancer primary prevention trial; individuals who had taken finasteride in the 6 months 
prior to randomization; individuals who had more than one PSA blood test in the three 
years prior to randomization; individuals who had a colonoscopy, sigmoidoscopy, or 
barium enema in the three years prior to randomization; or individuals who were 
unwilling or unable to sign the informed consent form." [21] 
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To strengthen our statistical models we excluded men with less than four PSA measures. 
To avoid information bias we excluded 3 groups of participants for potential 
misclassification: those who were reported to have cancer outcome but was not 
confirmed ("death certificate unconfirmable", "self/other reported unconfirmable”, 
"erroneous report of cancer", "borderline malignancy"); those who were classified as 
non-responsive  (refusal to continue with study activities or loss of contact before 
confirming outcome status); those who did not have  complete follow-up information  in 
response to a positive screen (had a positive screening result but were not captured in 
further diagnostic follow-up and were never confirmed to have cancer). We also excluded 
men who were diagnosed with benign hyperplasia (BPH) at baseline and those with 
incomplete information on baseline age, BMI and race (these are important covariate in 
analyses); Figure 4.1  represents the analytical cohort tree. 
Definitions measurements and assessments:  
The classification of PrCA into high biological risk and low biological risk was 
based on the prognostic stage introduced by The American Joint Committee on Cancer 
(AJCC) in 2010 incorporating pretreatment markers [9, 10]. Any PrCA that met even one 
of these criteria were considered high biological risk: PSA level ≥ 20ng/ml, cancer that 
has invaded prostate capsule, PrCA that involves more than one lobe, and Gleason score 
(if available) > 7.   Patients with PrCA who did not meet all of these criteria were 
considered to have PrCA of low biological risk (prognostic group IIa and below). Clinical 
stage was determined from the clinical assessment using the TNM staging system. Tumor 
stage was categorized according to the fifth edition of the American Joint Committee on 
Cancer (AJCC) Cancer Staging Manual. Gleason grade was determined using the biopsy 
 55 
Gleason score (range 2–10). All diagnosed cancers, deaths, and causes of death were 
ascertained by annual follow-up questionnaire and periodic linkage to the Social Security 
National Death Index. The underlying cause of death was determined in an uniform 
manner from the death certificate and relevant medical records.  Demographic, 
behavioral and medical data were available as part of the baseline questionnaire. Total 
(PSA) serum ng/ml testing was performed centrally at the University of California, Los 
Angeles, Immunogenetics Center [21, 110].   
Statistical methods:  
First we plotted the observed individual trajectories of PSA for all participants as a 
function of time for each study group so as to determine the suitable statistical model for 
the observed data. We used spaghetti plots to illustrate the individual trajectories and the 
loess option to fit the mean trajectories in each group separately [111].  We defined time 
as years to exit or diagnosis.  Our descriptive observed plots and evidence from previous 
studies  indicate that PSA levels increase with age/time, but that the growth rate may not 
be constant (i.e., is not linear-monotonic) especially in those with PrCA. To account for 
this pattern, we used multiphase non-linear mixed models framework to estimate PSA 
change over time in 2 different models: 
1) Linear-exponential piecewise PSA model:  In this model, we estimated the 
individual PSA as a function of time (years to diagnosis/exit). We hypothesized 
that each individual’s PSA trajectory starts with a phase of slow linear change 
followed by a phase of rapid exponential increase. The transition point from the 
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linear phase to exponential phase was considered unknown and unique for each 
individual influenced by random factors.  
We built the model in two stages:   
a. Because our hypothesis is that the pattern of change in PSA is significantly 
different among the healthy men and the two cancer groups, so as to allow 
different coefficient estimates per group, we started with an initial model that 
used an interaction term between the group type and time.  To account for 
individual level natural heterogeneity in the rate of growth, the transition point 
and the intercept in each group, we included random effects for their 
corresponding estimates. The full mixed-effect model for the data is fully 
described in appendix 1.  The most parsimonious model was determined by 
backwards elimination of non-significant terms. As expected, cancer groups 
exhibit a significant exponential term that is not significant in the cancer 
group. Also, the estimate of CP for the no cancer group was significantly low 
(very close to zero) while for the cancers groups had a significant value of 5-
7.   
 
b. We then used our reduced model (allowing a transition to an exponential 
phase among the cancer groups only)  to estimate average and individual 
PSAV as ng/ml/year per group while adjusting for baseline age , BMI 
(kg/m2), PSA measure (ng/ml) and race [African American (AA) versus 
others]. To investigate and account for possible effect-modification of these 
variables on PSA change over time, we included an interaction term between 
 57 
all of these variables and time. The simplified presentation of the reduced 
mixed-effect model is shown in appendix 1 simplified.  
 
2) Linear –Linear piecewise LOG PSA model:  
In this model, we estimated the change of PSA over time on the natural log 
transformed scale of the PSA measures. We regressed individual log [PSA-1] as a 
function of time (years to diagnosis/exit).   This transformation improves the distribution 
of the data, allows a realistic linear assumption of the time–PSA relationship and 
represents PSA change over time as an annual percent change instead of an absolute 
change, replaces the observed  linear-exponential relationship by linear-linear and 
simplifies derivation to allow for a single growth rate for all years post the accelerating 
point.  We also used this model in two stages as follows.  
a. We started with an initial model that allowed the same trend for all groups. We 
modeled a linear-linear multiphase model with unknown continuous change point. 
Fixed and random effects were included to estimate the mean, and allow for 
individual variation on the intercept, 1st and 2nd phase time coefficients and the 
transition point.  The full mixed-effect model for log PSA is described in 
appendix 1.  Again, the most parsimonious model was determined by backwards 
elimination of non-significant terms. The cancer groups exhibit a significant 
second time coefficient not significant in the no-cancer group.   
 
b. We then proposed the reduced model describe growth of log (PSA + 1) as a 
function of time to exit while adjusting for all potential confounders allowing 
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a transition to an exponential phase among the cancer groups only. The 
reduced mixed-effect model for log PSA is described in appendix 1.   
In both models (liner-exponential and linear-linear), we assumed the transition 
from one phase to another to be continuous so that even though there is a shift in 
function, the changeover to the new section is steady and incremental . PSA change over 
time was estimated by taking the 1st derivative of the final equation in each model.  The 
models included a time variable, main effects of baseline characteristics, and 
corresponding interactions with the time variable. The time variable corresponded to 
slope, and the interaction of time with baseline characteristics corresponded to the 
association of these characteristics with PSA slope.   
Results: 
Cohort demographics:  
The baseline characteristics among the three groups comprising the cohort are 
illustrated in Table 4.1,   chi-squared tests for association and two-sided t-tests are used 
for statistical comparisons.  Men with a diagnosis of PrCA (both high- and low-risk) 
compared with healthy men were older at baseline. They also had fewer years of follow-
up, higher PSA measure at baseline, slightly fewer PSA measurements per person and 
had a shorter period between their last PSA test and study exit. AAs and those with a 
family history of PrCA were more likely to be diagnosed with PrCA compared to non-
AAs or those without a family history. The two cancer groups were comparable with 
respect to all of these variables. However, men in the low-risk cancer group had shorter 
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duration of follow-up and shorter time between the last PSA and exit day as compared to 
men in the high-risk cancer group.  
Description of PSA changes over time: Figure 4.2 illustrates the observed 
trajectory of the three groups separately.  The observed patterns are consistent with past 
studies. For men in the no-cancer group, we observe a linear trend with a slightly 
increasing pattern. A similar linear pattern is observed among the two cancers groups, but 
only during the initial years of follow-up. In the low-risk cancer group, an inflection takes 
place around 2-3 years before diagnosis; as we move closer to the date of cancer 
diagnosis, the PSA values seem to increase in an accelerating pattern.  This linear-
exponential pattern is more pronounced among high-risk cancer patients. In the high-risk 
group, the inflection point leading to exponential pattern seems to take place much 
earlier, around 4-5 years before diagnosis.  Table 4.2 reports the unique change point 
statistics for the two cancer groups estimated from the final reduced models.  
Table 4.3 summaries PSA change/rate over time using different methods, the first 
method is the commonly used traditional formulas for PSAV, and the other methods are 
derived from our proposed model. The first estimate, arithmetic velocity is estimated 
using the arithmetic equation(1/(𝑛 − 1)) ∗ (∑ (𝑝𝑖 − 𝑝𝑖−1)/(𝑡𝑖 − 𝑡𝑖−1))
𝑛
𝑖=1 , where n = 
total number of PSA tests, p = PSA value, t = time at PSA test.  The other four measures 
were estimated by taking the 1st derivative of our reduced adjusted models and 
computing PSA rate before and after the change point separately.  Men who were 
diagnosed with high-risk PrCA have a statistically significant higher estimate of absolute 
PSA change over time across different methods of estimation. The annual percent (%) 
rate is higher among men who developed PrCA but comparable between high-risk and 
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low-risk PrCA. PSA annual change estimated by our models illustrates a narrower 95% 
CI (less variability around the mean values). Also, no other traditional method can 
capture the 2nd order effects that become evident when PSA growth begins to accelerate 
past the change point; this might be crucial to differentiate high-risk PrCA from low-risk 
PrCA.  
The relationship with baseline measurements:  
We examined the effect of age, race, BMI and PSA at baseline on the PSA rate of 
change by including an interaction term between each of these variables with time in each 
phase separately. Table 4.3 illustrates the parameter estimates corresponding to all 
interaction terms. Values are adjusted for all other variables in the table. Older men (≥65 
years) have higher absolute rate of change when compared to younger men.  The 
interaction term between BMI and time was not significant, suggesting that BMI did not 
have a significant association with PSA change with time.  AA and non-AA had 
comparable PSA rate of change.  PSA at baseline seems to be the most influential factor; 
those with higher PSA value at baseline had slower change with time.   
 PSA rate of change as annual percent change seemed to be more sensitive to race. 
AA had a higher PSA % change when compared to non-AA by 0.35% before the change 
point. Older men seem to have higher PSA % change as compared to those younger only 
before the change point. Also, as part of the design, the models test the association of the 
baseline characteristics on single PSA measure (mainly the PSA value at the change 
point, for those who had a change to exponential phase and the PSA at the exit point for 
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those who did not). AAs, older men, and those with higher PSA levels at baseline had 
higher PSA values at the exit/change point. Men with higher BMI had lower PSA values.  
 PSA growth curves across age, race and study groups:  
We used the 1st derivative of the linear-exponential model equation and the 
linear-linear model equation to calculate PSA change rate and annual % of PSA change 
respectively  at 1 year before exit; tables 4.5. These rates are illustrated for all study 
groups, stratified by age and race and adjusted for a baseline distribution of BMI and 
initial PSA value of 1.3 ng/ml. The absolute PSA rate among men in the high-risk 
cancer group appears to be significantly greater compared to no-cancer and low-risk 
groups. The annual percent (%) rate is higher among men who developed PrCA but 
comparable between high-risk and low-risk groups.  Figures 4.4 to 4.6 illustrate the 
estimated PSA growth curves across the three study  groups stratified by race and age.   
 Discussion: 
We used non-linear and linear mixed effect models to describe longitudinal data 
on PSA change among men who were diagnosed with high-risk PrCA, low-risk PrCA or 
not diagnosed with PrCA. To describe the absolute PSA change over time, we used a 
linear-exponential piecewise model.  To describe the annual relative (percentage) change 
we used a linear-linear piecewise model. In both sets of analyses, we selected the most 
parsimonious model that fit the data best. All models included random components which 
enable the models to account for natural heterogeneity between individuals due to 
random factors affecting PSA measures, natural (benign) PSA change with time, time of 
diagnosis, transition time and the progression of the tumors.  We accounted for multiple 
 62 
baseline factors that can explain some variability in PSA change over time. Across all 
groups of age, race, BMI and initial PSA, patients who ultimately were diagnosed with 
high-risk PrCA seem to represent a distinct PSA profile starting as early as 4-5 years 
prior to date of diagnosis when compared to those who did not have high-risk PrCA. Both 
cancer groups demonstrated an inflection in PSA trajectories, changing from a linear 
pattern into an exponential one; however, our findings suggest that low-risk cancer has 
less aggressive progression and a change time closer to the time of diagnosis than high-
risk cancer. These findings were consistent when considering both absolute and relative 
(expressed as a percentage) PSA change across time .When examining rate of PSA 
change 1 year prior to exit, we found men in the high-risk cancer group to have much 
higher absolute PSA change rate when compared to those in the other two groups, not 
only on average but across almost 99% of the distribution within each group.  
Several studies have examined PSA change over time; almost all studies reported 
the same pattern. Carter et al. [16] Pearson et al. [72] and Inoue. et al. [73] described the 
PSA pattern among multiple longitudinal studies using the non-linear mixed model 
approach. Similar to our results, they reported a transition time at which PSA starts to 
accelerate among individuals who developed PrCA. They also reported higher and earlier 
progression among those who were diagnosed with metastatic disease as compared to 
local disease.  The vast majority of PSAV studies did not consider this pattern of 
differential PSAV quantification by risk of PrCA. Furthermore, the various studies used 
differing formulas to compute PSAV. The range of the values we report here is within the 
range of previously reported values for PSA velocity and PSA annual percent change.   
The previously suggested thresholds of 0.4 ng/ml/year and 0.75 ng/ml/year to distinguish 
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high virulent PrCA are within the lower range of value we reported for men in the high-
risk cancer.   
Multiple researchers have reported that the inflection point represents a clinical 
change from the slow gradual expansion of prostatic epithelial volume due to normal 
prostate age-related growth to a rapid increase of peripheral PSA due to rupture in the 
prostate basement from significant tumor growth [72].  The two extremes are connected 
through an interval at which the malignant tumor is initiated but its contribution to 
peripheral PSA level is still minimal due to its small initial size and relatively intact 
prostate capsule [16, 72, 73, 108] 
We found several significant associations of baseline characteristics with PSA 
relative and absolute change over six years.  Age, race, and initial PSA were associated 
with single PSA and slightly modified PSA change over time while BMI was inversely 
associated with single PSA but was not significantly associated with PSA change over 
time. Older men tend to have higher PSA measurements that tend to increase at a higher 
rate. Men with higher PSA at baseline tend to have higher rate and continued to have 
higher PSA at the exit or change point. We observed a qualitative difference by race, but 
this did not reach statistical significance.  These results are consistent with results from 
previous studies.  Several studies have reported the inverse relationship between BMI and 
mean PSA [83, 112-114].  However, the influence of BMI on PSA change is not as 
evident.  Kristal et al. [113] reported an inverse association between BMI and PSA 
measures, and no association with PSAV.  A few studies have reported significant 
association between BMI and both PSA and PSA change [112, 114]. All of these studies 
suggest that the effect of BMI on PSA is due to a hemodilution effect, that is, the dilution 
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of PSA by increased plasma volume. Many studies reported that AAs present with higher 
PSA serum when diagnosed with PrCA [115].  However, few studies investigated the 
effect of race on PSA change. Sarma et al. [115] reported that the annual percent change 
in PSA among AAs was approximately twice as great at that of white men.  Also, Kristal 
et al. [113] and McGreevy et al. [116] described a more rapid change of PSA with age 
among AAs when compared to with whites and other race/ethnic groups. The magnitude 
of differences in PSA change across racial and age groups and the influence of initial 
PSA range from weak to modest, thus these characteristics do not seem to highly affect 
the clinical interpretation of PSA rate.  
Many previous studies investigated PSA change in relation to prostate cancer. 
Many have tried to use this concept to predict prostate cancer. While almost all studies 
reported clear distinct summary statistics (mean and median) for PSAV and PSA 
doubling time among those who ended up with PrCA when compared to those who did 
not, they also reported high intra-individual variability within the comparison groups 
(cancer and no cancer) . This natural intra-individual variability (random error, or 
“noise”) between multiple PSA measures made it difficult to find a threshold that can 
improve PrCA prediction and raised a considerable concern about the concept of PSA 
change and its clinical implications.  We are one of the few to report a clearly distinct 
range of calculated rates when considering high-risk cancer as compared to the low-risk 
cancer and no-cancer groups. Most past studies estimated the individual velocities using a 
linear model (mostly one phase and sometimes 2 phases) within a narrow time frame, 
using few PSA measures in close intervals. We built our analysis on Carter et al.’s work 
that was the first to propose the concept of PSA change. In their original work, Carter et 
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al. suggested a piecewise linear-exponential model to best describe the natural history of 
PrCA and to best quantify PSA change among those who ended up with PrCA. We used 
an appropriate method to calculate PSA rate of change at a given time using flexible 
models that did not assume a monotonic rate of change, used  5-6 PSA measures taken 
annually across a time frame of 1-14 years prior to exit, accounted for baseline 
characteristics and had a large enough sample size to control for within-individual 
variations. We believe that quantifying PSA growth in such a fashion allows for a 
rigorous definition and calculation of PSAV that captures what Carter et al. describe as 
“PSA velocity is the PSA variability corrected for the elapsed time between 
measurements”.   
Our study has some limitations worth noting. First, this is a retrospective analysis limited 
by the cohort characteristics of men participating in the PLCO study. The cohort has a 
limited number of young men and AAs. Including men at younger age and a higher 
representation of AAs would have strengthened our analysis. Second, the PSA measures 
were collected over the first six years of enrolment and follow-up continued for up to 14 
years, leaving a gap of up to 3-7 years of unknown PSA measures.   This gap period was 
significantly longer among men with no evidence of PrCA, and that may have introduced 
some bias. However, given the clear slow linear pattern of PSA change in this non-cancer 
group, it is unlikely that including the unknown measures would have changed our 
findings. Third, our calculated velocities might be sensitive to the proposed piecewise 
model. It could be that lower rates among the no-cancer group are underestimated by the 
linear model that was used for this group. However, to keep the estimated velocities 
independent of any pre-assumed pattern, we conducted a sensitivity analysis in which we 
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used our first full model to estimate PSA rate of change.  In this way, we allowed all 
individuals to either deviate into an exponential pattern or stay in a linear pattern, 
depending on what fit their observed PSA better. The calculated PSA rates did not 
change, and the magnitude of the differences between the three groups remained the 
same.  Fourth, information bias and misclassification is a threat. This is especially the 
case among the non-cancer group who did not have a biopsy to confirm their non-cancer 
status.  We limited this bias by restricting our analysis to only those with biopsies or 
those that never had a positive screening or if ever had positive screening were followed 
with a diagnostic follow-up procedure that confirmed their outcome status. Finally, those 
with fewer than 3 PSA measurements in addition to those who were lost during the 
follow-up might have lower or higher PSA measurements and might be of lower or 
higher risk of developing PrCA making our findings prone to selection bias. 
This PSA growth model is a real mathematical representation of the natural history of 
PrCA and thus shows clear differences of PSA rates among those who were diagnosed 
with high-risk PrCA when compared to low-risk PrCA and no-cancer groups. Our main 
finding is that PSA change rates in men in the low-risk cancer group and those with no 
cancer overlap across different age and race groups while those who were subsequently 
diagnosed with high-risk PrCA are significantly different. Moreover, this clear distinction 
takes place within a window of time relevant to early detection and can be measured and 
captured at least three years before diagnosis. These growth models can be used to solve 
the main problems of single PSA screening and have high clinical relevance. 
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Tables and figures:  
Men randomized to the 
intervention arm in the 
PLCO study (1993-2001) 
38,340 unique men  
 
 Exclude men with: Less than 
50 or greater than or equal to 75 
years of age at the time of 
randomization, prior cancer of 
the colon, rectum, lung, 
prostate, previous surgical 
removal of the entire prostate 
(prostatectomy), males who had 
more than one PSA blood test 
in the three years prior to 
randomization  (-6961) 
Meet the original PLCO 
inclusion criteria 
 
31,379  
 25,505 Exclude men with less than 4 
PSA measurements (-5,874)  
 
 25,292 Exclude men who were lost of 
follow up or refused to continue 
in the study before complete 
outcome assessment (-213) 
 
 
 
21,159 Exclude men with BPH at 
baseline (-4133) 
 21,113 Exclude men with suspicious 
screening results that do not 
have correspondent complete 
diagnostic procedures and final 
results (-46) 
 
Final analytical cohort  20, 888 Exclude men with  Missing 
information on baseline BMI (-
225)  
 
Figure 4.1 PLCO cohort selection tree 
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Table 4.1 Characteristics of PLCO participants by study groups (n=20,888)  
 
 Men with no 
cancer  
(19,196) 
Men with LRC* 
(1368) 
Men with 
HRC**(324) 
Comparison (p-value for 
difference between study 
groups by characteristic) 
Race, n(%)   NC*** 
vs. LRC 
NC*** 
vs. HRC 
LRC*** 
vs. HRC 
African American  742 (90.05) 62 (7.52) 20 (2.43) 
0.098 0.03 0.2 
None-African Americans  18454 (91.98) 1306 (6.51) 304 (1.52) 
Ethnicity, n (%)  (missing=606)   
0.32 0.88 0.74 non-Hispanic  18203 (91.84) 1310 (6.61) 308 (1.55) 
Hispanic 428 (92.84) 26 (5.64) 7 (1.52) 
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Family history, n(%)  (missing=144)  
<0.001 <0.001 0.33 
No  17773 (91.33) 1225 (7.06) 284 (1.62) 
Yes, immediate family member  1291 (87.09) 132 (9.96) 39 (2.94) 
Age, n (5)   (years)    
<= 55, n=2,228  2096 (94.08) 107 (4.8) 25 (1.12) 
0.0004 0.006 0.34 55-65, n= 13,658  12560 (91.96) 898 (6.57) 200 (1.46) 
>65, n=5002  4540 (90.76) 363 (26.54) 99 (1.96) 
       Mean  (95% CI) 61.42 (61.34-
61.49) 
62.21 (61.96-
62.46) 
62.73 (62.17-
63.29) 
<0.001 <0.001 0.08 
BMI, n (%)       
<= 30 kg/m2            14431 (91.58) 1068 (6.78) 258  (1.64) 0.016 0.0655 0.5399 
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>30 kg/m2                   4765 (92.87) 300 (5.85) 66    (1.29) 
Mean  (95% CI) 27.75 (27.67-
27.81) 
27.34 (27.14-
27.54) 
27.63  (27.22-
28.05) 
<0.001 0.6 0.20 
PSA at baseline (ng/ml)  
 mean/median (95% CI) 
1.05 /1.06 
   (1.04-1.06) 
2.51 /2.16 
 (2.42-2.59) 
2.91 /1.94 
(2.37-3.46) 
<0.001 <0.001 0.14 
Years of follow up  (years) 
mean/median (95% CI) 
11.49 /11.51 
(11.46-11.52) 
7.52/7.47  (7.37-
7.66) 
8.24 /7.85 
(7.54-8.16) 
<0.001 <0.001 0.053 
Number of PSA tests  
mean/median (95% CI) 
5.59 /6.00 
(5.58-5.60) 
5.28 /6.00 (5.24-
5.33) 
5.21 /5.00 
(5.12-5.30) 
<0.001 <0.001 0.16 
Years  from last PSA to exit or 
diagnosis  mean/median (95% CI) 
6.56/7.17 
(6.54-6.59) 
2.92/2.57 (2.79-
3.04) 
3.36 /3.32 
(3.07-3.64) 
<0.001 <0.001 0.005 
*LRC: Low-risk prostate cancer                                    **HRC: high-risk prostate cancer                                           ***NC: No Cancer 
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The figures illustrate a transition time at which PSA start 
to accelerate among individuals who developed prostate 
cancer.  
We also observe higher and earlier progression is 
apparent among those who were diagnosed with high-
risk disease as compared to the low-risk cases.  
 
 
Figure 4.2 Longitudinal trajectories of PSA for all PLCO participants by study group  
 No evidence of prostate 
cancer 
 Low-risk Cancer 
 High-risk Cancer 
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Table 4.2 Change point mean and median by study groups 
 
Model Outcome Function Change point  summary 
A
n
n
u
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S
A
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P
S
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n
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Group Mean  
(95% CI) 
Median 
 (25th ,75th ) 
Low-risk prostate 
cancer 
2.58 
 (2.58, 2.58) 
2.62( 
.31,3.02) 
High-risk prostate 
cancer 
5.21 
(4.85,5.58) 
5.24 
(4.75, 5.59) 
A
n
n
u
al
 %
 P
S
A
 r
at
e 
m
o
d
el
 
L
o
g
 P
S
A
 
L
in
ea
r-
li
n
ea
r 
Low-risk prostate 
cancer 
2.00 
(2.00,2.00) 
2.00 
(2.00,2.00) 
High-risk prostate 
cancer 
3.96 
(3.61,4.31) 
3.96 
(3.70,3.97) 
  
Table 4.3 PSA rate over time (velocity) in three study groups estimated by different 
methods 
 
Method  Men with 
NC**(1919
6) 
Men 
with 
LRC*** 
(1368) 
Men 
with 
HRC****
(324) 
Comparison (p-valued 
for difference between 
study groups) 
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 mean  
(95% CI) 
NC vs. 
LRC 
NC 
vs. 
HRC 
LRC 
vs. 
HRC 
Arithmetic velocity* 
(ng/ml/year) 
0.06   
(0.06-0.07) 
0.37 
(0.34-
0.39) 
0.79 
(0.55-
1.03) 
<0.01 <0.01 <0.01 
Annual rate  before 
change point 
(ng/ml/year) 
0.05  
(0.05-0.05) 
0.16 
(0.15-
0.17) 
0.13  
(0.11-
0.16) 
<0.01 <0.01 0.21 
Annual rate  after 
change point (1 years 
before diagnosis)  
ng/ml/year  
0.05 
 (0.05-
0.05) 
0.59 
(0.52-
0.66) 
2.60 
(2.11-
3.09) 
<0.01 <0.01 <0.01 
Annual % PSA rate  
before change point   
1.63 
(1.57-1.68) 
5.56 
(5.33-
5.78) 
5.06 
(4.54- 
5.57)  
<0.01 <0.01 0.31 
Annual % PSA rate 
after change point  
1.63 
(1.57-1.68) 
10.85 
(9.02-
12.68)   
12.10 
(10.3-
14.17) 
<0.01 <0.01 0.09 
* using the arithmetic equation𝑃𝑆𝐴𝑉 = (1/(𝑛 − 1)) ∗ (∑ (𝑝𝑖 − 𝑝𝑖−1)/(𝑡𝑖 − 𝑡𝑖−1))
𝑛
𝑖=1 , 
where n = total number of PSA tests,  p = PSA value, t = time at PSA test. 
** NC:No cancer                                                *** LRC:Low-Risk Prostate cancer  
****HR:High-risk Prostate Cancer 
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Table 4.4 Associations between baseline characteristics and PSA trajectory, reporting the 
coefficient estimate in the final reduced models 
 
 PSA rate 
before CP*  
%PSA change 
before CP   
PSA rate 
after CP  
%PSA rate  
after CP   
Single 
PSA 
Age       
≤55 Referent     
55-65 0.005 (0.19) 0.13% (0.12) -0.051 
(<0.001) 
-1.42% 
(0.32)  
0.11 
(0.009) 
 65≥  0.009 (0.01) 0.20% (0.04) 0.041 
(0.005) 
-1.03% 
(0.50) 
0.21 
(<0.001) 
BMI       
<=30 Referent     
>30 0.001 (0.22) 0.10% (0.23) 0.001 
(0.91) 
0.10% 
(0.71) 
0.03 
(<0.001) 
Race       
Non-African 
Americans 
Referent      
African 
Americans  
0.007 (0.22) 0.35% (0.01)  0.005 
(0.78) 
2.42% 
(0.14) 
0.07 
(0.27) 
Initial PSA  -0.003 
(<0.001) 
-0.60% 
(<0.001) 
0.004 
(0.005) 
1.36% 
(<0.001) 
0.85 
(<0.001) 
CP= change point  
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Table 4.5a Estimated annual  PSA rate of 1 year prior to exit stratified by race, age and study groups  and fixed at baseline BMI of 25 
and initial PSA of 1.3 
 
Race Age  Group  Mean  (95%CI)   Median  25TH 
Percentile 
 75th 
percentile  
Non-
African 
American 
Youngest  
(≤55) 
No cancer  0.05 (0.04, 0.05) 0.04 0.02 0.06 
Low-risk cancer  0.65 (0.53,0.77) 0.69 0.58 0.88 
High-risk cancer  2.82 (2.08,3.56) 1.95 1.63 3.57 
Middle 
(55-65)  
No cancer  0.05 (0.05,0.05) 0.04 0.02 0.07 
Low-risk cancer  0.47 (0.41,0.54) 0.55 0.42 0.71 
High-risk cancer  2.10 (1.65,2.54) 1.88 1.25 2.68 
Older  
(65≥) 
No cancer  0.06 (0.05,0.06) 0.04 0.02 0.07 
Low-risk cancer  0.92 (0.79,1.06) 1.07 0.81 1.40 
High-risk cancer  4.30 (3.50,5.11) 4.21 2.88 6.33 
Youngest   No cancer  0.05 (0.04,0.07) 0.04 0.03 0.05 
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Africans 
American 
(≤55)  Low-risk cancer  0.69 (0.50,0.88) 1.21 0.81 1.26 
High-risk cancer  3.04 (2.04,4.05) 1.90 1.89 1.91 
Middle 
(55-65)  
 No cancer  0.06 (0.05,0.07) 0.04 0.03 0.07 
Low-risk cancer  0.51 (0.36,0.65) 0.70 0.50 0.94 
High-risk cancer  2.26 (1.60,2.93) 2.50 1.75 3.71 
Older  
(65≥) 
No cancer  0.06 (0.05,0.07) 0.04 0.03 0.07 
Low-risk cancer  0.98 (0.73,1.22) 1.00 0.78 1.54 
High-risk cancer  4.62 (3.28,5.95) 3.82 2.11 4.09 
 
Table 4.5b Estimated annual % PSA rate 1 years prior to exit stratified by age, race, study group and fixed at baseline BMI of 25 and 
initial PSA of 1.3 
 
Race  Age  Group  Mean (95%CI)   Median 25T Percentile  75th percentile  
Non-
African 
Youngest  
(≤55) 
No cancer  1.48% (1.32%, 1.64%) 11.91% 10.62% 13.77% 
Low-risk cancer  11.67% (8.96%, 14.38%) 12.20% 11.25% 13.60% 
  
7
7 
America
n  
High-risk cancer  12.91% (10.01%, 15.81%) 13.21% 11.34% 15.39% 
Middle 
(55-65)  
No cancer  1.61% (1.55%, 1.68%) 11.88% 10.39% 13.76% 
Low-risk cancer  10.53% (8.64%, 12.42%) 11.52% 10.25% 13.07% 
High-risk cancer  11.79% (9.66%, 13.91%) 12.56% 10.81% 14.37% 
Older  
(65≥) 
No cancer  1.68% (1.57%, 1.78%) 11.87% 10.39% 13.76% 
Low-risk cancer  10.93% (8.61%, 13.26%) 11.81% 10.53% 13.33% 
High-risk cancer  12.18% (9.68%, 14.68%) 12.80% 11.08% 14.18% 
African 
America
ns  
Youngest  
(≤55) 
 No cancer  1.82% (1.53%, 2.12%) 11.85% 10.62% 13.25% 
 Low-risk cancer  14.11% (10.31%, 17.91%) 15.55% 14.43% 17.81% 
High-risk cancer  15.31% (11.52%, 19.10%) 9.36% 4.67% 14.04% 
Middle 
(55-65)  
 No cancer  1.96% (1.70%, 2.21%) 11.72% 10.33% 13.53% 
Low-risk cancer  13.00% (9.62%, 16.39%) 13.92% 12.75% 15.88% 
High-risk cancer  14.22% (10.87%, 17.57%) 15.93% 10.33% 20.55% 
Older  
(65≥) 
No cancer  2.02% (1.75%, 2.29%) 11.80% 10.46% 13.90% 
Low-risk cancer  13.40% (9.78%, 17.01%) 15.77% 13.52% 17.58% 
  
7
8 
High-risk cancer  14.61% (11.04%, 18.18%) 13.64% 4.26% 13.91% 
 
 
 
Figure 4.3 Predicted PSA growth curves by study group 
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Figure 4.4 Predicted PSA growth curves by study group and age 
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Figure 4.5 Predicted PSA growth curves by study group and race 
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CHAPTER 5 
 
Prostate Specific Antigen Rate Predicts High-Risk Prostate Cancer in a Large 
Perspective Screening Trial 2 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
2 Shoaibi , A., Rao, G., Cai, B., Rawl, J., Hebert, J.. Prostate Specific Antigen Rate Predicts High-Risk Prostate Cancer 
in a Large Perspective Screening Trial. To be submitted to the Journal of American Medical Association  
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Introduction:  
Because of its relatively high incidence, coupled with large racial disparities in 
virulence Prostate cancer (PrCA) [25] , represents a major public health challenge in the 
United States. The unique combination of high incidence but low virulence lies at the 
heart of this challenge [1] .  Although the incidence and mortality rate varies by age and 
race, the overall lifetime risk of PrCA is approximately 16% and the life time risk of 
death is between 2 to 3.4% [1] . The value of prostate specific antigen (PSA) in PrCA 
detection remains a controversy. A single PSA measurement is known to have high 
sensitivity but poor specificity; and this leads to over-detection and over-treatment of 
many individuals with indolent disease [117] . A reliable screening for PrCA is needed, 
because PrCA can still be aggressive, especially among African Americans and younger 
men.  
To improve the performance of PSA-based screening, multiple studies proposed 
the use of PSA change over time (PSA kinetics or PSA velocity(PSAV)) [83]. The 
natural serum PSA levels show a more rapid change in PrCA, and PSA velocity is 
recommended for monitoring the disease progression [118]. Carter et al. [16]  proposed 
the concept of using PSA kinetics for PrCA screening in1993, but we still don’t have 
consistent results confirming or refuting this application of PSA kinetics. In a recent 
systematic review, Loughlin [83] defined several problems in the PSA kinetics literature. 
He showed that many studies on this topic do not conform to the original definition to 
PSAV and the guidelines concerning the number of PSA tests and the interval of time 
between these tests. The original description of PSAV by Carter  et al. [16] was based on 
a non-linear mixed model with multiple measures of PSA (at least 4) over a long period 
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of time. In our previous unpublished observations [119], we replicated Carter’s work 
using the data from the Prostate Lung Colorectal and Ovarian Cancer (PLCO) [21]  study 
cohort. We used a flexible piece-wise model with a linear and exponential phase in a 
manner similar to what Carter had originally proposed to establish PSA growth curves 
and estimate PSA annual rate 2 and 1 years prior to the study exit. We found that men 
who developed high-risk prostate cancer had a distinct pattern of PSA change over time 
(PSA growth curve) both qualitatively and quantitatively.  
In this paper we focus on the differences between men who developed high-risk 
prostate cancer and those who did not. This latter group includes men with low-risk 
prostate cancer, men with benign hyperplasia (BPH) and men with no evidence of BPH 
or PrCA. These analyses are focused on answering the following research question:  Can 
PSA change over time (in magnitude and direction) be used to differentiate high-risk 
PrCA from any other condition that could be related to an increased PSA measure at any 
particular point in time and across different populations?  
We first tested the hypothesis that that the calculated PSA rate 2 and one year 
prior to diagnosis is highly associated with high-risk PrCA; and that this is above and 
beyond the association with a single PSA measurement. Second, we evaluated whether 
the calculated PSA rate accurately detects high-risk prostate cancer and distinguishes 
these cases from any other outcome. 
The definition of high-risk PrCA was based on tissue evaluation through biopsy 
or surgical samples, or both. We followed the prognostic classification of PrCA 
introduced in 2010 by American Joint Committee on Cancer (AJCC) [90] who 
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considered a PrCA meeting any of the following criteria as a disease with high clinical 
risk; PSA level ≥ 20ng/ml, cancer that invades prostate capsule, PrCA that involves more 
than one lobe, or Gleason score >7. The overwhelming evidence of the individual and 
public harm associated with over-detection and over-treatment of indolent prostate cancer 
provides the rationale behind our focus on high-risk prostate cancer. The increased 
detection of low-risk prostate cancer by a single PSA testing is the foundation of the 
controversy that led to the current recommendations against PSA-based screening. 
Studies suggest that the main harm of PSA testing is the hazardous treatment of many 
latent prostate cancers, many of which may never have  led to harm [120]. Consequently, 
we aim to evaluate the predictive value of estimated PSA growth curves and their derived 
PSA annual rate to distinguish high-risk prostate cancer from anything else among a 
screened population of men 50-75 years of age.  
 Methods:  
Study population:  We conducted a case-control study nested within the PLCO 
trial. The PLCO Participants were men and women (ages 50–74) recruited from ten 
centers in the United States (Birmingham, AL; Denver, CO; Detroit, MI; Honolulu, HI; 
Marshfield, WI; Minneapolis, MN; Pittsburgh, PA; Salt Lake City, UT; St Louis, MO; 
and Washington, DC). For the PrCA screening component, men were enrolled between 
November 1993 and July 2001. We conducted our analysis on 38,340 men who were 
randomized into the screening arm. These men were offered annual serum PSA screening 
tests and digital rectal examination (DRE) for 6 and three years respectively. Men with a 
P and SA test result >4 ng/ml, or a DRE exam suspicious for prostate cancer were 
referred to their medical-care providers for a diagnostic workout and follow-up. Outcome 
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data was collected through annual mailed follow-up questionnaires, and medical and 
pathologic records related to diagnostic follow-up of prostate cancer were obtained by 
study personnel from medical providers. Linkage to the National Death Index was also 
conducted, and death certificates and medical and pathology records related to death were 
obtained. Data were collected on cancer diagnoses and deaths from all causes that 
occurred through December 31, 2009 or up to 13 years from trial entry, resulting in a 
median follow-up time of 12.4 years.  
For this prostate cancer nested case-control set, we included all men who were 
randomized to the screening arm and complied with receiving at least 4 PSA screening 
tests. We initially categorized men into 4 groups; men who developed high-risk PrCA, 
men who developed low-risk PrCA, men who were diagnosed with BPH during the 
follow-up and men with no evidence of PrCA or BPH diagnosis. We retrospectively 
followed men in the four groups and estimated their individual PSA growth curves using 
PSA measures from enrolment date to exit date (diagnosis of PrCA for men in the cancer 
groups, or end of the follow-up for men in the no cancer groups). We then used the PSA 
growth curves equation to calculate PSA annual rate of change 1 and two years prior to 
exit. To avoid misclassification bias we excluded 3 types of participants; those who were 
reported to have a cancer outcome that was not confirmed; those who were classified as 
non-responsive (refusal to continue with study activities or loss of contact) without 
outcome assessment; and those who did not have complete diagnostic follow-up 
information in response to a positive screen (PSA above 4ng/ml or a suspicious DRE 
examination result). We also excluded men who reported ever to have been diagnosed to 
have BPH at baseline. Men who were diagnosed with BPH during the follow-up and did 
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not develop prostate cancer were included in the BPH group; those who had a diagnosis 
of BPH and prostate cancer were classified as prostate cancer. Finally, we excluded data 
from men with missing information on BMI at baseline (is this is an important covariate 
in analyses). Figure 4.1 shows the analytical cohort tree and the resulting four cancer 
status groups (analysis group).  
Statistical methods: A non-linear mixed regression approach was used to establish 
individual and mean PSA growth curves and to estimate summary statistics of PSA 
annual rate of change. The details of our non-linear mixed model are described elsewhere 
[119]. In brief, a linear exponential piece-wise function was used with unknown 
continuous transition and random effect on the intercept, linear coefficient, exponential 
coefficient and the inflection point. Cancer status group (analysis group), age, race, PSA 
at baseline and body mass index were all included as main covariates. To allow for PSA 
rate to vary by cancer status group, age, race and PSA at baseline, interaction terms 
between time and all of these factors also were included. To estimate the growth curves 
independent of the cancer status, the linear exponential piece-wise function was used 
regardless of the cancer status group. The random effects for the inflection point and the 
time coefficient allows individual-level variability so that every individual can have the 
best fit line for his own observed PSA measure. It follows that those with constant linear 
pattern (as expected for men in the no-cancer groups) had individual estimates of an 
inflection point that was very close to zero (or not different from zero), effectively 
making their estimated PSA growth line to one linear phase. PSA was used in the model 
is in its natural scale; therefore PSA rate or velocity (PSAV) was represented by annual 
change (ng/ml/year). PSA individual rates were calculated at 1 and two years prior to exit 
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by taking the 1st derivative of the estimated mean model function and adding the 
individual effects. 
A Cox proportional hazards model was used to estimate the association between 
PSA annual rate and the risk to high-risk prostate cancer. We started with a reduced Cox 
model that included age, race, family history, BMI, smoking and single PSA measure to 
predict high-risk prostate cancer. Since we have multiple PSA measures per men, we 
used the value of closest PSA result to the exit date (i.e., the last PSA screening test 
result). We then fit a full model that included the estimated PSA rates in addition to all 
other covariates (including last single PSA measure), we reported the Hazard Ratio (HR) 
of PSA rate, while adjusting for PSA single measure and compared the goodness-of-fit 
statistics of the reduced model to those from the full model.  
The sensitivity, specificity, area under the curves (AUC) and ROC and their 95% 
CI for predicting high-risk prostate cancer were estimated for PSA annual rates. We 
included both PSA annual rate and a single PSA measure in the logistic model and 
constructed the two ROC curves for comparison; we reported the difference in the AUC 
between the two curves and the adjusted 95% confidence intervals with p-value. 
Results:  
Table 5.1 describes baseline characteristic of the analytical cohort and the four 
analysis groups. The Chi-square test and t-test, for categorical and continuous variables, 
were used to test for statistical differences between different groups. Of the total 
analytical cohort (20,888 men); 1,386 (6.55%) men were diagnosed with low-risk 
prostate cancer, 324 (1.55%) men were diagnosed with high-risk cancer, 7,813 (37.40%) 
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men were diagnosed with BPH and 11,383 (54.50%) men were right censored from the 
study for reaching end of follow-up without evidence of BPH or PrCA. Thus, the overall 
incidence of prostate cancer was 8.10%, and almost 19.00% of these cases were classified 
as high-risk prostate cancer. African Americans (AA) accounted for 3.49% of the total 
analytical cohorts. African Americans were more likely to be diagnosed with prostate 
cancer as compared to other races. Also, 24.39% of the PrCA cases among African 
Americans were classified as high-risk cancer compared to 18.88% among men of other 
races, the difference was not statistically significant. Men with BMI higher than 30kg/m2 
were 24.56% of the total cohort, and they were not at higher risk of prostate cancer or 
BPH. Men with family history of prostate cancer in a first-degree relative (7.69% of the 
total cohort) were at higher risk of prostate cancer when compared to those without. 
Older men were more likely to have cancer. African Americans, men with family history 
of prostate cancer in a first-degree relative and those above 65 years of age were at higher 
risk of being diagnosed with high-risk prostate cancer (as opposed to not) . PSA at 
baseline was the lowest among men in the no-cancer group (1.28ng/ml (95% CI 1.26-
1.30)) and slightly higher among the BPH group (1.32ng/ml (95% CI: 1.29-1.35)). Men 
in both cancer groups had comparable PSA at baseline; 2.51ng/ml (95% CI: 2.42-2.59) in 
the low-risk and 2.88ng/ml (95% CI: 2.34-3.42) in the high-risk cancer group. The 
median follow-up time was the longest among men in the BPH group at 12.49 years, 
while those in the no-cancer group had a median follow-up of 11.62 years. The follow-up 
time for the cancer groups was significantly lower at 7.49 years in the low-risk group and 
8.26 years in the high-risk cancer group. The median number of PSA tests was 6.00 
across no-cancer, BPH and low-risk cancer groups and 5 in the high-risk cancer. Men in 
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the low-risk cancer group had the lowest number of years between last PSA screening 
test and the day of diagnosis (gap period)  with a median of 2.63 years; men in the high-
risk cancer group had a longer median follow-up period of 3.33 years. Men in the no-
cancer group had the longest gap period; of 6.75 years.  
Figure 5.1 and 5.2  illustrate the mean PSA growth curve as estimated by the non-linear 
mixed model among different strata of race, age and study group combination. The 
adjusted mean annual rate among men in the no-cancer group was 0.06 ng/ml/year (95% 
CI:  0.053-0.061) for African Americans and 0.06ng/ml/year (95% CI: 0.053-0.059) for 
non-African Americans. The mean rate among men in the BPH group was also 0.06 
ng/ml/year (95% CI: 0.056-0.065) for African Americans and 0.06 ng/ml/year (95% CI: 
0.057-0.062) for non-African Americans. The mean linear rate among men in the low-
risk cancer group was 0.09 ng/ml/year (95% CI: 0.078-0.100) for African Americans and 
0.09 ng/ml/year (95% CI: 0.078-0.098) for non-African Americans. The mean rate 
among men in the high-risk cancer group was 0.13 ng/ml/year (95% CI: 0.096-0.156) for 
African Americans and 0.13 ng/ml/year (95% CI: 0.095-0.156) for non-African 
Americans. Among men with prostate cancer, PSA measures start to increase in an 
exponential phase, the inflection point took place during the 2 to six years prior to 
diagnosis. Men in the high-risk prostate cancer group demonstrated an earlier inflection 
point  (5.64 years prior to diagnosis) and had a higher exponential coefficient of  e^0.34  
(e^0.28-e^0.39) as compared to men in the low-risk cancer group, who had a median 
inflection point of 3 years  prior diagnosis and an exponential coefficient of e^0.16  
(e^0.11 - e^0.21). All of these estimates were adjusted for mean baseline PSA measure, 
BMI and age.  
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After the inflection point (years closer to the exit), the rate of PSA change per 
year was not constant for the cancer groups. We estimated PSA rate for 1 and two years 
prior to exit by taking the 1st derivatives of the growth curve equation in each group. 
Table 5.2 and 5.3 show the age and race-specific mean and median annual PSA rate 1 and 
two years prior to exit respectively. Overall, men who developed high-risk cancer had 
higher PSA change rates as compared to other groups, regardless of age and race. Figure 
5.2-5.7 show the box-plot of the estimated annual PSA rates for all participants and by 
different age and race strata. Panel (a) shows annual PSA rate 1 year prior to exit and 
panel (b) shows annual PSA rate 2 years prior to exit. The high-risk cancer group shows 
higher values with a slight overlap with any of the other three groups. Among African 
Americans, there is almost a complete separation.  
In a cox regression analysis, increased annual PSA rate was highly associated 
with increased high-risk prostate cancer risk in the model that adjusted for all other 
covariates including last screened PSA level. When used as a numeric variable in the Cox 
proportional hazards model, the adjusted HR for annual PSA rate (one year prior to 
diagnosis) was 1.06 (1.055-1.072). However, using a threshold of 0.371ng/ml/year, the 
adjusted hazard ratio was 3229 (1636-6370) for PSA rate one year prior to diagnosis > 
0.371 ng/ml per year versus ≤ 0.371. Once PSA rate (as a categorical variable) was 
included to the Cox model, the fit statistics improved significantly. Table 5.4 shows the 
fit statistics comparison between the reduced (using all covariates including PSA single 
test) and the full model (using all covariates, PSA single test and PSA annual rate cut-
off). 
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The sensitivity and specificity for predicting high-risk prostate cancer for selected 
cut-off points of annual PSA rate are shown in table 5.5. We ran a logistic regression for 
PSA rate at 1 and two years prior to exit separately. The 1st part of table 5.5 shows the 
results for PSA rate at one year prior to exit. We selected the thresholds that produced the 
highest area under the curve in the ROC procedures for AA, non-AA, young (≤55) , 
middle-age (55-65), old (>65) and in the overall cohort. We started with the threshold 
that produced the highest sensitivity while keeping specify above 90%. Among AA, a 
threshold of 0.22 detected 100% of the cases with a specificity of 97.8% (that also 
corresponds to the threshold with the highest area under the curve in the ROC procedure). 
Among non-African Americans, a threshold of 0.10 detected correctly 99.7% of the cases 
but with a lower specificity of 90.8%. We then selected the threshold that had the next 
highest sensitivity with the highest specificity possible. Among AA, a higher threshold of 
1.20 had a perfect specificity of 99.8% but a sensitivity of 95.0%. Among non-African 
Americans, a higher threshold of 0.31 correctly detected 98.1% of the cases, with higher 
specificity of 96.7%. Among non-African Americans, a threshold of 0.37 corresponds to 
the highest point on the ROC curve and thus has the best combination of sensitivity 
(97.4%) and specificity (97.2%). The thresholds varied by age; men between 55 and 65 
years of age had lowest thresholds; a PSA annual rate of 0.130 detected 99.5% of the 
cases with a lower specificity of 95.6%. A higher threshold of 0.30 had the best 
combination of almost 98% for both sensitivity and specificity in this group of middle-
age men. The younger group (<=55), had an almost perfect performance (100% 
sensitivity and 99.6 % specificity) at a PSA annual rate threshold of 0.99. Among older 
men (>65), the best combination of sensitivity and specificity (98% for both) was at the 
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threshold of 0.93. When considering the PSA rate 2 years prior to exit (part 2 of table 4) 
the results are similar; but with slightly lower threshold values, given that a high-risk 
prostate cancer diagnosis is likely to happen in the next 2 years as compared to the next 1 
year. Overall, a threshold of 0.11 ng/ml/year is highly sensitive to high-risk prostate 
cancer but had a lower specificity of 91%. A threshold of 0.37 has the best combination 
of sensitivity (97.2%) and specificity of (97.3%) to detecting high-risk prostate cancer in 
a window time of one year. The overall estimates are more likely to reflect the case of 
non-AA between 55 and 65 years of age, since this group accounts for the majority of the 
data. 
The ROC curves and the AUCs for annual PSA rate 1 year prior to exit are shown 
in figures 5.8-5.10. The AUC values are displayed on each curve. The curves illustrate 
high sensitivity and specificity measures obtained by PSA rate thresholds, all groups 
show high AUC values. The ROC curves and the AUC for a single PSA level (last PSA) 
alone and the annual PSA rate (1 year prior to exit) alone for all participants are both 
shown figure 5.11. The ROC curves for comparison clearly show that the PSA rate 
improved the prediction of high-risk prostate cancer. The AUC for a single PSA 
measurement is 81.44 (79.25-83.63) while the AUC for PSA rate is 99.50 (99.34-99.66), 
the added value of PSA rate above the prediction of a single PSA is 18.07 (15.89-20.24) 
p-value <.0001.  
Discussion and conclusion  
We used non-linear mixed model to establish individual PSA growth curves 
among 20,888 PLCO trial participants (aged 50-75) using at least four measurements of 
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annual PSA measures taken prior to prostate cancer diagnosis. After adjusting for age, 
race, and baseline PSA and BMI, we confirm that PSA growth curves for men who 
developed high-risk prostate cancer are significantly different and distinguished them 
from all other men. On average, the curves start to diverge and accelerate their departure 
from one another as early as five years prior to the clinical detection of the disease. At a 
fixed point on the curve, PSA annual change rate can be estimated by taking the 1st 
derivative of the curve equation at that point. We estimated these values for all 
participants at two different time points; 1 and two years prior to diagnosis or exit of the 
study. The estimated PSA rates were highly associated with the risk of high-risk prostate 
cancer independently of one single recent PSA measurement. Using a logistic regression 
and ROC procedures we estimated the best threshold to distinguish high-risk prostate 
cancer from any other condition. A threshold of 0.37ng/ml/year has the best combination 
of sensitivity (97.2%) and specifies of (97.3%) to detect high-risk prostate cancer time 
window of 1 year prior to the clinical detection in this cohort of men. When compared 
with one single PSA measure, the estimated PSA annual rate highly improved the 
detection of high-risk prostate cancer.  
Our work builds on early findings by Carter et al. [16] and Pearson et.al. [121, 
122] who estimated PSA growth curves to calculate PSA rate among men with prostate 
cancer. We used the same non-linear regression function proposed by Carter and Pearson 
for PSA change over time among men who developed prostate cancer. However, we used 
the same function for all men in our data regardless of the cancer status, and we allowed 
every individual to have their own unique PSA growth curve. Thus, the estimated PSA 
rates were independent of the cancer outcome. In our results, most men on the BPH and 
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the no-cancer group had a very small estimate of the proposed inflection point and the 
exponential time coefficient. The reported values of PSA rates for these men might be 
overestimated as a result of proposing exponential term in the regression function. If the 
overestimation for the non-cancer groups is true, the results will be slightly biased toward 
the null. Even though we used a novel approach to define and estimate PSA annual rate, 
the summary statistics of our PSA rates are close to those reported by previous findings. 
Carter et al. [123], reported a mean PSA velocity of (0.5 -2 ng/ml/year) for men who 
developed prostate cancer. Tang et al. [124] reported a mean PSA velocity of 0.02-0.06 
ng/ml/year among healthy men. Similar to our findings, studies that investigated potential 
threshold values for PSA velocity to predict prostate cancer, reported threshold values 
that ranged around 0.3-0.6ng/ml/year [125] [84] . 
There is a large body of literature on the topic of PSA kinetics. The debate on the 
value of PSA kinetics in improving prostate cancer detection had started 20 years ago and 
remains a controversial topic today. In their systematic review, Vickers et al. [84] 
concluded that; studies that investigated PSA kinetics either found single PSA to be a 
better predictor than PSA kinetics, or found  trivial differences in favor of PSA kinetics, 
or had serious methodological shortcomings. In contrast, two recently published studies 
concluded that PSA change over time does in deed improve prostate cancer detection. 
Wallner et al. [18]  evaluated whether the rate of change in serum PSA levels 
(represented by annual percent change) accurately detects prostate cancer in a managed 
population of 219,388 men passively followed from 1998 to 2008. Similar to ours, their 
results indicated that multiple measures of PSA improve the accuracy of aggressive 
prostate cancer detection when compared to single measurements of PSA. Orsted et al. 
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[19] investigate the same question among 7,455 men in the Copenhagen city heart study. 
They also concluded that adding long-term PSAV to baseline PSA values improves 
classification of prostate cancer risk and mortality. Our results and the results of these 
two recent studies provide insight into the potential use of PSA annual rate as a predictive 
marker for aggressive prostate cancer.  
In a recent systematic review, Loughglin [83] discusses multiple factors 
contributing to the PSA velocity controversy, many of which can explain why our results 
may be different from others. First, there are wide range of PSAV/kinetics definitions and 
estimation methods. We took a conservative approach and used a minimum 4 PSA 
measurement approach to compute PSA annual rate. Many studies used only two 
measurements, which does not conform to professional society guidelines. We used 
balanced data of equal annual intervals across all PSA measures and over a long duration; 
i.e. of 7 to 11 years. These factors contributed in building a stable statistical regression 
model that estimates annual PSA rate; it also allowed us to avoid the linear restriction and 
consider an exponential pattern for PSA change in the years prior to prostate cancer 
detection. What is common between this study and other studies that reported positive 
results, is the long-term measurements of PSA that were used to define and estimate 
PSAV. This observation supports Loughglin argument regarding the need for an uniform 
definition and sufficient PSA test over a sufficient period. Second, Loughglin brings into 
attention the high collinearity between PSA and PSAV reported in previous studies 
(r=0.70) that makes the added value of PSAV questionable. Unlike other studies, we did 
not find a high correlation between the last PSA measure and the calculated PSA rates. 
Interestingly, Pearson correlation coefficient between the two measures in our data was 
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only 0.3. This might be due to the novel non-linear mixed method we used to estimate 
PSA rates.  
Lastly, we proposed a different question; unlike other studies we focused on 
distinguishing high-risk prostate. The increased detection of indolent prostate cancer is 
main limitation of a single PSA test [14] . It is well established that the challenge is to 
improve screening specificity of clinically significant disease (i.e., PrCA associated with 
a high probability of morbidity or death, therefore, should necessitate medical treatment). 
Cases of low-risk cancers (i.e., Prognostic group I, IIA) are more likely to die from other 
causes before PrCA becomes clinically advanced enough to cause significant morbidity 
and mortality. Diagnosing and treating such low-risk PrCA is more likely to cause harm 
than benefit [126] .     
We acknowledge the following limitations; first, this analysis could be 
strengthened by including a more diverse sample, in terms of age and race. These 
findings are likely to be applicable for European American men between 55 and 65 years 
of age.  African Americans are at higher risk of aggressive prostate cancer. This racial 
group might have a distinct natural history to the disease. PSA growth curves have the 
potential to detect these differences and account for it in establishing screening criteria. 
We observed some qualitative differences among AA, but the number of AA was small 
to establish or refute this hypothesis. Second, we conducted this analysis on a screened 
population; this has the advantage of minimizing outcome misclassification. However, 
cancers detected by screening as compared to those that are detected clinically tend to 
have lower PSAs and PSA rates. Also, the time over which the PSA is measured and the 
time intervals may be different in natural practice and have the potential to change the 
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calculated PSA rates. A sensitivity analysis with multiple scenarios of PSA number and 
shorter sampling intervals would be informative. We are unable to conduct such analysis 
using the PLCO data as the PSA tests are well balanced by design. Third, information 
bias and misclassification can still be a threat, particularly among men in the non-cancer 
and BPH group who didn’t have a biopsy or a clinical examination to confirm their non-
cancer or BPH status. We limited this bias by restricting our analysis to only those with 
biopsies (positive or negative)/ or those that never had a positive screening. So, 
individuals who had a positive screening and were not followed with a diagnostic 
prostate biopsy or BPH diagnosis were excluded.  
We are not the first to report that calculated PSA rate is independently associated 
with prostate cancer risk, but we are the first to propose a non-linear mixed regression 
model to estimate PSA annual rate across all men (and not only those that developed 
prostate cancer). So, we are the first to show that these estimated PSA rates significantly 
increase diagnostic accuracy of a clinically meaningful prostate cancer. While we found 
an increased risk of high-risk prostate cancer across the continuum of increasing PSA 
rates, we were still able to define specific threshold to distinguish cases with high 
probability of having the disease within 1 to 2 years.  
In a cohort of 20,888 men, we analyzed existing repeated measures of PSA and 
developed a regression algorithm that improved both sensitivity and specificity of the 
PSA-based screening test to detect high-risk prostate cancer. In this study, the estimated 
PSA growth curves and the derived annual PSA rates are means for differentiating 
“significant” prostate cancer from any other condition that could be related to an 
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increased PSA measure at any particular point in time. Further research is required to 
validate this algorithm and its ability to distinguish high-risk prostate cancer
  
9
9 
Tables and Figures 
Table 5.1 Characteristics of participants by study group (n= 20888) 
 
Table (1): characteristics of participants by study  group  (n= 20888)  
 Men with no 
cancer 11,383 
(54.50%) 
Men with 
BPH 7,813 
(37.40%)  
Men with 
LRC 1386 
(6.55%) 
Men with 
HRC 324 
(1.55%)  
Comparison  
Race   HRC 
vs. No-
cancer  
HRC 
vs.BPH 
 HRC 
vs. LRC 
HRC vs. 
others  
African American 
N=824(3.49) 
586 (71.12) 156 (18.93) 62 (7.52) 20 (2.43) 
0.41 <.0001 0.22 0.04 
Others N=20,064(96.06) 10797 (53.69) 7657 
(38.16) 
1306 (6.51) 304 (1.52)  
  
1
0
0 
BMI    
0.02 0.2608 0.54 0.08 
<= 30 kg/m2 N= 15,757 
(75.44%) 
8419 (53.43) 6012 
(38.15)  
1068 (6.78) 258 (1.64) 
>30 kg/m2 N=5131 
(24.56%) 
2964 (57.77) 1801 (35.1) 300 (5.85) 66   (1.29)  
Family history of prostate cancer in a first-degree relative (missing=144)  
0.0005 0.0015 0.29 0.0012 
No  N=19,282 (92.31%) 10,547 (54.7) 7226 
(37.48) 
1225 (6.35) 284 (1.48) 
Yes N=1462 (7.69%) 754  (51.57) 537 (36.73) 132 (9.03) 39 (2.67) 
Age (years)  
0.1255 <.0001 0.34 0.0093 
<= 55 N=2,228(10.67%)  1203 (53.99) 893 (40.08) 107 (4.8) 25 (1.12) 
55-65 N=13,658 
(65.39%) 
7131 (52.21) 5429 
(39.75) 
898 (6.57) 200 (1.46) 
>65 N=5002 (23.95%) 3049 (60.96) 1491 
(29.81) 
363 (7.26) 99 (1.98) 
  
1
0
1 
PSA at baseline 
mean/median (95% CI) 
1.28 (1.26-
1.30) / 0.99 
1.32 (1.29-
1.35)/ 0.99 
2.51 (2.42-
2.59)/ 2.16 
2.88 (2.34-
3.42) /1.95 
<.0001 <.0001 0.1832 <.0001 
Years of follow up 
mean/median (95% CI) 
11.17(11.13-
11.21) / 11.62 
11.92 
(11.90-
12.00)/ 
12.49 
7.54 (7.39-
7.68)/ 7.49 
7.86 (7.54-
8.17) / 8.26 
<.0001 <.0001 0.0589 <.0001 
Number of PSA tests 
mean/median (95% CI) 
5.52 (5.52-
5.54)/ 6 
5.67 (5.65-
5.68)/6 
5.29(5.24- 
5.33)/ 6  
5.21 (5.12-
5.31) /5  
<.0001 <.0001 0.1409 <.0001 
Years  from last PSA to 
exit or diagnosis  
6.30 (6.26-
6.33) / 6.75 
6.94 (6.91-
6.97)/ 7.44 
2.93 (2.801-
3.05)/ 2.63 
3.37 (3.09-
3.66/ 3.33 
<.0001 <.0001 0.0054 <.0001 
 
  
1
0
2 
 
 
Figure 5.1 Predicted mean PSA growth curve by study group and race 
  
1
0
3 
 
 
 
 
 
 
 
Figure 5.2 Predicted mean PSA growth curve by study group and age for African-Americans and non-African Americans.  
AA= African Americans,  
NON-AA= none African Americans,  
 BPH= Benign hyperplasia 
HRC= high-risk cancer,  
LRC= low-risk cancer, 
NC=No evidence of prostate cancer or BPH, young-age>=55, 55>middle-age<=65, older-age>65.  
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Table 5.2 Estimated Annual PSA rate (ng/ml/year) 1 year prior to exit stratified by race, 
age and study groups and fixed at baseline PSA of 1.3 
 
Race  Age  Group  mean  (95%CI) Median  25
TH
 Perc.   75
th
 
perc.  
N
o
n
-A
fr
ic
an
 A
m
er
ic
an
  
Youngest  No cancer 0.05 (0.05,0.06) 0.01 -0.02 0.03 
BPH 0.05 (0.05,0.06) 0.01 -0.02 0.03 
LRC 0.38 (0.31,0.45) 0.36 0.15 0.61 
HRC 2.81 (2.14,3.49) 2.11 1.50 3.55 
Middle No cancer 0.06 (0.05,0.06) -0.01 -0.10 0.02 
BPH 0.06 (0.06,0.06) -0.02 -0.11 0.02 
LRC 0.20 (0.17,0.23) 0.17 0.10 0.35 
HRC 1.73 (1.34,2.12) 1.45 0.99 1.90 
Older No cancer 0.06 (0.05,0.06) 0.02 -0.02 0.06 
BPH 0.06 (0.06,0.06) 0.01 -0.05 0.06 
LRC 0.54 (0.45,0.63) 0.67 0.42 0.95 
HRC 4.00 (3.32,4.69) 3.60 2.59 5.74 
A
fr
ic
an
 A
m
er
ic
an
s 
 
Youngest  No cancer 0.05 (0.05,0.06) 0.01 0.00 0.03 
BPH 0.05 (0.05,0.06) 0.01 0.00 0.03 
LRC 0.28 (0.14,0.43) 0.71 0.13 1.19 
HRC 2.18 (1.34,3.02) 1.38 1.19 1.57 
Middle No cancer 0.06 (0.05,0.06) 0.00 -0.12 0.03 
BPH 0.06 (0.06,0.07) -0.01 -0.12 0.03 
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LRC 0.12 (0.01,0.22) 0.12 0.06 0.18 
HRC 1.30 (0.80,1.79) 1.58 1.32 2.24 
Older No cancer 0.06 (0.05,0.06) 0.02 -0.01 0.05 
BPH 0.06 (0.06,0.07) 0.01 -0.12 0.03 
LRC 0.42 (0.23,0.62) 0.39 0.10 0.85 
HRC 3.14 (1.94,4.33) 2.36 1.44 3.32 
BPH= Benign hyperplasia HRC= high-risk cancer,  LRC= low-risk cancer, 
NC=No evidence of prostate cancer or BPH, young-age>=55, 55>middle-age<=65, older-
age>65 
 
Table 5.3 Estimated Annual PSA rate (ng/ml/year) 2 year prior to exit stratified by race, 
age and study groups and fixed at baseline PSA of 1.3 
 
Race Age  Group  mean  (95%CI) Median  25
TH
 Perc.   75
th
 
perc.  
N
o
n
-A
fr
ic
an
 A
m
er
ic
an
 
Younges
t 
No cancer 0.05 (0.05,0.06) 0.01 -0.02 0.03 
BPH 0.05 (0.05,0.06) 0.01 -0.02 0.03 
LRC 0.32 (0.27,0.38) 0.23 0.11 0.41 
HRC 2.02 (1.59,2.45) 1.65 1.08 2.54 
Middle  No cancer 0.06 (0.05,0.06) 0.01 -0.08 0.04 
BPH 0.06 (0.06,0.06) 0.00 -0.09 0.04 
LRC 0.18 (0.16,0.21) 0.12 0.09 0.22 
HRC 1.32 (1.06,1.59) 1.16 0.74 1.50 
Older No cancer 0.06 (0.05,0.06) 0.02 -0.02 0.05 
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BPH 0.06 (0.06,0.06) 0.01 -0.05 0.05 
LRC 0.44 (0.38,0.51) 0.43 0.15 0.67 
HRC 2.76 (2.34,3.18) 2.72 1.84 4.08 
N
o
n
-A
fr
ic
an
 A
m
er
ic
an
 
Younges
t 
No cancer 0.05 (0.05,0.06) 0.02 0.00 0.04 
BPH 0.05 (0.05,0.06) 0.01 0.00 0.03 
LRC 0.25 (0.14,0.36) 0.13 0.11 0.91 
HRC 1.62 (1.07,2.17) 1.02 0.87 1.18 
Middle  No cancer 0.06 (0.05,0.06) 0.01 -0.05 0.04 
BPH 0.06 (0.06,0.07) 0.01 -0.05 0.05 
LRC 0.11 (0.02,0.20) 0.11 0.06 0.14 
HRC 1.03 (0.68,1.38) 1.25 1.10 1.81 
Older No cancer 0.06 (0.05,0.06) 0.02 0.00 0.05 
BPH 0.06 (0.06,0.07) 0.01 -0.13 0.05 
LRC 0.36 (0.22,0.51) 0.27 0.10 0.56 
HRC 2.24 (1.49,2.99) 1.73 1.00 2.56 
BPH= Benign hyperplasia HRC= high-risk cancer,  LRC= low-risk cancer, 
NC=No evidence of prostate cancer or BPH, young-age>=55, 55>middle-age<=65, older-
age>65 
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Table 5.4 Cox  model fit statistics for high-risk prostate cancer  with and without PSA 
annul rate  , calculated at one year prior to exit and used as a categorical variable  with a 
threshold of > 0.371ng/ml/year 
 
 -2 LOG L AIC SBC p-value of the --2 
LOG L 
Model without PSA rate  6018.42 6040.42 6081.97 <.0001 
Model with PSA rate  3679.73 3703.73 3749.06 
 
 
 
Figure 5.3 Box plot of PSA rate (ng/ml/year) 1 years prior to exit by study group 
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Figure 5.4 Box plot of PSA rate (ng/ml/year) 2 years prior to exit by study group 
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Figure 5.5 Box plot of PSA rate (ng/ml/year) 1 year prior to exit by study group and age 
among African Americans  
 
  
 
AA= African 
Americans, NON-AA= 
none African 
Americans,  BPH= 
Benign hyperplasia, 
HRC= high-risk cancer, 
LRC= low-risk cancer, 
NC=No evidence of 
prostate cancer or 
BPH,  young-age>=55, 
55>middle-age<=65, 
older-age>65 
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Figure 5.6 Box plot of PSA rate (ng/ml/year) 2 year prior to exit by study group and age 
among African Americans,  
AA= African 
Americans, NON-AA= 
none African 
Americans, BPH= 
Benign hyperplasia, 
HRC= high-risk cancer, 
LRC= low-risk cancer, 
NC=No evidence of 
prostate cancer or 
BPH, young-age>=55, 
55>middle-age<=65, 
older-age>65 
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Figure 5.7 Box plot of PSA rate (ng/ml/year) 1 year prior to exit by study group  
and age among non-African Americans 
 
 
 
 
 
AA= African Americans, 
NON-AA= none African 
Americans, BPH= Benign 
hyperplasia, HRC= high-
risk cancer, LRC= low-risk 
cancer,  
NC=No evidence of 
prostate cancer or BPH, 
young-age>=55, 
55>middle-age<=65, 
older-age>65 
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Figure 5.8 Box plot of PSA rate (ng/ml/year) 2 year prior to exit by study group and 
age among non-African Americans  
  
AA= African 
Americans, NON-
AA= none African 
Americans,  B 
Benign 
hyperplasia, HRC= 
high-risk cancer, 
LRC= low-risk 
cancer, NC=No 
evidence of 
prostate cancer or 
BPH,  young-
age>=55, 
55>middle-
age<=65, older-
age>65 
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Table 5.5 Measurements of test performance for the prediction of high-risk prostate 
cancer by selected anneal PSA rate thresholds stratified by patient population 
 
  PSA rate 
threshold 
(ng/ml/year) 
Sensitivity Specificity True 
+VE 
True -
VE 
False 
+VE 
False 
-VE 
1 AA 0.22 100.0% 97.8% 20 796 18 0 
1.20 95.0% 99.8% 19 812 2 1 
Non-
AA 
0.10 99.7% 90.8% 303 18112 1841 2 
0.31 98.0% 96.7% 298 19300 653 6 
0.37 97.4%  97.2%  296 19404 549 8 
Young  0.99 100.00% 99.60% 25 2216 8 0 
Middle 
age  
0.13 99.50% 95.60% 199 12987 603 1 
0.30 98.00% 97.90% 196 13308 282 4 
0.33 97.00% 98.10% 194 13338 252 6 
Old  0.93 98.00% 98.00% 97 4855 98 2 
1.06 97.00% 98.50% 96 4879 74 3 
Over 
all 
0.10 99.7%  90.9%  323 18867 1900 1 
0.29 98.1%  96.7%  318 20081 686 6 
0.37 97.2%  97.3%  315 20208 559 9 
2 AA 0.18 100.0% 98.8% 20 804 10 0 
0.87 95.0% 99.6% 19 811 3 1 
0.10 99.7% 92.4% 303 18437 1516 1 
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Non-
AA 
0.19 98.0%  96.7%  298 19288 665 6 
0.27 97.4%  97.6%  296 19481 472 8 
Young  0.91 100.0%  99.6%  25 2216 8 0 
Middle 
age  
0.99 99.5% 95.6% 199 12991 599 1 
0.15 98.0%  96.6%  196 13127 463 4 
0.31 97.0%  98.7%  194 13407 183 6 
Old  0.90 98.0%  98.6%  97 4882 71 2 
1.06 97.0%  98.7%  96 4891 62 3 
Over 
all 
0.11 99.7%  92.4%  323 19187 1580 1 
0.19 98.1%  96.7%  318 20086 681 6 
0.27 97.5%  97.7%  316 20284 483 8 
AA= African Americans, NON-AA= none African Americans,  young-age>=55, 55>middle-
age<=65, older-age>65 
 
 
 
 
Figure 5.9 AUC curves of PSA rate (ng/ml/year) 1 year prior to exit for all participants 
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Figure 5.10 AUC curves of PSA rate (ng/ml/year) 1 year prior to exit for African-
Americans  
    
 
 
Figure 5.11 AUC curves of PSA rate (ng/ml/year) 1 year prior to exit for non African-
Americans  
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 ROC area for PSA rate = 99.50 (99.34-99.66) , ROC area for PSA single measurmnet= 
81.44 (79.25-83.63) , the difference = 18.07 (15.89-20.24) p-value<.0001   
 
 
Figure 5.12 ROC curves for PSA rate and single PSA measure (last PSA) 
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CHAPTER 6 
 
The use of PSA rate to predict high-risk prostate cancer among veterans; a 
validation study 3 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
3 Shoaibi , A., Rao, G., Cai, B., Rawl, J., Hebert, J.. The use of PSA rate to predict high-risk prostate cancer among 
veterans; a validation study To be submitted to Urology  
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Introduction:  
Prostate cancer (PrCA) screening, an issue of public health significance, 
represents a major modern medical controversy.  This is because prostate specific antigen 
(PSA)-based screening was implemented routinely at the population level for several 
decades (i.e., from the early 1990s until the late 2000). This is thought to have resulted in 
‘PrCA stage migration’ – where most of the newly detected PrCA were indolent and of 
low risk in terms of both detracting from individuals’ quality of life and mortality [127]. 
The conclusion of several expert panels charged with examining this issue [105, 128, 
129] was that detection and treatment of low-risk PrCA caused more iatrogenic harm 
than benefit, because most of these patients with newly diagnosed low-risk PrCA are 
unlikely to suffered from PrCA-related morbidity or mortality [24]. 
An alternative to using a single PSA value for PrCA screening is using multiple 
serial PSAs over time [130]. PSA is a relatively inexpensive test which, when used 
serially, can enable computing PSA kinetics or PSA velocity [83]. These parameters are 
thought to provide insights into the natural history of the process of prostate 
carcinogenesis [16]. Despite the appeal this theoretical possibility, there is no conclusive 
evidence, such as through a randomized control trial, that can inform regarding the 
effectiveness of PSA kinetics in detecting PrCA and the evidence from observational 
studies have varied [33, 131-135].  Earlier studies showed that there is a significant and 
independent association between PSA velocity (PSAV) and the risk of PrCA; a threshold 
of 0.35-0.75 was proposed to indicate prostatic biopsy [16, 73, 118, 121, 136, 137]. Many 
other studies contradicted these early findings and disproved any additional value of 
PSAV over a PSA single test in predicting PrCA [83, 84, 117]. Amidst all this 
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controversy, PSAV is still considered useful, and current guidelines recommend 
considering PSAV when available along with many other factors to make the decision 
about the need for prostatic biopsy [101].  
In light of the recommendations against routine population level PrCA screening 
using PSA by the United States Preventive Services Task Force (USPSTF) and other 
professional organizations [101], individual-level screening, based on shared-decision 
making between the patient and provider is now more important than ever. In the absence 
of population-level screening, it may be speculated that over time there will be an under-
detection of high risk PrCA and a reverse stage migration towards high-risk PrCA. This 
has important implications as reductions seen in prostate cancer mortality over the past 
quarter of a century has, at least in part, reflected aggressive population-based PSA 
screening. Risk PrCA, is more likely to impact the morbidity and mortality of the affected 
individual – and there is a need for tool that can specifically predict the occurrence of 
high-risk PrCA [24]. 
In our previous work (currently under review) [138], using data from 22,000 
participants in the Prostate Lung Colorectal and Ovarian trial (PLCO), we established 
PSA growth curves to distinguish men who developed high-risk PrCA or either were 
diagnosed with low-risk PrCA or were found to have no PrCA. Using these growth 
curves, we estimated an individual’s age- and race-adjusted annual PSA rate at one and 
two years prior to PrCA diagnosis. We found that these age- and race-adjusted PSA rates 
could accurately detect high-risk PrCA cases and differentiate them, with high sensitivity 
and specificity, from low-risk PrCA or no PrCA. In this study, we aimed to validate our 
method of defining PSA growth rate and then use the previously proposed threshold 
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levels to predict high-risk PrCA. To achieve this aim we used data from enterprise-wide 
national electronic health record in the Department of Veterans Affairs (VA) to: a) 
investigate the pattern of PSA change over time in VA cohort; b) estimate annual PSA 
rate for individuals in the VA cohort; and c) use thresholds derived from our previous 
work in the PLCO data to predict high-risk PrCA cases. The VA data is different from 
the clinical trial data of PLCO in that the PSA values were not derived at regular 
intervals. As such, these data represent what would be available in real-world clinical 
care delivery (and in a predominantly male cohort of Veterans). These Veterans are 
known to have higher comorbidity, along with a relatively higher representation of 
African Americans. The higher African-American representation, a feature not present in 
PLCO, allows us to further test our model, by stratified analysis by race. This is 
important as African Americans are known to be diagnosed with PrCA at later stages, 
and therefore have disproportionately higher morbidity and mortality.  
Methods: 
Data sources: We extracted data from the VA national electronics health record 
system; containing demographic, administrative claims, vital signs, mortality, laboratory 
results, pharmacy dispensation and cancer registry as part of VA Corporate Data 
Warehouse (CDW). The VA CDW data included detail information on cancer staging 
(TNM clinical and pathological), histological grade including Gleason score, cancer 
treatment and dates of diagnosis – all data were stored inside the VA research 
environment - Veterans Affairs Informatics and Computing Infrastructure (VINCI). All 
VA data sources are linkable using a common individual patient-level identifier; i.e., 
scrambled SSN, a unique individual-level identifier. The utility, accuracy, validity, and 
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access methodology of the available data, including both pharmacological and 
laboratory-derived, have been described previously [85-88].  PSA serum measurements at 
the VA hospitals labs are all done in compliance with the quality control standards of the 
of the Clinical Laboratory Improvement Amendments (CLIA). This study was approved 
by the IRB of the WJB Dorn VA Medical Center and has received appropriate approvals 
from VA regulatory entities such as National Data System. 
Cohort definition: We identified all men who were between the ages of 50 to 75 
years when they had their first VA-based PSA test between January 1st 2002 and 
December 31st 2011. We chose the cut-off of December 2011, because until 2012 
eligible Veterans were more likely to be invited for annual PSA-based screening, and 
used January 1st 2002 in order to make the total study period 10 years. Any Veteran who, 
at the time of his first PSA had any coded documentation of the following were excluded: 
PrCA, Benign prostatic hyperplasia (BPH), any other prostatic pathology or other cancer 
either in the administrative claims data or in cancer registry or history of any form of 
surgical intervention of the prostate (such as prostatectomy partial or full, prostatic 
resection including transurethral resection of prostate, or even prostate biopsy), any 
history hormonal treatment such as orchiectomy or 5-alfa-reductase inhibitors (Proscar/ 
Propecia/finasteride or Dutestiride).  Also excluded were men who during follow-up were 
coded for prostate cancer using ICD9 code on claims data but did not have a 
corresponding entry in the cancer registry or were present in cancer registry, but did not 
have TNM stage or Gleason score – these patients are more likely to be either 
misclassified or have incomplete data. All patients were censored on either December 
31st 2011, date of diagnosis of PrCA, date of BPH diagnosis (unless they also 
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subsequently had PrCA, in which case PrCA was used in preference to BPH) or were 
given hormonal treatment or prostatic surgery – whichever came first. In addition, as our 
model was dependent on having at least 4 serial PSA measures – we artificially restricted 
only to those patients who had at-least 4 PSA measures between date of first PSA and 
date of exit/censor or cancer diagnosis. The 4 PSA measures had to be such that there 
was at-least a 1-year gap between the first PSA and any subsequent PSA that was not the 
last PSA, there was a 1-year gap between the last PSA and any previous PSA that was not 
the first PSA, and there was at-least a 3-year gap between the first and the last PSA – this 
ensured that cohort represents being screening approximately annually for a minimum of 
3 years.  
Cohort follow-up: Cases were those who met our PrCA criteria (i.e. classifiable 
into either low-risk or high-risk PrCA using VA CDW cancer registry data). We then 
created random sample of controls for the case series. For every case, we randomly 
selected from the cohort equal numbers of patients with BPH and no cancer or BPH. We 
then retrospectively followed these patients starting with their first PSA until either 
outcome or censor. Baseline variables were race (classified as either African American or 
not African American), age at first PSA, baseline PSA, baseline BMI classified as either 
obese (≥30kg/m2) or not obese (<30kg/m2). 
Statistical analysis:  
To investigate the pattern of PSA change, we plotted the observed individual trajectories 
of PSA as a function of time for the four analysis groups. We then used “spaghetti plots” 
to illustrate the individual trajectories and the locally weighted scatter plot smoothing 
regression to fit the mean trajectories in each group separately [24].  We defined time as 
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number years to censor or outcome. To estimate individual PSA growth curves, we used 
the non-linear mixed model approach with the same linear-exponential piece-wise 
function that was established in our previous work [138]. The random effect in the mixed 
model for repeated measure analysis allows for individual-to-individual variation 
(between-individual) and account for within-individual variation.  By taking the 1st 
derivative of the PSA growth curve equation we estimated PSA annual rate at a fixed 
time point of 1 year prior to exit. We then used age- and race-specific thresholds derived 
previously from the PLCO PSA growth curves to predict high-risk prostate cancer cases 
in the VA validation cohort using a logistic regression model. The sensitivity, specificity, 
area under the curves (AUC) and ROC and their 95% CI for predicting high-risk prostate 
cancer were estimated for these PSA annual rates. We included both PSA annual rate and 
a single PSA measure in the logistic model and constructed the two ROC curves for 
comparison. Finally, a logistic regression model was used to estimate the association 
between PSA annual rate and the risk to high-risk prostate cancer while adjusting for age, 
race, BM and single PSA measure to predict high-risk prostate cancer. Since we have 
multiple PSA measures per men, we used the value of closest PSA result to the exit date 
(i.e., the last PSA screening test result).  
Results:  
Approximately 2.5 million veterans were screened for PrCA between January 2002 and 
December 2011; 680,390 of these men met our study criteria. Of those, 7,347 men were 
diagnosed with PrCA. From the remaining pool of 673,565 men (60,894 with BPH and 
611, 581 normal prostate), we randomly selected 7,347 men with normal prostate (no 
diagnosis of prostate abnormality) and another 7,347 men with BPH. Out of the PrCA 
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cases, 4,315 (58.73%) were diagnosed with high-risk prostate cancer and 3,032 (41.27%) 
men were diagnosed with low-risk cancer.  Table 6.1 and 6.2 describe baseline 
characteristic of the analytical cohort and by analytic group, respectively. The Chi-square 
test for categorical variables was used to test for statistical differences between different 
analytic groups.  Men in the cancer groups were more likely to be African American and 
of older age compared to men without cancer. A higher proportion of obese men were 
significantly more likely to be diagnosed high-risk PrCA (44.38%) compared to low-risk 
PrCA group (40.93%). Similarly, the proportion of older men (>65) in the high-risk 
PrCA group (26.58%) was significantly higher compared to low-risk PrCA group 
(18.73%). The proportion of AA in the high-risk PrCA group (22.90%) was slightly 
higher that their proportion in low-risk PrCA group (21.73%) but the difference was not 
statistically significant. Men in high-risk PrCA group were more likely to be African 
American and of older age when compared to all other groups combined.  
Men in the cancer groups had, on average, higher number of PSA tests, shorter 
duration of follow up, higher PSA at baseline and shorter duration between the last PSA 
and the exit date when compared with men in the other two non-cancer groups (Table 
6.2). Men in the low-risk PrCA had a slightly shorter period of follow up when compared 
to men in the high-risk PrCA group (5.76 years vs. 5.89 years). The two cancer groups 
had comparable number of PSA tests, PSA level at base line and the number of years -
between the last PSA and the diagnosis date.  Men in the non-prostate cancer group had 
the longest duration of follow up; 6.93 years, almost a year longer when compared to the 
other three groups.  The number of years between the last PSA test and the exit date was 
less than 1 year in all groups and was shortest among men in the high-risk PrCA group 
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(0.20 years) compared to 0.74 years among men in the normal prostate group. The 
median of PSA tests ranged between 7 in the cancer groups and 6 in the non-cancer 
groups. PSA at baseline was the lowest among men in the normal prostate group, with an 
average of 1.06 ng/ml and a median of 0.80 ng/ml. Men in the BPH group had a baseline 
PSA that was significantly higher than those in normal prostate group (1.38 ng/ml vs. 
1.09 ng/ml) but significantly lower than men in high-risk (2.82 ng/ml) and low-risk PrCA 
groups (2.66 ng/ml).  
Figure 6.1 illustrates the means of PSA measures (ng/ml) at each year before exit 
for all the four groups. Figure 6.2 shows the longitudinal trajectories of PSA over time as 
obtained by the locally weighted scatter plot smoothing regression (loess). Figure 6.3 
shows the individual trajectories for a random sample for the four groups separately using 
the same loess method. In the three graphs, the x-axis is on a negative scale representing 
the number of years before exit (or time to exit). The trend in the two PrCA groups shows 
higher PSA values across all the years of follow-up as compared to the other two groups. 
Similar to our earlier observations (in the PLCO cohort), men in the normal prostate and 
the BPH group follow a slightly increasing linear trend. Closer to the exit point, the BPH 
group shows higher PSA values (that also corresponds to the time of BPH diagnosis). 
Men in the cancer groups show an increasing trend; a few years before diagnosis the line 
seems to evince an exponentially increasing pattern.  Men in the high-risk PrCA group 
show a slightly more rapid change as compared to men in the low-risk PrCA group. 
  Table 6.3 and 6. 4 show the mean of PSA annual change rate estimated by the 
piece-wise model across different race, age and the four analytic group and adjusted on 
baseline PSA of 1.73ng/ml.  Table 6.3 shows the mean years prior the change point 
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across the four groups stratified by race while table 6.4 shows the corresponding means 
after the change point and one year prior to the exit days.  As expected, PSA annual rates 
are similar among men in the high-risk and the low-risk group prior to the change point, 
post the change point and at 1 year prior to exit; men at the high-risk group have 
significantly higher PSA annual change rates as compared to all other groups and across 
all age and race groups. Also, African Americans had significantly higher rates across 
different groups, both prior to and after the change point. 
Table 6.4 illustrates sensitivity and specificity of the previously reported PSA rate 
thresholds for predicting high-risk prostate cancer (the first cell in each group). In 
addition, we reported other PSA values that resulted in the best combination of sensitivity 
and specify in the logistic regression AUC curves.  A threshold 0.37  ng/ml that we had 
previously found using PLCO data had an overall threshold sensitivity of 95.5% and 
specificity of 85.2%. The predictive values were fairly homogenous across age and race 
groups. However, unlike what we observed previously, PSA rates performed better 
among non-African American versus African Americans. An overall threshold of 0.82 
ng/ml had both sensitivity and specificity of about 90%.  
In a logistic regression a (Table 6.5), increased annual PSA rate at 1 year prior to 
exit or diagnosis was strongly associated with high-risk PrCA in the model that adjusted 
for all other covariates including PSA level at the time of last screening.  Using a 
threshold of 0.37 ng/ml/year, the adjusted odds ratio was 71.43 (83.33-85.82) for PSA 
rate one year prior to diagnosis > 0.375 ng/ml per year versus ≤ 0.375.  
The ROC curves and the AUC for a single PSA level (last PSA) alone and the 
annual PSA rate (1 year prior to diagnosis) alone for all participants are shown in figure 
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6.3. The ROC curves for comparison show that the PSA rate improved the prediction of 
high-risk PrCA. The AUC for a single PSA measurement is 89.99 (89.57-90.41) while 
the AUC for PSA rate is 93.3 (92.86-93.71) the added value of PSA rate above the 
prediction of a single PSA is 3.29 (2.82-3.76)  p-value <.0001.  
Discussion and conclusion: 
 Using a piece-wise mixed model that used more than a hundred thousand PSA 
values from 22,041 Veterans belonging to one of the four outcome groups - we were able 
to establish PSA growth curves and estimate individual-level age- and race-adjusted 
annual PSA rate at 1 year prior to PrCA diagnosis or exit. Then, using a threshold of 0.37 
ng/ml/year, we were able to successfully distinguish high-risk PrCA cases from low-risk 
PrCA, BPH and normal prostate with a sensitivity of 95.5% and a specificity of 86.2 %. 
Further, when compared to the predictive value of a single most recent PSA, the 
performance of our model driven PSAV was significantly improved.  
The findings supports that the trends of PSA change over time computed using 
our piece-wise model performs well to predict high-risk PrCA. Even though the 
sensitivity and specificity of the PLCO data generated cut-off was found to perform less 
effectively in the VA validation cohort, it still had a relatively good performance. We had 
found that men with normal prostate had a (predominantly) linear pattern in the PLCO 
cohort, and this was confirmed in the VA validation cohort. A significantly higher linear 
rate among men in the BPH group was observed in the VA data as compared to the 
PLCO data. This might be explained by the fact that data on BPH was self-reported in the 
PLCO data but not in the VA data. For the cancer groups we had found a clear change 
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point in the PLCO data, and this was again found in the VA dataset - where the PSA 
growth pattern shifted from a linear pattern to an exponential pattern. In the PLCO data, 
the change point took place around 4-5 years prior to diagnosis. However, in the VA data, 
a change point was evident 2-3 years prior diagnosis.  The mean and median of the PSA 
annual rate prior the change point was slightly higher for both high-risk and low-risk 
PrCA in the VA compared to the PLCO data. After the change point, the PSA annual rate 
was significantly higher in the VA data for low-risk PrCA and was the annual PSA rates 
for low-risk and high-risk PrCA were very close, with high-risk PrCA having higher 
rates. This explains why the PLCO driven threshold of 0.375 didn’t perform as well in 
the VA cohort as compared to the PLCO cohort. Nevertheless, compared to traditional 
single value PSA, the threshold of 0.375 ng/ml/year was still able to significantly 
improve the specificity and sensitivity to detect high-risk PrCA. 
Care delivery patterns and the uniqueness of the cared population in the VA may 
explain why our model-generated PSAV was not able to predict high-risk PrCA with as 
much accuracy as it did in the PLCO data. The VA cohort is a health-care system-based 
population that is known to have distinct characteristics such as higher comorbidity 
burden along with poor health outcomes. In the VA, we found that the predominant 
number of the PrCA cases were high-risk, compared to only about 20% in the PLCO 
data. On its face, indicates that the VA population is at higher-than-population-average 
risk of prostate cancer, while the PLCO population is at lower-than-population-average 
risk. There are many potential explanations for this. There may be a real tendency toward 
higher-risk disease for a tendency to delay diagnosis [63, 67, 139]. Also, Veterans are 
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known to receive some of medical care outside the VA, but then shift most of their care 
to a VA medical center upon diagnosis of a serious medical condition.  
Additionally, because of prior occupational exposures, such as Agent Orange, VA 
patients may have a different risk-profile compared to the PLCO population. There also 
could be a difference in data standards, for example, the PLCO data were collected based 
on strict clinical trial protocols, while the VA data may be more prone to error as the data 
collection is based on routine clinical data entered manually at various relatively 
independent medical centers across the United States. The overall length of the study in 
the PLCO was longer; i.e., 14 years, and there was a significant gap period between the 
last PSA and the end of follow-up for individuals without PrCA. This was due to the fact 
that, in the PLCO, active PSA-based screening occurred only in the first 6 years, 
followed by a long period of passive follow-up. By contrast, in the VA because Veterans 
were encouraged to receive PSA screening annually. This resulted in a much shorter gap 
between end of follow-up and last PSA as compared to PLCO. This interval may have 
slightly biased the PLCO results away from the null. This is because the calculated PSA 
rate for men with no cancer was driven from PSA measures taken several years before 
the end of the study; while for men with PrCA more recent measures were naturally 
available. Third, while the same definition of low-risk PrCA was applied in both studies, 
low-risk PrCA in the PLCO study were predominantly at the lower end of the of the case 
definition (TNM stage 1 and Gleason score of less than 6), the VA cases were likely to be 
at the higher end (TNM stage 2B and Gleason score of 6) .  
In addition to our findings that serial PSA based measures, when appropriately 
modeled, can predict high-risk PrCA, recently, two other independent research have 
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reported similar results [18, 19, 138]. Wallner et al. used routine clinical care data from 
219,388 members of the Kaiser Permanente Health Plan in Southern California (1998 - 
2008). In that study, PSAV accurately predicted PrCA cases, with higher specificity and 
sensitivity for high-grade PrCA when compared to single PSA test. Similarly, Orsted et 
al. used data from 7,455 participants in the Copenhagen City Heart Study. Their findings 
indicated that long-term PSA change may be used to identify men with a low probability 
of PrCA mortality [140]. Although the overarching message appears to be similar, each 
study was methodological different, mainly because of heterogeneity in defining and 
estimating PSA change/PSAV, the number of PSA tests to use, and the time interval 
between the tests.  
The main limitation of this is study is information bias. In biomarker-based 
studies, a new indicator is compared to what is considered a “gold standard” criteria or 
the “truth”. We used raw oncology files extracted from the VA electronic medical record 
to classify high-risk and low-risk PrCA. The definition was based on TNM staging and 
Gleason score documented through different data entry patterns at the point of source that 
may have led to errors – potentially leading to misclassification. We tried to minimize 
this bias by restricting our analysis to those with clear, unambiguous information on 
confirmed stage – it is possible that patients with high risk PrCA are more likely to have 
higher quality unambiguous data compared to lower risk PrCA. As this is a retrospective 
analysis, confounding cannot be eliminated. There always is a possibility that the 
differences we observed in the PSA rates among the four groups are confounded by 
unknown and unmeasured factors.  
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In this study, we have applied our previously developed statistical model on an 
independent and distinct validation cohort. The results of our findings in the validation 
cohort were comparable to that obtained in the model-building cohort. This evidence of 
robustness of our original model supports the conclusion that it is possible to use serial 
measurements of PSA to differentiate, with a high degree of precision, if a patient is 
likely to develop high-risk PrCA. Patients with suspected high-risk PrCA are the ideal 
candidates for prostate biopsies as confirmation of PrCA and subsequent treatment may 
improve the outcomes of these patients. At the same time, our model will be able to avoid 
unnecessary biopsies among patients who may have a single elevated PSA that is not 
reflective of high-risk PrCA. This has important public health and policy implications. 
Next steps will involve further validation in an alternate dataset and subsequent 
prospective cohort study.
  
1
3
2 
Tables and figure 
Table 6.1 Age, Body mass index (BMI) and race by analysis group (n=22, 041)  
 
 Normal prostate 
7,347  
BPH  
7,347 
LRC  
3,032 
HRC 
4,315 
Comparison  
Race       HRC 
vs. 
normal 
HRC 
vs. 
BPH 
 HRC 
vs. 
LRC 
HRC 
vs. 
others  
PrCA vs. 
None-
PrCA 
African American     
3,252 (14.75)    
861 (11.72) 744(10.13) 659(21.73) 988(22.90) 
<0.001 <0.001 0.23 <0.001 <0.001 
Others  18,789 
(85.25) 
6,486 (88.28) 6,603(89.87) 2,373(78.2
7) 
3,327(77.10) 
BMI  (kg/m2 )      0.25 0.7 0.00 0.78 0.01 
  
1
3
3 
<= 30 kg/m2  
12,303(55.82) 
4,006(54.53) 4,106(55.89) 1,791(59.0
7) 
2,400(55.62) 
>30 kg/m2 
9,738(44.18) 
3,341(45.47) 3,241(44.11) 1,241(40.9
3) 
1,915(44.38) 
Age (years)      
<0.001 <0.001 <0.001 <0.001 <0.001 
<= 55       5,088 
(22.72)  
2,247(27.20) 1,601(21.79) 655 (21.60) 816(18.91) 
55-65  11,621 
(52.72) 
4,195(50.80) 3,696(50.31) 1,809(59.6
6) 
2,352(54.51) 
>65          5,412 
(24.55) 
1817(22.00) 2,050(27.90) 568(18.73) 1,147(26.58) 
 
  
1
3
4 
Table 6.2. Mean and median of follow up duration, number of PSA tests, and PSA at baseline by analysis group (n=22, 041) 
 
 Men with no cancer 
7,347  
Men with BPH 7,347 Men with LRC 
3,032 
Men with HRC 
4,315 
 Mean (95% 
CI)/Median 
Mean (95% 
CI)/Median 
Mean (95% 
CI)/Median 
Mean (95% 
CI)/Median 
Years of follow up  6.93(6.89,6.96)/6.93 6.01(5.98,6.05)/5.82 5.79(5.73,5.84)/5.53 5.89(5.84,5.93)/5.66 
Years  from last PSA to exit  0.74(0.72,0.76)/0.50 0.39(0.37,0.40)/0.13 0.21(0.20,0.22)/0.16 0.20(0.19,0.21)/0.15 
Number of PSA tests  6.54(6.49,6.60)/6.00 6.32(6.26,6.37)/6.00 7.62(7.52,7.73)/7.00 7.47(7.38,7.55)/7.00 
PSA at baseline  (ng/ml) 1.09(1.07,1.12)/0.80 1.38(1.35,1.41)/1.00 2.82(2.76,2.88)/2.50 2.66(2.61,2.71)/2.30 
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Figure 6.1 Mean and inter-quartile range of PSA values over years of follow up by 
analysis group 
 
 
 
Figure 6.2 Longitudinal trajectories of PSA for the analytical cohort as a function of time 
in the 4 analytical groups 
  
1
3
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Table 6.3 Estimated Annual PSA rate of change prior to the change point stratified by race, age and analysis groups and fixed at 
baseline PSA of 1.73ng/ml 
 
Race  Age  Normal prostate (7,347) BPH (7,347) LRC (3,032) HRC (4,315) 
Non-African Americans <=55 0.05  (0.03, 0.05) 0.08 (0.05, 0.08) 0.23 (0.2, 0.24) 0.24 (0.21,0.25) 
55-65 0.06 (0.04, 0.07) 0.09 (0.06, 0.10) 0.24 (0.21,0.26) 0.25 (0.22,0.27) 
>65 0.06 (0.04, 0.07) 0.09 (0.06,0.10) 0.24 (0.21, 0.26) 0.25 (0.22,0.27) 
African American <=55 0.10 (0.07, 0.10) 0.13 (0.09, 0.13) 0.28 (0.24,29) 0.29 (0.25, 0.30) 
55-65 0.11 (0.08, 0.12) 0.14 (0.10, 0.15) 0.29 (0.25,0.31) 0.30 (0.26,0.32) 
>65 0.10 (0.07,0.10) 0.14 (0.10, 0.15) 0.29 (0.25, 0.31) 0.30 (0.26,0.32) 
 
Table 6.4 Estimated Annual PSA rate (ng/ml/year) of 1 year prior to exit stratified by race, age and analysis groups  and fixed at 
baseline PSA of 1.73 ng/ml 
 
Race  Age(years)  Normal prostate (7,347) BPH (7,347) LRC (3,032) HRC (4,315) 
Non-African Americans <=55 0.05  (0.03, 0.05) 0.08 (0.05, 0.08) 1.38 (1.36,1.38) 2.55 (2.41, 2.57) 
  
1
3
7 
55-65 0.06 (0.04, 0.07) 0.09 (0.06, 0.10) 1.24 (1.17,1.30) 2.26 (2.06, 2.43) 
>65 0.06 (0.04, 0.07) 0.09 (0.06,0.10) 1.27 (1.21,1.34) 2.33 (2.12, 2.5) 
African American <=55 0.10 (0.07, 0.10) 0.13 (0.09, 0.13) 1.62(1.55,1.70) 3.02 (2.78, 3.21) 
55-65 0.11 (0.08, 0.12) 0.14 (0.10, 0.15) 1.46 (1.34,1.61) 2.69 (2.38, 304) 
>65 0.10 (0.07,0.10) 0.14 (0.10, 0.15) 1.49 (1.38,1.66) 2.76 (2.44, 3.13) 
 
Table 6.5 Measurements of test performance for the prediction of high-risk prostate cancer by  for PLCO driven and other selected 
anneal PSA rate thresholds , stratified by race and age 
 
 
 PSA rate cut off (ng/ml/year) Sensitivity Specificity True +VE True –VE  False +VE False -VE 
African American 1.20 89.0% 80% 874 1786 446 108 
0.99 89.1% 80.0% 857 1785 447 107 
Non-African 
Americans 
0.37 95.5% 86.7% 3081 13345 2043 145 
0.80 90% 89.3% 2886 13747 1641 340 
  
1
3
8 
age≤55 years 0.88 89.6% 88.9% 708 3703 461 82 
0.55 95.0% 86.7% 750 3612 553 40 
55-65 years 0.33 95.6% 83.0% 2188 7644 1564 102 
0.77 90.0% 86.1% 2059 7929 1279 230 
Age >65 years 0.90 89.0 91.1 1005 3871 376 124 
0.42 95.0% 88.8 1072 3771 476 57 
067 92% 90% 1038 3821 426 91 
Overall Ages 0.37 95.5% 85.2% 4018 15018 2602 190 
0.82 90% 89.0% 3773 15499 2121 435 
 
Table 6.6 Results from a logistic model predicting high-risk prostate cancer 
 
 
Factor Odds ratio (95% CI)  P-VALUE 
PSA annual rate* 71.43 ( 58.82-83.33) <.001 
  
1
3
9 
Last PSA single measure** (ng/ml) 1.22 (1.20-1.23) <.001 
Age at baseline** 1.03 (1.02-1.04) <.001 
Race*** 1.12 (0.99-1.27) 0.06 
Body mass index (kg/m2)**** 0.97 ( 0.91-1.03) 0.32 
*used as a dichotomous variable,   ≥0.375 ng/ml/year  versus  <0.375ng/ml/year **used as continues variable  *** used as African 
American versus others  *** used as a dichotomous variable, <30 kg/m2 versus ≥ 30kg/m2 
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Figure6.3. ROC curves for PSA rate and single PSA measure (last PSA): 
 
ROC area for PSA rate = 93.3 (92.86-93.71) , ROC area for PSA single 
measurmnet= 89.99 (89.57-90.41) , the difference = 3.29 (2.82-3.76)  p-
value<.0001   
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CHAPTER 7: SUMMARY 
 
This chapter consists of two sections. The first is an overall summary of our 
scientific query and the interpretation of our results in the overall context of prostate 
cancer prevention and control. In the second I will shed the light on the personal 
experience that shaped the journey of perusing this research over the last four years of my 
life.  
7.1. PSA growth curves: an approach for PrCA screening  
Prostate cancer (PrCA) screening is a significant public health issue, especially 
among populations at high risk of an aggressive PrCA. The development and discovery 
of biomarkers to predict risk of PrCA aggressiveness at the time of detection remains an 
unmet clinical need in prostate cancer prevention and control [36]. This dissertation 
analyzed a very large and robust dataset consisting of existing repeated measures of 
prostatic specific antigen (PSA).  Its role was to develop and validate a tool to improve 
both sensitivity and specificity of the PSA-based screening test to detect PrCA, while, for 
the first time, differentiating high-risk PrCA from all other prostatic conditions (including 
indolent PrCA). Using this dataset [from the Prostate Lung Colorectal and Ovarian trial 
data (PLCO) trial] and an even larger confirmatory/validation dataset through the 
Veterans Administration, we showed that there is real potential to improve screening 
specificity for high-risk PrCA through investigating PSA trends over time. 
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We used the PLCO trial data for PSA growth model building. Using 6 years of 
annual PSA measurements we established the PSA growth curves for four groups of men; 
those who developed high-risk PrCA, those who developed low-risk PrCA, those who 
developed benign prostatic hyperplasia (BPH) and those who were not diagnosed with 
either PrCA or BPH until the end of the study period. We used these curves to estimate 
PSA annual rate of change (defined as an absolute and relative change) at pre-specified 
time points; one and two years before diagnosis for each individual in the cohort. We 
then used the area under the curve (AUC) method to estimate the specificity and the 
sensitivity of the prediction of high-risk PrCA using selected PSA annual rate thresholds. 
After developing the model using the PLCO data, which produced excellent results, we 
validated our work using the VA data - where we replicated the work done in the PLCO 
data to estimate PSA growth curves equation in the VA cohort. During this process we 
further tuned the original model. We then used model derived individual patient curves to 
estimate individual PSA annual rate at one year prior to diagnosis. Finally, we used the 
PSA annual rate thresholds derived from the PLCO data analysis to predict high-risk 
PrCA among the VA cohort.  
  We built our statistical methods to model the relation between PSA and time/age 
(PSA growth curves) based on a priori knowledge of current consensus evidence that 
PSA increases with age/time and that this increase (or growth pattern) is linear among 
patients with normal prostate tissue and becomes non-linear among patients who develop 
low-risk PrCA and high-risk PrCA [16]. We built on and validated past findings that the 
pattern of transition from linear PSA growth to a non-linear growth is a harbinger to 
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high-risk PrCA; i.e., the pattern of transition (rate and curve) is different between high-
risk PrCA and low-risk PrCA. To account for this difference in patterns and to estimate 
individual growth model parameters, we used a non-linear mixed-effect model. These 
models are very effective in allowing non-linear functions that take into account random 
effects that, in turn, allow for individual-to-individual variation. In the select models 
piece-wise function we specified that every individual may have an unknown point in 
time at which they transition from a linear to an exponential phase. While building and 
validating these models we accounted for baseline age, race, BMI and initial PSA. We 
accounted for these variables by including them as source of variation on the intercept 
and on the slope over both the linear and the exponential phase.  
Our results show that PSA annual change rates varied significantly by cancer 
status (i.e., both in distinguishing PrCA from other conditions and in differentiating 
virulent PrCA from indolent PrCA) in both cohorts. The differences between the means 
and medians of PSA rate values across the 4 groups of men (high-risk PrCA, low-risk 
PrCA, BPH and healthy men) were large and robust across different estimation methods. 
This is an observation that has been replicates over 20 years of research on PSA kinetics. 
Nevertheless, what is more important about our findings is that the distribution of the 
individual PSA annual rates shows substantial variability. A distinct range and 
significantly higher values were observed among men who developed high-risk PrCA – 
starting many years prior to diagnosis (versus all others). This resulted in a substantially 
higher area under the curve; 99.50 (99.34-99.66), in a logistic regression model that used 
these individual PSA annual rates to predict high-risk PrCA among the PLCO cohort. A 
threshold of 0.37ng/ml/year had the best combination of sensitivity and specificity; i.e., 
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of 97.2%, and 97.3% respectively.  In the VA validation cohort, the same pattern was 
observed. However, men in the low-risk PrCA group had higher annual PSA rates as 
compared to the same group in the PLCO cohort. This resulted in a lower area under the 
curve of 93.3 (92.86-93.71) in the logistic regression model and the same threshold of 
0.37ng/ml/year predicted high-risk PrCA with a sensitivity of 95.5% and a specificity of 
86.2 %. In both cohorts, when compared to the predictive value of a single most recent 
PSA, the performance of our model driven PSA rate was significantly improved. 
Using non-linear mixed models we were able to detect substantial differences in 
PSA rates among people who developed high-risk cancer and those who did not. The 
method and the design we adapted is in agreement with the main concept of PSA 
velocity. As described by Carter [108], velocity (rate) here is not merely the random 
fluctuation of PSA values across different measuring time (by chance) or across different 
characteristics such as age, race and BMI. Rather, it is the variability corrected for 
elapsed time between measurements and for other sources of variability [108]. It is 
important to note that the PSA rates and the thresholds calculated and reported here may 
be specific to underlying piece-wise function that we used to establish the growth curves. 
Thus, we caution that the thresholds reported here to identify high-risk PrCA should not 
be applied to PSA annual rates or velocity driven by other methods.  
The PSA growth curves can be further developed and populated to be used as a 
true bench-to-bed-side tool: indeed, this would be a research product that combines both 
bench and applied research. Such a tool would be different from currently available PSA 
change nomograms (PSA doubling or regression algorithms) – as these traditional tools 
rely completely on a linear PSA increase assumption and mostly use only two PSA 
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measurement points.  Few studies have modeled PSA growth curves using linear and 
exponential equations to represent change over time with an acceleration of growth at 
some point prior to disease onset – but were based on small sample size, lacked sufficient 
geographical and racial variability along with generalizability, and were not translated to 
an outcome appropriate to applied research [73]. The traditional measures of PSA, 
although sometimes applied for PSA screening – were originally developed for post-
treatment monitoring of PrCA recurrence. As such, they have not been validated for this 
new purpose.  In contrast, our approach was designed to develop a tool exclusively for 
PSA-based PrCA screening so as to facilitate shared decision making regarding the need 
for prostate biopsy between physician and patient – by providing information on prior 
probability of finding high-risk PrCA.  
There are some limitations that should be considered when interpreting our 
results. First, this work is based on retrospective data and is prone to design-inherent 
biases. Misclassification is possible; ideally the outcome status is confirmed by a 
prostatic biopsy, which confirms the existence or the absence of a tumor. However, it is 
impossible to biopsy every participant, and thus those who were classified in the non-
PrCA group might - in reality - have PrCA. This is more of an issue in the VA data rather 
than in the PLCO data. While not every participant was biopsied to confirm the absence 
of a tumor in the PLCO study, everyone was screened and closely followed. The VA 
analysis is based on routine clinical data entered manually at various relatively 
independent medical centers across the united the states.   Misclassification in both cases 
would represent random error and is likely to attenuate our results. Misclassification 
could exist among men with a BPH diagnosis, specifically in the PLCO trial where BPH 
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is not one of the study’s main outcomes. Data on BPH was self-reported and collected 
retrospectively. It is possible that some of the men in the normal prostate group had BPH 
or vice versa. This source of error does not influence our sensitivity and specificity 
results for distinguishing high-risk PrCA. However, the reported PSA growth curves for 
men with BPH should be interpreted with caution. Second, selection bias also is possible. 
In both cohorts baseline PSA measures were slightly higher than what would be expected 
in the general population. In the VA cohort, the proportion of high-risk cancer was much 
higher than what we expected or what was observed in the PLCO cohort. These 
observations indicate that the two cohorts might be different in terms of health status than 
that of the general population. Third, the scope of this research is establishing the PSA 
growth curves as they best fits the observed long-term change of PSA over time using at 
least 4 measures of PSA taken over long periods of time. Thus the derived PSA annual 
change rates thresholds may not be applicable to other methods defining and estimating 
PSA velocity.  Fourth, in PLCO, where we established our models, the representation of 
African-America race was limited.  By contrast, in the VA analysis there not only was a 
significant representation of African Americans, but also there was important variability 
compared to other races with regard to PSA annual rates and their predictive values. 
Further research is needed to investigate the influence of race in applying the concept of 
PSA kinetics. Finally, confounding cannot be eliminated. There is a possibility that the 
differences we observed in the PSA rates among the four groups are confounded by 
unknown and unmeasured factors.   
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These findings do not confirm the absolute effectiveness of PSA-based screening 
using the concept of PSA velocity; rather they shed the light on the potential use of PSA 
kinetics to distinguish high-risk PrCA with a high degree of precision; this is an 
important addition to the growing evidence that supports this concept. Patients with 
suspected high-risk PrCA are the ideal candidates for early detection and subsequent 
treatment. At the same time, this approach is able to avoid unnecessary biopsies among 
patients who may have a single elevated PSA that is not reflective of high-risk PrCA. 
More research is required to refine and validate a decision algorithm incorporating PSA 
serial measurements in addition to other factors such as digital rectal examination results 
and other non PSA biomarkers.  
7.2. The journey of this dissertation  
I joined the doctorate program in epidemiology and biostatistics at the University 
of South Carolina in fall 2011, as a Fulbright-sponsored scholar all the way from the 
West Bank/ Palestine. As he was helping me pack for the long-journey away from home, 
my father asked if I will help “cure” diabetes. I smiled and said “No, I will help prevent 
cancer.” He smiled back. At that time, I don’t think I was dreaming of preventing cancer 
– I think I was dreaming of crossing the Mediterranean, Europe and the Atlantic – more 
occupied by the excitement and challenges that lay ahead – but the seed for cancer 
research was there somewhere. At the University of South Carolina orientation, I met Dr. 
Susan Steck. I told her about this seed inside me for cancer epidemiology, and she 
introduced me to my mentor, Dr. James Hebert. Our 1st meeting was in that 1st week of 
my life in Columbia, SC was amazing, I knew I wanted to work with him for the next 
many years – I knew who would help me with my PhD dissertation.   
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A month after our first meeting, Dr. Hebert asked me to join him at a urology 
patient group meeting where he gave a talk about Prostate Cancer screening. This was a 
follow-up to the recommendation by United States Preventive Services Task Force 
(USPSTF) against routine population level screening of PrCA using PSA.  I clearly 
remember a wide conference room occupied with middle aged men, mostly of color, 
expressing their disapproval of the new recommendation. Here my mentor displayed a 
colorful world map to a captive audience showing an inverse relationship between PrCA 
screening and PrCA mortality, there were a lot of concerned faces in the audience. As he 
finished his talk, Dr. Hebert was asked the same question many times in several ways -- 
“what is the alternative?” “What do we do now?” “Do we just not know until it’s too 
late?” In every question there was a story of PrCA screening saving someone’s life – a 
brother, a husband, a father or even their own life. I listened as my mentor, tried hard to 
explain that the result of the recent randomized trial is not an invalidation of their own 
life stories but rather a bigger absolute perspective of scientific research that may apply 
for many but not for all. We left the building with a thought that occupied my mind for 
many months to come; “what can we do?”  
I am not sure when Dr. Hebert shared the idea of PSA kinetics as a potential 
solution, but I think it was a seed he planned during our drive back from this meeting. He 
asked me to meet another graduate student Dr. Gowtham Rao, “he is a very sharp student 
from India, he is doing his research using the VA data” he said “a few months ago he 
wrote a grant proposing to improve PSA based screening using serial measure of PSA, 
you should discuss the idea with him”.  I had coincidently met Gowtham – and we had 
talked about the idea he had written as part of his PhD dissertation under Dr. Hebert. His 
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enthusiasm, and Dr. Hebert's trust grew my interest in investigating PSA kinetics, in one 
year, under the supervision of my mentor and my doctorate committee and with 
prodigious assistance from Gowtham, the research scope, question and design took a 
shape – leading to my doctorate dissertation proposal. 
I proposed my dissertation in May 2013, that day I walked out of the room fully 
confident of the idea, of my understanding of the problem, and of my familiarity with the 
statistical methods to be used. In the course of the nineteen months that followed, my 
confidence level momentously fluctuated. As I pulled through different challenges, I 
came to realize two main facts about the work we do; first, your knowledge and skills at 
the beginning of the research work is only the onset of an incremental accumulation of 
deeper and broader comprehension of the problem in hand. As you go back and forth 
between your data and the findings of others in the field, you realize how little you knew 
when you first started. Second, the heart of any research project is the research question. 
We do everything to better answer a specific scientific query. But the reality is that there 
is no single research work – not even a randomized control trail – that can fully answer 
any research question once and for all. The more answers your results indicate, the more 
questions are to be asked. These two facts combined, make the finish line of a research 
project hazy, but as one of my mentors told me once “a good dissertation is a complete 
dissertation;” that is precisely why a doctorate degree is not the end of the journey. It is 
rather the starting point.   
In the last four years I learned that your mentors are the ones who make or break 
your success. I was blessed by mentors back home that are way ahead of their time. They 
are the reason I started this journey in the 1st place. It is hard to believe how progressive, 
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scientifically oriented, and influential they are.  Their lives are series of success stories of 
bringing change. In a place like Palestine where scientific research (especially in the field 
of public health) is not merely an academic process, but it is a systematic approach of 
documenting and analyzing the political, social and economic injustice that we 
collectively face and that shape our health outcomes. Because of them, I came here with 
sufficient baseline training and extremely open mind set to admire science and peruse 
knowledge, I came here ready to learn and grow. I was blessed again with my mentorship 
here at the University of South Carolina. I still wonder if it was a matter of pure luck.  
My mentor Dr. James Hebert, inspired, motivated, supervised, and carefully oriented this 
dissertation and my whole learning journey. Everything about working with him is 
exciting; there were times that I really wanted to drop this whole idea of PSA kinetics. 
Fitting the appropriate mathematical model, figuring out the details of the statistical 
method and its interpretation were extremely challenging.  Each time that I got close to 
giving up, he faced me with creative solutions and profound excitement about the idea 
which kept me going.  He provided unlimited support every step on the way. He inspired 
the idea, gave me full lead and ownership, trusted my work and only took over when I 
needed him to.  He has unlimited energy, he thinks big and acts big. This kind of 
mentorship makes any dissertation project very stimulating and valuable.   
I also learned that no matter how smart you are, good work is always a reflection 
of team work.  Fellow students are a great resource to solve many problems along the 
way.  I learned to be always ready to help my colleagues, as there will be a time when I 
will need their help. They are also the main supporting system, because we all go through 
this journey, we can easily relate to each other’s obstacles.   I learned that over a four-
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year journey, both my strengths and limitations will surface. It is not wise to mask your 
limitations to your team or your supervisors. They both need to know, because only they 
can help you avoid irreversible mistakes.  In a fair environment – even when highly 
competitive – being honest, taking responsibility, and working hard to avoid and correct 
mistakes do pay off.  
My biggest lesson of all is that there is a dynamic relationship between stress, 
momentum, productivity and quality of the resulting work. The biggest challenge in 
working toward a PhD is to find the balance between stress and productivity that will 
keep the momentum and produce good quality of work at the right time.  The structure of 
our program of study is fairly lucid, but every dissertation has its own circumstances and 
time-limiting steps.  One of my fellow students once told me “doing a PhD feels like 
being lost in a desert”, this is fairly true. The first eight months after I proposed the 
dissertation idea, time passed fast and I felt like I accomplished nothing. My productivity 
was going down and at one point I felt like I lost the momentum.  I was struggling with 
the statistical methods, learning the details was a very slow process and tangible results 
seemed so far away. I also was easily distracted, and gave other work priority over my 
dissertation efforts, a pattern commonly described by PhD students.   When I realized that 
I was falling behind my timeline, the stress started to push my productivity, results started 
to emerge and I gained back my momentum. I was about to catch up with my timeline 
when I was faced with the biggest challenge of my dissertation work; data access 
problems.  My access to the VA network was disabled, the data source for the third aim 
of my dissertation proposal. Ironically, I had gained access back in 2011 and used the VA 
data for all of the preliminary analysis. At that critical time, I lost all my access privileges 
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and the IRB approval for this particular research was closed.  This was a problem that I 
did not anticipate and, at that point, I had no time to lose.  Still, I had to patiently wait 
almost two months to regain access to the data.  With such stress, we stretch our 
productivity above our limits but we also increase the possibility of irreversible mistakes. 
I eventually learned that if I had maintained even momentum throughout the four years, I 
could have adhered to my timeline and thus avoided much of the time stress that was 
created at the end. Delays in data access and other problems are common; the implication 
can be minimized by proper time management. The challenge is to find this optimum 
level of stress that will keep you focused on your dissertation project, maintain your 
productivity but does not jeopardize the quality of your work.  
In December 2014 (one week from today) I am to defend the results of my 
dissertation work. From the day my father helped me packing until today, many things 
happened. I did not cure Diabetes nor did I prevent Cancer, but I overcame many of the 
challenges – those I anticipated and many others. I was stretched beyond of what I 
thought were my limits. I was exposed to opposite perceptions of mine; all of that 
contributed to an exponential growth of my character, my values, my academic 
knowledge and skills and more importantly to my perception of health and wellbeing. At 
the end of this stage of my training, and at the starting point of my research journey I am 
fully committed to use what I learned and will further learn to help preventing and 
controlling Cancer.
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APPENDIX A-DESCRIPTION OF THE STATISTICAL MODELS  
 
1. A. The initial linear-exponential piecewise PSA model used an interaction term 
between the group type and time.  To account for individual level natural heterogeneity in 
the rate of growth, the transition point and the intercept in each group, we included 
random effects for their corresponding estimates. The full mixed-effect model for the 
data can be written as:  
𝑃𝑆𝐴𝑖𝑗 = 
{
 
 
 
 𝛽0 + (𝛽𝑔 ∗ 𝐺) + (𝛽𝑐 ∗ 𝐶) + 𝑏𝑖 + [(𝛽𝑡 + 𝛽𝑡𝑔 ∗ 𝐺 + 𝛽𝑡𝑐 ∗ 𝐶 + 𝑏𝑡𝑖)
∗ ((𝐶𝑃 + 𝛽𝑐𝑝𝑔 ∗ 𝐺 + 𝑏𝑐𝑝𝑖) − 𝑥)],   𝑥 < 𝑐𝑝
(𝛽0 + (𝛽𝑐 ∗ 𝐶) + (𝛽𝑔 ∗ 𝐺) + 𝑏𝑖) ∗
 𝑒(𝛽𝑡2+𝛽𝑡2𝑔∗𝐺+𝛽𝑡2𝑐∗𝐶+𝑏𝑡2𝑖)∗(𝐶𝑃+𝛽𝑐𝑝𝑔∗𝐺+𝑏𝑐𝑝𝑖−𝑥)
 
Where 𝑃𝑆𝐴𝐼𝐽 is the PSA measure for i
th individual jth occasion. 
Coefficients of the linear phase:   
𝛽0 is the value of PSA at the transition between linear and exponential phase 
𝑏𝑖  is the random effect for 𝛽0 
𝛽𝑔 is the coefficient corresponding to the group effect 
G is a categorical indicator of the group, and is replaced in the model by 2 binary dummy 
variables as follow:  {
𝑔1 = 1 𝑓𝑜𝑟 𝐿𝑜𝑤 − 𝑟𝑖𝑠𝑘  𝑝𝑟𝑜𝑠𝑡𝑎𝑡𝑒 𝑐𝑎𝑛𝑐𝑒𝑟 , 𝑒𝑙𝑠𝑒 𝑔1 = 𝑜,
𝑔2 = 1 𝑓𝑜𝑟 𝐻𝑖𝑔ℎ − 𝑟𝑖𝑠𝑘 𝑝𝑟𝑜𝑠𝑡𝑎𝑡𝑒 𝑐𝑎𝑛𝑐𝑒𝑟 , 𝑒𝑙𝑠𝑒 𝑔2 = 0,
 
𝛽𝑐 is a vector of the coefficients corresponding to the effect of the set of covariates    
C is a matrix representing the individual covariate values 
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𝛽𝑡  is the linear coefficient corresponding to the effect of time, i.e. the linear rate of 
change 
𝛽𝑡𝑔 is the coefficient corresponding to the effect of the group on  the linear rate of 
change; i.e., interaction between time and group     
𝛽𝑡𝑐 is the coefficient corresponding to the effect  of covariates  on  the linear rate of 
change, i.e. interaction between time and covariates 
𝑏𝑡𝑖 is the random effect on 𝛽𝑡  
X is time (years) before exit/diagnosis 
CP is the change point (inflection point) between linear and exponential phase 
𝛽𝑐𝑝𝑔 is the coefficient corresponding to the effect  of group on the change point 
𝑏𝑐𝑝𝑖 is the random effect on cp   
Coefficients of the exponential phase: 
𝛽𝑡2 is the exponential rate constant during the exponential PSA phase    
β
t2g
 is the coefficient corresponding to the effect  of group  on  the exponentia 
l rate constant    i. e. , interaction between time and group in phase 2       
β
t2c 
 is a vector of coefficients corresponding to the effect  of covariats  on 
  the exponential rate constant, ie interaction between time and covariates in the  
second stage             
bt2i is the random effect on βt2  
1. B. The reduced linear-exponential piecewise model  (allowing a transition to an 
exponential phase among the cancer groups only) estimates average and individual PSAV 
as ng/ml/year per group while adjusting for baseline age , BMI (kg/m2), PSA measure 
(ng/ml) and race [African American (AA) versus others]. We included an interaction 
 163 
term between all of these variables and time. The reduced mixed-effect model can be 
simplified to :   
𝑃𝑆𝐴𝐼𝐽 = { 
𝛽0
∗ + 𝑏𝑖 + 𝛽𝑡 
∗ + 𝑏𝑡𝑖 ∗ (𝑐𝑝 − 𝑥), 𝑥 < 𝑐𝑝 𝑎𝑛𝑑 𝑓𝑜𝑟 𝑛𝑜 𝑐𝑎𝑛𝑐𝑒𝑟 𝑔𝑟𝑜𝑢𝑝 
𝛽0
∗ ∗  𝑒(𝛽𝑡2
∗ + 𝑏𝑡2𝑖)∗(𝑐𝑝
∗+𝑏𝑐𝑝𝑖−𝑥) , 𝑥 ≥ 𝑐𝑝                                                        
 
 
Where the set of ( 𝛽0
∗, 𝛽𝑡
∗, 𝛽𝑡2
∗  , 𝑐𝑝∗) is adjusted for group and effect of age, BMI (kg/m2 
), PSA measure (ng/ml) , and race (AA versus others).  
𝛽0
∗: 𝑃𝑆𝐴 𝑎𝑡 𝑡ℎ𝑒 𝑡𝑟𝑠𝑖𝑡𝑖𝑜𝑛 𝑝𝑜𝑖𝑛𝑡 𝑓𝑜𝑟 𝑐𝑎𝑛𝑐𝑒𝑟 𝑔𝑟𝑜𝑢𝑝𝑠 𝑎𝑛𝑑 𝑎𝑡 𝑒𝑥𝑖𝑡 𝑓𝑜𝑟 𝑛𝑜 𝑐𝑎𝑛𝑐𝑒𝑟 𝑔𝑟𝑜𝑢𝑝  
𝑏𝑖 ∶ 𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑛 𝛽0
∗  
𝛽𝑡 
∗ ∶ 𝑙𝑖𝑛𝑒𝑎𝑟 𝑡𝑖𝑚𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡   
𝑏𝑡𝑖: 𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑛  𝛽𝑡 
∗     
𝛽𝑡2
∗ : 𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡𝑖𝑎𝑙 𝑡𝑖𝑚𝑒  𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡   
𝑏𝑡2𝑖: 𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑛  𝛽𝑡2
∗  
𝑐𝑝∗: 𝑖𝑠 𝑡ℎ𝑒 𝑐ℎ𝑎𝑛𝑔𝑒 𝑝𝑜𝑖𝑛𝑡 between linear and exponential phase    
𝑏𝑐𝑝𝑖 ∶ 𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑛 𝐶𝑃  
 
2. A.  The full mixed-effect model for log PSA : 
𝐿𝑜𝑔 (𝑃𝑆𝐴 + 1)
=  
{
 
 
 
 
 
𝛽0 + (𝛽𝑔 ∗ 𝐺) + (𝛽𝑐 ∗ 𝐶) + 𝑏𝑖 + [
(𝛽𝑡 + 𝛽𝑡𝑔 ∗ 𝐺 + 𝛽𝑡𝑐 ∗ 𝐶 + 𝑏𝑡𝑖) ∗
((𝐶𝑃 + 𝛽𝑐𝑝𝑔 ∗ 𝐺 + 𝑏𝑐𝑝𝑖) − 𝑥)
] , 𝑥 < 𝑐𝑝
 𝛽0 + (𝛽𝑐 ∗ 𝐶) + (𝛽𝑔 ∗ 𝐺) + 𝑏𝑖 + [(𝛽𝑡2 + 𝛽𝑡2𝑔 ∗ 𝐺 + 𝛽𝑡2𝑐 ∗ 𝐶 + 𝑏𝑡2𝑖) ∗
((𝐶𝑃 + 𝛽𝑐𝑝𝑔 ∗ 𝐺 + 𝑏𝑐𝑝𝑖) − 𝑥)], 𝑥 ≥ 𝑐𝑝
 
Where  
𝛽0 𝑖𝑠 the value of log (PSA)at the trasition between the 1st and the 2nd  linear phase    
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𝛽𝑔 𝑖𝑠 𝑡ℎ𝑒  𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑐𝑜𝑟𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑖𝑛𝑔 𝑡𝑜 𝑡ℎ𝑒 𝑝𝑎𝑡𝑖𝑛𝑒𝑡 𝑔𝑟𝑜𝑢𝑝 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑛 𝛽0    
G is a categorical indicator of the group, and is replaced in the model by 2 binary dummy 
variables as follow:  {
𝑔1 = 1 𝑓𝑜𝑟 𝐿𝑜𝑤 − 𝑟𝑖𝑠𝑘  𝑝𝑟𝑜𝑠𝑡𝑎𝑡𝑒 𝑐𝑎𝑛𝑐𝑒𝑟 , 𝑒𝑙𝑠𝑒 𝑔1 = 𝑜,
𝑔2 = 1 𝑓𝑜𝑟 𝐻𝑖𝑔ℎ − 𝑟𝑖𝑠𝑘 𝑝𝑟𝑜𝑠𝑡𝑎𝑡𝑒 𝑐𝑎𝑛𝑐𝑒𝑟 , 𝑒𝑙𝑠𝑒 𝑔2 = 0,
 
𝛽𝑐𝑖𝑠 𝑎 𝑣𝑒𝑐𝑡𝑜𝑟 𝑜𝑓  coefficient corresponding  𝑡ℎ𝑒 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑒𝑡 𝑜𝑓 covariate on 𝛽0     
C is a matrix representing the individual covariate values  
𝑏𝑖 𝑖𝑠 𝑡ℎ𝑒 𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑓𝑓𝑒𝑐𝑡 𝑓𝑜𝑟 𝛽0  
𝛽𝑡 is the 1st phase linear  coefficient, i. e. the linear rate of change at the 1st phase   
𝛽𝑡𝑔 𝑖𝑠 𝑡ℎ𝑒  𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑐𝑜𝑟𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑖𝑛𝑔 𝑡𝑜 𝑡ℎ𝑒 𝑒𝑓𝑓𝑒𝑐𝑡  𝑜𝑓 𝑔𝑟𝑜𝑢𝑝  𝑜𝑛  𝑡ℎ𝑒 1𝑠𝑡 𝑙𝑖𝑛𝑒𝑎𝑟 
 𝑟𝑎𝑡𝑒 𝑜𝑓 𝑐ℎ𝑎𝑛𝑔𝑒  𝑖𝑒. 𝑖𝑛𝑡𝑒𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑡𝑖𝑚𝑒 𝑎𝑛𝑑 𝑔𝑟𝑜𝑢𝑝 𝑎𝑡 𝑡ℎ𝑒 1𝑠𝑡 𝑝ℎ𝑎𝑠𝑒     
𝛽𝑡𝑐  𝑖𝑠 𝑡ℎ𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑐𝑜𝑟𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑖𝑛𝑔 𝑡𝑜 𝑡ℎ𝑒 𝑒𝑓𝑓𝑒𝑐𝑡  𝑜𝑓 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑡𝑠  𝑜𝑛  𝑡ℎ𝑒 1𝑠𝑡  
𝑙𝑖𝑛𝑒𝑎𝑟 𝑟𝑎𝑡𝑒 𝑜𝑓 𝑐ℎ𝑎𝑛𝑔𝑒    
𝑏𝑡𝑖 𝑖𝑠 𝑡ℎ𝑒 𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑛 𝛽𝑡         
𝑋 𝑖𝑠 𝑡𝑖𝑚𝑒 (𝑦𝑒𝑎𝑟𝑠)𝑏𝑒𝑓𝑜𝑟𝑒 𝑒𝑥𝑖𝑡/𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠  
𝐶𝑃 𝑖𝑠 𝑡ℎ𝑒 𝑐ℎ𝑎𝑛𝑔𝑒 𝑝𝑜𝑖𝑛𝑡 between the 1st and the 2nd  linear phases    
𝛽𝑐𝑝𝑔 𝑖𝑠 𝑡ℎ𝑒  𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑐𝑜𝑟𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑖𝑛𝑔 𝑡𝑜 𝑡ℎ𝑒 𝑒𝑓𝑓𝑒𝑐𝑡  𝑜𝑓 𝑔𝑟𝑜𝑢𝑝 𝑜𝑛 𝑡ℎ𝑒 𝑐ℎ𝑎𝑛𝑔𝑒  
𝑝𝑜𝑖𝑛𝑡    
𝑏𝑐𝑝𝑖 𝑖𝑠 𝑡ℎ𝑒 𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑛 𝑐𝑝   
Coefficients of the 2nd phase: 
𝛽𝑡2 is the difference in rate of change between the 1st and the 2nd phase      
𝛽𝑡2𝑔 𝑖𝑠 𝑡ℎ𝑒  𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑐𝑜𝑟𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑖𝑛𝑔 𝑡𝑜 𝑡ℎ𝑒 𝑒𝑓𝑓𝑒𝑐𝑡  𝑜𝑓 𝑔𝑟𝑜𝑢𝑝  𝑜𝑛 𝛽𝑡2          
 𝑖𝑒. 𝑖𝑛𝑡𝑒𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑡𝑖𝑚𝑒 𝑎𝑛𝑑 𝑔𝑟𝑜𝑢𝑝 𝑖𝑛 𝑝ℎ𝑎𝑠𝑒 2       
𝛽𝑡2𝑐  𝑖𝑠 𝑖𝑠 𝑎 𝑣𝑒𝑐𝑡𝑜𝑟 𝑜𝑓 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡𝑠 𝑐𝑜𝑟𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑖𝑛𝑔 𝑡𝑜 𝑡ℎ𝑒 𝑒𝑓𝑓𝑒𝑐𝑡  𝑜𝑓 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑠  
 165 
𝑜𝑛  𝛽𝑡2   
𝑏𝑡2𝑖 𝑖𝑠 𝑡ℎ𝑒 𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑛 𝛽𝑡2  
Based on this model, the rate of change at the second phase is the addition of  𝛽𝑡 and  𝛽𝑡2 
 
 2.B. The reduced mixed-effect model for log PSA : 
𝑃𝑆𝐴𝐼𝐽
= {  
𝛽0
∗ + 𝑏𝑖 + 𝛽𝑡 
∗ + 𝑏𝑡𝑖 ∗ (𝑐𝑝 − 𝑥),                 𝑥 < 𝑐𝑝 𝑎𝑛𝑑 𝑓𝑜𝑟 𝑛𝑜 𝑐𝑎𝑛𝑐𝑒𝑟 𝑔𝑟𝑜𝑢𝑝 
𝛽0
∗ + (𝛽𝑡2
∗ + 𝑏𝑡2𝑖) ∗ (𝑐𝑝
∗ + 𝑏𝑖𝑐𝑝 − 𝑥) ,      𝑥 ≥ 𝑐𝑝                                                        
 
 
Where the set of ( 𝛽0
∗, 𝛽𝑡
∗, 𝛽𝑡2
∗  , 𝑐𝑝∗) is adjusted for group and all other coverlets effect.  
𝛽0
∗: log (𝑃𝑆𝐴) 𝑎𝑡 𝑡ℎ𝑒 𝑡𝑟𝑠𝑖𝑡𝑖𝑜𝑛 𝑝𝑜𝑖𝑛𝑡               𝑏𝑖 ∶ 𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑛 𝛽0
∗             
                  𝛽𝑡 
∗ ∶ 𝑙𝑖𝑛𝑒𝑎𝑟 𝑡𝑖𝑚𝑒 𝑐𝑜𝑒𝑓𝑓𝑐𝑖𝑒𝑛𝑡                  𝑏𝑡𝑖: 𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑛  𝛽𝑡 
∗                                         
𝛽𝑡2
∗ : 𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡𝑖𝑎𝑙 𝑡𝑖𝑚𝑒 𝑐𝑜𝑒𝑓𝑓𝑐𝑖𝑒𝑛𝑡       𝑏𝑡2𝑖: 𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑛  𝛽𝑡2
∗  
𝑐𝑝∗: 𝑖𝑠 𝑡ℎ𝑒 𝑐ℎ𝑎𝑚𝑔𝑒 𝑝𝑜𝑖𝑛𝑡 between linear and exponential phase  𝑏𝑖𝑐𝑝 ∶
𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑛 𝐶𝑃  
